Boqii Holding Limited (BQ) 20-F 22 Jul 21 2021 FY Annual report (foreign) Financial data

Cover Page

Cover Page	12 Months Ended
	Mar. 31, 2021shares
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Registrant Name	Boqii Holding Ltd
Entity Central Index Key	0001815021
Current Fiscal Year End Date	--03-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Entity Address, Country	CN
ICFR Auditor Attestation Flag	false
Entity Incorporation, State or Country Code	E9
Document Accounting Standard	U.S. GAAP
Ordinary Shares [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding	67,542,837
Class A Ordinary Shares [Member]
Document Information [Line Items]
Title of 12(b) Security	Class A ordinary shares, par value US$0.001 per share
No Trading Symbol Flag	true
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding	54,505,108
Class B Ordinary Shares [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding	13,037,729
American Depositary Shares [Member]
Document Information [Line Items]
Title of 12(b) Security	American depositary shares, each ADS represents 0.75 Class A ordinary shares, par value US$0.001 per share
Trading Symbol	BQ
Security Exchange Name	NYSE

Consolidated Balance Sheets

Consolidated Balance Sheets ¥ in Thousands, $ in Thousands	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)
Current assets:
Cash and cash equivalents	$ 44,605	¥ 292,237	¥ 88,352
Short-term investments	25,725	168,546
Accounts receivable, net	6,980	45,732	44,980
Inventories, net	13,974	91,551	63,056
Prepayments and other current assets	13,013	85,261	76,720
Amounts due from related parties	1,750	11,465	5,982
Total current assets	106,047	694,792	279,090
Non-current assets:
Property and equipment, net	1,280	8,386	4,981
Intangible assets	4,508	29,537	33,538
Operating lease right-of-use assets	4,462	29,234	14,951
Long-term investments	11,345	74,330	73,432
Goodwill	6,133	40,184	40,184
Other non-current asset	627	4,111	11,019
Total non-current assets	28,355	185,782	178,105
Total assets	134,402	880,574	457,195
Current liabilities
Short-term borrowings (including amounts of the consolidated VIEs and VIEs' subsidiaries without recourse to the Company of RMB2,761 and RMB3,484 as of March 31, 2020 and 2021, respectively)	13,061	85,566	75,223
Accounts payable (including amounts of the consolidated VIEs and VIEs' subsidiaries without recourse to the Company of RMB 331,760 and RMB 439,879 as of March 31, 2020 and 2021, respectively)	10,966	71,848	88,005
Salary and welfare payable (including amounts of the consolidated VIEs and VIEs' subsidiaries without recourse to the Company of RMB3,789 and RMB4,851 as of March 31, 2020 and 2021, respectively)	963	6,309	4,465
Accrued liabilities and other current liabilities (including amounts of the consolidated VIEs and VIEs' subsidiaries without recourse to the Company of RMB116,516 and RMB225,709 as of March 31, 2020 and 2021, respectively)	4,587	30,055	37,883
Amounts due to related parties, current (including amounts of the consolidated VIEs and VIEs' subsidiaries without recourse to the Company of RMB45 and RMB910 as of March 31, 2020 and 2021, respectively)	139	910	45
Other debts, current (including amounts of the consolidated VIEs and VIEs' subsidiaries without recourse to the Company of nil as of March 31, 2020 and 2021, respectively)			76,252
Contract liabilities (including amounts of the consolidated VIEs and VIEs' subsidiaries without recourse to the Company of RMB7,621 and RMB3,706 as of March 31, 2020 and 2021, respectively)	590	3,866	7,702
Operating lease liabilities, current (including amounts of the consolidated VIEs and VIEs' subsidiaries without recourse to the Company of RMB6,652 and RMB7,726 as of March 31, 2020 and 2021, respectively)	1,231	8,063	7,969
Derivative liabilities (including amounts of the consolidated VIEs and VIEs' subsidiaries without recourse to the Company of nil as of March 31, 2020 and 2021, respectively)	1,526	9,996	14,351
Total current liabilities	33,063	216,613	311,895
Non-current liabilities
Deferred tax liabilities (including amounts of the consolidated VIEs and VIEs' subsidiaries without recourse to the Company of RMB2,593 and RMB1,852 as of March 31, 2020 and 2021, respectively)	1,367	8,958	10,591
Operating lease liabilities, non-current (including amounts of the consolidated VIEs and VIEs' subsidiaries without recourse to the Company of RMB5,375 and RMB19,997 as of March 31, 2020 and 2021, respectively)	3,052	19,997	5,375
Long-term borrowings (including amounts of the consolidated VIEs and VIEs' subsidiaries without recourse to the Company of RMB982 and RMB872 as of March 31, 2020 and 2021, respectively)	10,390	68,075	53,148
Other debts, non-current (including amounts of the consolidated VIEs and VIEs' subsidiaries without recourse to the Company of RMB147,774 and RMB415,122 as of March 31, 2020 and 2021, respectively)	66,133	433,292	165,774
Amounts due to related parties, non-current (including amounts of the consolidated VIEs and VIEs' subsidiaries without recourse to the Company of RMB10,450 and nil as of March 31, 2020 and 2021, respectively)			11,521
Total non-current liabilities	80,942	530,322	246,409
Total liabilities	114,005	746,935	558,304
Commitments and contingencies (Note 28)
Mezzanine equity:
Redeemable Non-controlling Interest, Equity, Carrying Amount
Receivable for issuance of preferred shares			(94,758)
Redeemable non-controlling interests	908	5,946
Total mezzanine equity	908	5,946	1,857,947
Shareholders' deficit:
Common Stock Value
Additional paid-in capital	499,498	3,272,612
Statutory reserves	465	3,047	2,627
Accumulated other comprehensive loss	(3,079)	(20,172)	11,204
Accumulated deficit	(421,240)	(2,759,882)	(2,016,758)
Receivable for issuance of ordinary shares	(63,094)	(413,377)	(9)
Total shareholders' deficit	12,618	82,674	(2,002,797)
Non-controlling interests	6,871	45,019	43,741
Total shareholders' deficit	19,489	127,693	(1,959,056)
Total liabilities, mezzanine equity and shareholders' deficit	134,402	880,574	457,195
Ordinary Shares [Member]
Shareholders' deficit:
Common Stock Value			139
Total shareholders' deficit			139
Series A Redeemable Convertible Preferred Shares [Member]
Mezzanine equity:
Redeemable Non-controlling Interest, Equity, Carrying Amount			484,122
Series B Redeemable Convertible Preferred Shares [Member]
Mezzanine equity:
Redeemable Non-controlling Interest, Equity, Carrying Amount			527,682
Series C Redeemable Convertible Preferred Shares [Member]
Mezzanine equity:
Redeemable Non-controlling Interest, Equity, Carrying Amount			420,419
Series D Redeemable Convertible Preferred Shares [Member]
Mezzanine equity:
Redeemable Non-controlling Interest, Equity, Carrying Amount			188,183
Series D-1 Redeemable Convertible Preferred Shares [Member]
Mezzanine equity:
Redeemable Non-controlling Interest, Equity, Carrying Amount			164,282
Series D-2 Redeemable Convertible Preferred Shares [Member]
Mezzanine equity:
Redeemable Non-controlling Interest, Equity, Carrying Amount			89,464
Series E Redeemable Convertible Preferred Shares [Member]
Mezzanine equity:
Redeemable Non-controlling Interest, Equity, Carrying Amount			¥ 78,553
Class A Ordinary Shares [Member]
Shareholders' deficit:
Common Stock Value	56	364
Class A Ordinary Shares [Member] | Ordinary Shares [Member]
Shareholders' deficit:
Total shareholders' deficit		364
Class B Ordinary Shares [Member]
Shareholders' deficit:
Common Stock Value	$ 12	82
Class B Ordinary Shares [Member] | Ordinary Shares [Member]
Shareholders' deficit:
Total shareholders' deficit		¥ 82

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) ¥ in Thousands, $ in Thousands	Mar. 31, 2021USD ($)$ / sharesshares	Mar. 31, 2021CNY (¥)shares	Mar. 31, 2020USD ($)$ / sharesshares	Mar. 31, 2020CNY (¥)shares
Short-term borrowings	$ 13,061	¥ 85,566		¥ 75,223
Accounts payable	10,966	71,848		88,005
Salary and welfare payable	963	6,309		4,465
Accrued liabilities and other current liabilities	4,587	30,055		37,883
Amounts due to related parties, current	139	910		45
Other debts, current | ¥				76,252
Contract liabilities	590	3,866		7,702
Operating lease liabilities, current	1,231	8,063		7,969
Derivative liabilities	1,526	9,996		14,351
Deferred tax liabilities	1,367	8,958		10,591
Operating lease liabilities, non-current	3,052	19,997		5,375
Long-term borrowings	10,390	68,075		53,148
Other debts, non-current	66,133	433,292		165,774
Amounts due to related parties, non-current  | ¥				¥ 11,521
Common Stock, Shares, Issued			22,238,454	22,238,454
Common Stock, Shares, Outstanding			22,238,454	22,238,454
Nonrecourse [Member] | Variable Interest Entity, Primary Beneficiary [Member]
Short-term borrowings | ¥		3,484		¥ 2,761
Accounts payable | ¥		439,879		331,760
Salary and welfare payable | ¥		4,851		3,789
Accrued liabilities and other current liabilities | ¥		225,709		116,516
Amounts due to related parties, current | ¥		910		45
Other debts, current | ¥		0		0
Contract liabilities | ¥		3,706		7,621
Operating lease liabilities, current | ¥		7,726		6,652
Derivative liabilities	$ 0	0	$ 0	0
Deferred tax liabilities | ¥		1,852		2,593
Operating lease liabilities, non-current | ¥		19,997		5,375
Long-term borrowings | ¥		872		982
Other debts, non-current | ¥		415,122		147,774
Amounts due to related parties, non-current  | ¥		¥ 0		¥ 10,450
Ordinary Shares [Member]
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.001		$ 0.001
Common Stock, Shares Authorized	153,000,000	153,000,000	153,000,000	153,000,000
Common Stock, Shares, Issued	0	0	22,238,454	22,238,454
Common Stock, Shares, Outstanding	0	0	22,238,454	22,238,454
Series A Redeemable Convertible Preferred Shares [Member]
Convertible Preferred Shares, Par Value Per Share | $ / shares	$ 0.001		$ 0.001
Convertible Preferred Shares, Authorized	11,000,000	11,000,000	11,000,000	11,000,000
Convertible Preferred Shares, Issued	0	0	10,340,000	10,340,000
Convertible Preferred Shares, Outstanding	0	0	10,340,000	10,340,000
Series B Redeemable Convertible Preferred Shares [Member]
Convertible Preferred Shares, Par Value Per Share | $ / shares	$ 0.001		$ 0.001
Convertible Preferred Shares, Authorized	10,000,000	10,000,000	10,000,000	10,000,000
Convertible Preferred Shares, Issued	0	0	9,067,384	9,067,384
Convertible Preferred Shares, Outstanding	0	0	9,067,384	9,067,384
Series C Redeemable Convertible Preferred Shares [Member]
Convertible Preferred Shares, Par Value Per Share | $ / shares	$ 0.001		$ 0.001
Convertible Preferred Shares, Authorized	6,000,000	6,000,000	6,000,000	6,000,000
Convertible Preferred Shares, Issued	0	0	5,518,101	5,518,101
Convertible Preferred Shares, Outstanding	0	0	5,518,101	5,518,101
Series D Redeemable Convertible Preferred Shares [Member]
Convertible Preferred Shares, Par Value Per Share | $ / shares	$ 0.001		$ 0.001
Convertible Preferred Shares, Authorized	3,000,000	3,000,000	3,000,000	3,000,000
Convertible Preferred Shares, Issued	0	0	2,526,026	2,526,026
Convertible Preferred Shares, Outstanding	0	0	2,526,026	2,526,026
Series D-1 Redeemable Convertible Preferred Shares [Member]
Convertible Preferred Shares, Par Value Per Share | $ / shares	$ 0.001		$ 0.001
Convertible Preferred Shares, Authorized	3,000,000	3,000,000	3,000,000	3,000,000
Convertible Preferred Shares, Issued	0	0	2,178,530	2,178,530
Convertible Preferred Shares, Outstanding	0	0	2,178,530	2,178,530
Series D-2 Redeemable Convertible Preferred Shares [Member]
Convertible Preferred Shares, Par Value Per Share | $ / shares	$ 0.00001		$ 0.00001
Convertible Preferred Shares, Authorized	2,000,000	2,000,000	2,000,000	2,000,000
Convertible Preferred Shares, Issued	0	0	1,182,803	1,182,803
Convertible Preferred Shares, Outstanding	0	0	1,182,803	1,182,803
Series E Redeemable Convertible Preferred Shares [Member]
Convertible Preferred Shares, Par Value Per Share | $ / shares	$ 0.001		$ 0.001
Convertible Preferred Shares, Authorized	7,000,000	7,000,000	3,000,000	3,000,000
Convertible Preferred Shares, Issued	0	0	1,042,623	1,042,623
Convertible Preferred Shares, Outstanding	0	0	1,042,623	1,042,623
Class A Ordinary Shares [Member]
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.001		$ 0.001
Common Stock, Shares Authorized	129,500,000	129,500,000	0	0
Common Stock, Shares, Issued	54,505,108	54,505,108	0	0
Common Stock, Shares, Outstanding	54,505,108	54,505,108	0	0
Class B Ordinary Shares [Member]
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.001		$ 0.001
Common Stock, Shares Authorized	15,000,000	15,000,000	0	0
Common Stock, Shares, Issued	13,037,729	13,037,729	0	0
Common Stock, Shares, Outstanding	13,037,729	13,037,729	0	0

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss ¥ in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2021USD ($)$ / sharesshares	Mar. 31, 2021CNY (¥)¥ / sharesshares	Mar. 31, 2020CNY (¥)¥ / sharesshares	Mar. 31, 2019CNY (¥)¥ / sharesshares
Net revenues:
Total revenues	$ 154,307	¥ 1,010,985	¥ 770,237	¥ 803,831
Total cost of revenue	(125,719)	(823,686)	(611,470)	(599,477)
Gross profit	28,588	187,299	158,767	204,354
Operating expenses:
Fulfillment expenses	(18,344)	(120,188)	(115,887)	(184,846)
Sales and marketing expenses	(24,451)	(160,201)	(128,387)	(157,482)
General and administrative expenses	(17,396)	(113,972)	(54,277)	(67,007)
Other income, net	163	1,067	2,398	3,851
Loss from operations	(31,440)	(205,995)	(137,386)	(201,130)
Interest income	2,679	17,553	400	114
Interest expense	(4,220)	(27,650)	(59,268)	(18,654)
Other gain (losses), net	1,730	11,332	6,984	(9,814)
Fair value change of derivative liabilities	1,735	11,369	13,345	(2,274)
Loss before income tax expenses	(29,516)	(193,391)	(175,925)	(231,758)
Income taxes expenses	133	871	512	141
Share of results of equity investees	(106)	(696)	(520)	91
Net loss	(29,489)	(193,216)	(175,933)	(231,526)
Less: Net income attributable to the non-controlling interest shareholders	187	1,228	3,091	2,715
Net loss attributable to Boqii Holding Limited	(29,676)	(194,444)	(179,024)	(234,241)
Less: Accretion on convertible redeemable preferred shares to redemption value	18,449	120,873	(204,796)	(392,550)
Less: Accretion on redeemable non-controlling interests to redemption value	(21)	(138)
Less: Deemed dividend to preferred shareholders	(1,915)	(12,547)	(1,142)	(723)
Net loss attributable to Boqii Holding Limited's ordinary shareholders	(13,163)	(86,256)	(384,962)	(627,514)
Net loss	(29,489)	(193,216)	(175,933)	(231,526)
Other comprehensive income (loss):
Foreign currency translation adjustment, net of nil tax	(4,907)	(32,148)	2,021	3,808
Unrealized securities holding gains	118	772	3,209	1,711
Total comprehensive loss	(34,278)	(224,592)	(170,703)	(226,007)
Less: Total comprehensive loss attributable to non- controlling interests shareholders	187	1,228	3,091	2,715
Total comprehensive loss attributable to Boqii Holding Limited	$ (34,465)	¥ (225,820)	¥ (173,794)	¥ (228,722)
Net loss per share attributable to Boqii Holding Limited's ordinary shareholders
— basic | (per share)	$ (0.20)	¥ (1.29)	¥ (17.31)	¥ (28.22)
— diluted | (per share)	$ (0.20)	¥ (1.29)	¥ (17.31)	¥ (28.22)
Weighted average number of ordinary shares
— basic | shares	66,953,610	66,953,610	22,238,454	22,238,454
— diluted | shares	66,953,610	66,953,610	22,238,454	22,238,454
Product Sales [Member]
Net revenues:
Total revenues	$ 153,118	¥ 1,003,197	¥ 767,496	¥ 797,995
Total cost of revenue | ¥		(820,300)	(610,600)	(599,200)
Online Marketing And Information Services And Other Revenue [Member]
Net revenues:
Total revenues	$ 1,189	7,788	2,741	5,836
Total cost of revenue | ¥		¥ (3,400)	¥ (900)	¥ (300)

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Deficit ¥ in Thousands, $ in Thousands	USD ($)	CNY (¥)	Ordinary Shares [Member]CNY (¥)shares	Ordinary Shares [Member]Common Class A [Member]CNY (¥)shares	Ordinary Shares [Member]Common Class B [Member]CNY (¥)shares	Additional Paid-in Capital [Member]CNY (¥)	Statutory reserves [Member]CNY (¥)	Accumulated other comprehensive income [Member]CNY (¥)	Accumulated deficit [Member]CNY (¥)	Non-controlling interests [Member]CNY (¥)	Receivable for issuance of ordinary shares [Member]CNY (¥)
Beginning Balance , Shares at Mar. 31, 2018 | shares			20,938,500
Beginning Balance at Mar. 31, 2018		¥ (1,001,509)	¥ 130			¥ 197,565		¥ 455	¥ (1,199,220)	¥ (439)
Foreign currency translation adjustment		3,808						3,808
Appropriations to statutory reserves							¥ 1,650		(1,650)
Accretion to redemption value of redeemable convertible preferred shares (Note 20)		(392,550)				(197,565)			(194,985)
Capital contribution from non-controlling interests		250								250
Deemed dividend to preferred shareholders (Note 20)		(723)							(723)
Unrealized securities holding gains, net of tax		1,711						1,711
Acquisition of subsidiaries		2,101								2,101
Net loss		(231,526)							(234,241)	2,715
Ending Balance, Shares at Mar. 31, 2019 | shares			20,938,500
Ending Balance at Mar. 31, 2019		(1,618,438)	¥ 130				1,650	5,974	(1,630,819)	4,627
Share-based compensation , Shares | shares			1,299,954
Share-based compensation			¥ 9								¥ (9)
Foreign currency translation adjustment		2,021						2,021
Appropriations to statutory reserves							778		(778)
Accretion to redemption value of redeemable convertible preferred shares (Note 20)		(204,796)							(204,796)
Deemed dividend to preferred shareholders (Note 20)		(1,142)							(1,142)
Unrealized securities holding gains, net of tax		3,209						3,209
Acquisition of subsidiaries		36,023					199		(199)	36,023
Net loss		(175,933)							(179,024)	3,091
Ending Balance, Shares at Mar. 31, 2020 | shares			22,238,454
Ending Balance at Mar. 31, 2020		(1,959,056)	¥ 139				2,627	11,204	(2,016,758)	43,741	(9)
Share-based compensation		55,031				55,022					9
Foreign currency translation adjustment		(32,148)						(32,148)
Appropriations to statutory reserves							420		(420)
Accretion to redemption value of redeemable convertible preferred shares (Note 20)		120,873							120,873
Accretion to redemption value of redeemable non-controlling interests (Note 21)		(138)							(138)
Capital contribution from non-controlling interests		50								50
Deemed dividend to preferred shareholders (Note 20)		(12,547)							(12,547)
Unrealized securities holding gains, net of tax		772						772
Exercise of CMB Warrant (Note 20)		(665,448)							(656,448)
Receivable for issuance of convertible redeemable preferred shares		(413,377)									(413,377)
Conversion of ordinary shares into Class A and Class B ordinary shares , Shares | shares			(22,238,454)	10,033,850	12,204,604
Conversion of ordinary shares into Class A and Class B ordinary shares			¥ (139)	¥ 63	¥ 76
Issuance of Class A ordinary shares upon initial public offering ("IPO"), net of cost of issuance (Note 19) , Shares | shares				5,250,000
Issuance of Class A ordinary shares upon initial public offering ("IPO"), net of cost of issuance (Note 19)		395,071		¥ 36		395,035
Conversion of Series A convertible redeemable preferred shares upon completion of the IPO , Shares | shares				7,844,137
Conversion of Series A convertible redeemable preferred shares upon completion of the IPO		461,445		¥ 53		461,392
Conversion of Series B convertible redeemable preferred shares upon completion of the IPO , Shares | shares				8,557,980
Conversion of Series B convertible redeemable preferred shares upon completion of the IPO		504,337		¥ 57		504,280
Conversion of Series C convertible redeemable preferred shares upon completion of the IPO , Shares | shares				4,684,976	833,125
Conversion of Series C convertible redeemable preferred shares upon completion of the IPO		331,465		¥ 32	¥ 6	331,427
Conversion of Series C+ convertible redeemable preferred shares upon completion of the IPO , Shares | shares				6,883,520
Conversion of Series C+ convertible redeemable preferred shares upon completion of the IPO		662,808		¥ 47		662,761
Conversion of Series D convertible redeemable preferred shares upon completion of the IPO , Shares | shares				2,526,026
Conversion of Series D convertible redeemable preferred shares upon completion of the IPO		181,004		¥ 17		180,987
Conversion of Series D—1 convertible redeemable preferred shares upon completion of the IPO , Shares | shares				2,178,530
Conversion of Series D—1 convertible redeemable preferred shares upon completion of the IPO		164,859		¥ 15		164,844
Conversion of Series D—2 convertible redeemable preferred shares upon completion of the IPO , Shares | shares				1,182,803
Conversion of Series D—2 convertible redeemable preferred shares upon completion of the IPO		92,314		¥ 8		92,306
Conversion of Series E convertible redeemable preferred shares upon completion of the IPO , Shares | shares				5,885,210
Conversion of Series E convertible redeemable preferred shares upon completion of the IPO		455,980		¥ 40		455,940
Repurchase of Ordinary Shares , Shares | shares				(521,924)
Repurchase of Ordinary Shares		(31,386)		¥ (4)		(31,382)
Net loss	$ (29,489)	(193,216)							(194,444)	1,228
Ending Balance, Shares at Mar. 31, 2021 | shares				54,505,108	13,037,729
Ending Balance at Mar. 31, 2021	$ 19,489	¥ 127,693		¥ 364	¥ 82	¥ 3,272,612	¥ 3,047	¥ (20,172)	¥ (2,759,882)	¥ 45,019	¥ (413,377)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows ¥ in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)	Mar. 31, 2019CNY (¥)
Cash flows from operating activities:
Net loss	$ (29,489)	¥ (193,216)	¥ (175,933)	¥ (231,526)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization expense	1,081	7,083	4,588	3,172
Provision for inventories	(1)	(8)	273	527
Provision for doubtful accounts	(16)	(107)	271	92
Interest expense of other debts	3,298	21,611	53,934	17,077
Interest receivable for issuance of ordinary shares	(2,350)	(15,394)
Amortization of right-of-use assets	1,784	11,687	15,708	17,919
Interest of lease liabilities	244	1,596	1,353	1,636
Share of results of equity investees	20	131	520	(91)
Loss on disposal of property and equipment	3	20	31	67
Gain on disposal of other debts	(1,045)	(6,846)	(10,095)
Gain from the re-measurement of the previously held equity interest to the fair value in the business acquisition			(481)
Share-based compensation expense	8,398	55,022
Fair value change of derivative liabilities	(1,735)	(11,369)	(13,345)	2,274
Deferred tax expense	(288)	(1,889)	(661)	(141)
Changes in operating assets and liabilities, net of effects of businesses acquired:
Accounts receivable	(134)	(880)	(16,010)	(10,543)
Inventories	(5,928)	(38,839)	15,486	14,453
Prepayments and other current assets	(7,456)	(48,853)	3,331	(430)
Amounts due from related parties	(406)	(2,663)	(1,944)	13,326
Operating lease liabilities	(1,961)	(12,850)	(18,183)	(19,284)
Accounts payable	(3,362)	(22,029)	(19,535)	(15,750)
Salary and welfare payable	384	2,518	355	(1,527)
Accrued liabilities and other current liabilities	100	667	574	916
Amounts due to related parties	162	1,062	(105)	(2)
Contract liabilities	(798)	(5,229)	1,887	2,585
Other non-current assets	1,723	11,289	(7,931)	(974)
Net cash used in operating activities	(37,772)	(247,486)	(165,912)	(206,224)
Cash flows from investing activities:
Loans receivables advanced to a third party	(7,539)	(49,392)	(37,671)	(11,907)
Repayments on loans receivables from a third party	6,836	44,790	12,013	2,500
Loans receivables advanced to a related party	(735)	(4,814)
Acquisition of subsidiaries, net of cash and cash equivalents acquired			1,783	(893)
Increase in short-term investments	(25,725)	(168,546)
Purchase of intangible assets			(2)	(34)
Purchase of property and equipment	(993)	(6,509)	(1,204)	(2,019)
Disposal of property and equipment	1	4	5	286
Acquisitions of long-term investments			(50,000)	(10,745)
Disposal of equity investees			20
Acquisition of additional interests in subsidiaries from non-controlling interests	8	50		250
Net cash used in investing activities	(28,147)	(184,417)	(75,056)	(22,562)
Cash flows from financing activities:
Proceeds from issuance of convertible redeemable preferred shares, net of issuance costs	54,157	354,825	41,197	68,138
Proceeds from short-term and long-term borrowings	13,408	87,846	162,501	57,638
Repayments of short-term and long-term borrowings	(11,295)	(74,000)	(43,533)	(65,798)
Proceeds from issuance of other debts, net of issuance costs	2,586	16,940	134,867	139,335
Repayments of other debts	(19,968)	(130,827)
Proceeds from exercise of share option	1	9
Proceeds from the initial public offering, net of underwriter discounts and commissions and other offering costs paid	60,090	393,698
Net cash flows generated from financing activities	98,979	648,491	295,032	199,313
Net increase (decrease) in cash, cash equivalents and restricted cash	33,060	216,588	54,064	(29,473)
Cash, cash equivalents and restricted cash at beginning of year	13,485	88,352	27,217	50,207
Effects of exchange rate changes on cash, cash equivalents and restricted cash	(1,940)	(12,703)	7,071	6,483
Cash, cash equivalents and restricted cash at end of year	44,605	292,237	88,352	27,217
Supplemental schedule of non-cash investing and financing activities:
Accretion on convertible redeemable preferred shares	18,449	120,873	(204,796)	(392,550)
Accretion on redeemable non-controlling interests	(21)	(138)
Deemed dividend to preferred shareholders	(1,915)	(12,547)	(1,142)	(723)
Non-cash consideration paid for business acquisitions			(33,440)
Unpaid cash consideration for business acquisitions				(8,271)
Additional ASC 842 supplemental disclosure:
Cash paid for fixed operating lease costs included in the measurement of lease obligations in operating activities	1,961	12,850	18,183	19,284
Right-of-use assets obtained in exchange for operating lease obligations	$ 3,964	¥ 25,970	¥ 10,051	¥ 19,570

Organization and principal acti

Organization and principal activities	12 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and principal activities	1. Organization and principal activities (a) Principal activities Boqii Holding Limited (“Boqii Holding”), was incorporated under the laws of the Cayman Islands in June 2012, as an exempted company with limited liability. Boqii Holding, its subsidiaries, consolidated variable interest entities (“VIEs”) and VIEs’ subsidiaries (collectively referred as the “Company”), operate as an online one-stop The Company’s consolidated financial statements include the financial statements of the Company, its subsidiaries, consolidated VIEs and VIEs’ subsidiaries. As of March 31, 2021, the Company’s principal subsidiaries, consolidated VIEs and major VIEs’ subsidiaries are as follows: Name of subsidiaries and VIE Place of incorporation Date of incorporation or acquisition Percentage of direct or indirect Principal activities Subsidiaries: Boqii Corporation Limited (“Boqii Corporation”) Hong Kong July 2012 100% Investment holding Boqii International Limited Hong Kong August 2016 100% Investment holding Xingmu International Limited British Virgin Islands August 2019 51% Investment holding Xingmu HK Limited Hong Kong November 2019 51% Investment holding Nanjing Xinmu Information Technology Co., Ltd. (“Xingmu WFOE”) Nanjing, the PRC November 2019 51% Technology development and sales of merchandise Xincheng (Shanghai) Information Technology Co., Ltd. (“Shanghai Xincheng”) Shanghai, the PRC November 2012 100% Technology development and sales of merchandise Shanghai Yiqin Pets Products Co., Ltd. Shanghai, the PRC February 2013 100% Technology development and sales of merchandise Consolidated VIEs Guangcheng (Shanghai) Information Technology Co., Ltd. Shanghai, the PRC November 2012 100% Operates the Company’s own online e-commerce Nanjing Xingmu Biotechnology Co., Ltd. Nanjing, the PRC November 2019 51% Biotechnology research and development Subsidiaries of VIEs Boqii (Shanghai) Information Technology Co., Ltd. Shanghai, the PRC August 2014 90% Technology development Tianjing Guangcheng Information Technology Co., Ltd. Tianjin, the PRC June 2017 100% Sales of merchandise Nanjing Cuida Biotechnology Co. Ltd.(“Cuida”) Nanjing, the PRC April 2017 70% Biotechnology extension services Taizhou Xingmu Biotechnology Co., Ltd. Taizhou, the PRC November 2019 80% Biotechnology research and development (b) Consolidated variable interest entities In order to comply with the PRC laws and regulations which prohibit or restrict foreign investments into companies involved in restricted businesses, the Company operates online platforms that provide internet information services and engages in other foreign-ownership-restricted businesses through certain PRC domestic companies (the PRC Domestic Companies, or the “VIEs”). The equity interests of the PRC Domestic Companies are held by certain management members of the Company or onshore nominees of certain investors of the Company (“Nominee Shareholders”), who act as nominee equity holders of the PRC Domestic Companies on behalf of Shanghai Xincheng and Xingmu WFOE, the Company’s wholly owned subsidiaries in the PRC (the “WFOEs”). The WFOEs entered into a series of contractual arrangements with the PRC Domestic Companies and their respective Nominee Shareholders (the “Contractual Arrangements”). These Contractual Agreements cannot be unilaterally terminated by the Nominee Shareholders or the PRC Domestic Companies. Through the Contractual Arrangements, the Nominee Shareholders have granted all their legal rights including voting rights and disposition rights of their equity interests in the PRC Domestic Companies to the WFOEs. The Nominee Shareholders do not have the power to direct the activities of the PRC Domestic Companies that most significantly impact their economic performance. The Nominee Shareholders do not have the obligation to absorb losses of the PRC Domestic Companies that could potentially be significant to them or the right to receive benefits from the PRC Domestic Companies that could potentially be significant to them. Accordingly, the PRC Domestic Companies are considered as variable interest entities of the Company, through the WFOEs. In accordance with Accounting Standards Codification (“ASC”) 810-10-25-38A, the Based on the above, the Company, through the WFOEs, is the ultimate primary beneficiary of the VIEs. Accordingly, the financial statements of the VIEs and their subsidiaries are consolidated in the Company’s consolidated financial statements. Loan Agreements Pursuant to the relevant loan agreements, the WFOEs have granted interest-free loans to the relevant Nominee Shareholders of the relevant VIEs with the sole purpose of providing funds necessary for the capital injection to the relevant VIEs. The loans can only be repaid by transfer of the equity interests of the relevant VIEs held by the Nominee Shareholders, and shall be repaid upon the occurrence of, among other events, the WFOEs exercise of their options to purchase the relevant VIEs’ equity interests under the Exclusive Option Agreements (refer to following section for further details). Any proceeds received by the Nominee Shareholders from transfer of the equity interests shall also be repaid to the WFOEs as part of the loan repayments. Other events that will lead to loan repayments include: the Nominee Shareholders receiving a written notice from the relevant PRC subsidiaries requesting loan repayments; the death or loss of capacity for civil conduct of the Nominee Shareholders; the Nominee Shareholders no long acting as shareholders of the relevant VIEs or employees of the relevant VIEs, PRC subsidiaries or their related parties; the Nominee Shareholders being involved in criminal activities; or, any third party making a claim in an amount over RMB 500,000 against the Nominee Shareholders. The loans shall be considered fully repaid when the Nominee Shareholders have transferred all equity interests held by them to the WFOEs or a party designated by the WFOEs. The Loan Agreements shall remain valid until the Nominee Shareholders repaid the relevant loans to the WFOEs. Exclusive Option Agreements The Nominee Shareholders of the VIEs have granted the WFOEs the exclusive and irrevocable right to purchase or to designate one or more person(s) at their discretion to purchase part or all of the equity interests in the VIEs from the Nominee Shareholders for a purchase price at any time, subject to the lowest price permitted by PRC laws and regulations. The VIEs and their Nominee Shareholders have agreed that without prior written consent of the WFOEs, their respective Nominee Shareholders cannot sell, transfer, pledge or dispose their equity interests, and the VIEs cannot sell, transfer, pledge or dispose, but not limit to, the equity interests, significant assets, significant revenue and significant business. Also as agreed, the VIEs cannot declare any dividend or change capitalization structure of the VIEs and cannot enter into any loan or investment agreements. Furthermore, the Nominee Shareholders have agreed that any proceeds but not limited to the sales of the Nominee Shareholders’ equity interest in relevant VIEs should be gratuitously paid to the WOFEs or one or more person(s) at their discretion. The Exclusive Option Agreement will remain effective until all equity options in VIEs held by such Nominee Shareholders are transferred or assigned to the WFOEs or their designated representatives. Proxy Agreement and Power of Attorney Pursuant to the irrevocable power of attorney, each of the Nominee Shareholders appointed the WFOEs as their attorney-in-fact Exclusive Consultation and Service Agreements Pursuant to the Exclusive Consultation Service Agreements, the WFOEs have agreed to provide to the VIEs services, including, but not limited to, design and maintenance of the E-Commerce Intellectual Property License Agreements Pursuant to the intellectual property license agreements, the WFOEs have granted a non-exclusive non-transferable Equity Interest Pledge Agreements Pursuant to the relevant equity interest pledge agreements, the Nominee Shareholders of the VIEs have pledged 100% equity interests in relevant VIEs to the WFOEs to guarantee performance by the Nominee Shareholders of their obligations under the Exclusive Option Agreements, the Proxy Agreement and Power of Attorney and the Loan Agreements, as well as the performance by the VIEs of their obligations under the Exclusive Option Agreements, the Exclusive Consultation and Service Agreements and Intellectual Property License Agreements. In the event of a breach by the VIEs or any of their Nominee Shareholders of contractual obligations under the Contractual Agreements, as the case may be, the WFOEs, as pledgee, will have the right to dispose of the pledged equity interests in the relevant VIEs and will have priority in receiving the proceeds from such disposal. The Nominee Shareholders of the VIEs also covenant that, without the prior written consent of the WFOEs, they will not dispose of, create or allow any encumbrance on the pledged equity interests. The Equity Interest Pledge Agreements will remain in effect so long as any of the Loan Agreements, the Exclusive Consultation Service Agreements, the Exclusive Option Agreements, the Proxy Agreement and Power of Attorney, or the Intellectual Property License Agreements, as mentioned above, remains in effect or any guaranteed obligations of the VIEs, or, to the extent applicable, its Nominee Shareholders, remains outstanding under the Contractual Agreements. The pledge was registered with the relevant local administration and will remain binding until the VIEs and their Nominee Shareholders discharge all their obligations under the Contractual Arrangements. The registration of the equity pledge enables the WFOEs to enforce the equity pledge against third parties who acquire the equity interests of the VIEs in good faith. One set of existing Contractual Agreements were initially entered into in September 2012 by Shanghai Xincheng (one of the Company’s WOFEs), Shanghai Guangcheng (one of the Company’s VIEs) and its nominee shareholders, was subsequently amended and restated on substantially similar terms in September 2017, October 2019 and August 2020, respectively. The other set of existing Contractual Agreements were entered into in September 2019 by Xingmu WFOE (one of the Company’s WOFEs), Nanjing Xingmu (one of the Company’s VIEs) and its Nominee Shareholders. The Loan Agreements, Exclusive Option Agreements, Proxy Agreement and Power of Attorney, Exclusive Consultation and Service Agreements, Intellectual Property License Agreements and Equity Interest Pledge Agreements were amended to reflect the changes of shareholders’ holding in the VIE in their respective dates. No other material terms or conditions of these agreements were changed or altered. There was no impact to the Group’s effective control over the VIEs and the Group continues to consolidate the VIEs. (c) Risks in relations to the VIE structure Under the Contractual Agreements with the consolidated VIEs, the Company has the power to direct activities of the consolidated VIEs and VIEs’ subsidiaries through the Company’s relevant PRC subsidiaries, and can have assets transferred freely out of the consolidated VIEs and VIEs’ subsidiaries without restrictions. Therefore, the Company considers that there is no asset of the consolidated VIEs that can only be used to settle obligations of the respective consolidated VIEs, except for the registered capital of the consolidated VIEs amounting to RMB52 million and RMB52 million as of March 31, 2020 and 2021. Since the consolidated VIEs and VIEs’ subsidiaries are incorporated as limited liability companies under the PRC Law, creditors of the consolidated VIEs and VIEs’ subsidiaries do not have recourse to the general credit of the Company. The Company believes that the Company’s relevant PRC subsidiaries’ Contractual Arrangements with the consolidated VIEs and the Nominee Shareholders are in compliance with PRC laws and regulations, as applicable, and are legally binding and enforceable. However, uncertainties in the PRC legal system could limit the Company’s ability to enforce these contractual arrangements. In addition, if the current structure or any of the contractual arrangements were found to be in violation of any existing or future PRC law, the Company may be subject to penalties, which may include but not be limited to, the cancellation or revocation of the Company’s business and operating licenses, being required to restructure the Company’s operations or terminate the Company’s operating activities. The imposition of any of these or other penalties may result in a material and adverse effect on the Company’s ability to conduct its operations. In such case, the Company may not be able to operate or control the VIEs, which may result in deconsolidation of the VIEs. The following table set forth the assets, liabilities, results of operations and changes in cash, cash equivalents and restricted cash of the consolidated VIEs and their subsidiaries taken as a whole, which were included in the Company’s consolidated financial statements with intercompany transactions eliminated (RMB in thousands): As of March 31, 2020 2021 RMB RMB Cash and cash equivalents 36,977 17,886 Accounts receivable, net 36,682 63,331 Amounts due from related parties 4,752 11,466 Inventories, net 38,400 11,349 Prepayments and other current assets 47,215 45,098 Property and equipment, net 4,933 8,372 Intangible assets 1,315 909 Operating lease right-of-use 13,565 27,736 Goodwill 494 494 Long-term investments 73,432 74,330 Other non-current 1,004 2,433 Total assets 258,769 263,404 As of March 31, 2020 2021 RMB RMB Short-term borrowings 2,761 3,484 Accounts payable 331,760 439,879 Amounts due to related parties, current 45 910 Salary and welfare payable 3,789 4,851 Accrued liabilities and other current liabilities 116,516 225,709 Contract liabilities 7,621 3,706 Operating lease liabilities, current 6,652 6,058 Deferred tax liabilities 2,593 1,852 Operating lease liabilities, non-current 5,375 19,997 Long-term 982 872 Other debts, non-current 147,774 415,122 Amounts due to related parties, non-current 10,450 — Total liabilities 636,318 1,122,440 Year Ended March 31, 2019 2020 2021 RMB RMB RMB Total revenues 761,121 672,093 783,892 Cost of revenues (557,275 ) (509,168 ) (670,319 ) Net loss 150,002 61,805 166,502 Net cash used in operating activities (108,063 ) 22,099 88,703 Net cash used in investing activities (12,722 ) (43,435 ) (37,214 ) Net cash provided by financing activities 118,070 44,228 (70,434 ) Effects of foreign exchange rate changes on cash and cash equivalents 3,826 (8,268 ) (146 ) Net increase in cash and cash equivalents 1,111 14,624 (19,091 ) Cash and cash equivalents at beginning of the year 21,242 22,353 36,977 Cash and cash equivalents at end of the year 22,353 36,977 17,886

Principal Accounting Policies

Principal Accounting Policies	12 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Principal Accounting Policies	2. Principal Accounting Policies (a) Basis of preparation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). Significant accounting policies followed by the Company in the preparation of the accompanying consolidated financial statements are summarized below. (b) Basis of consolidation The Company’s consolidated financial statements include the financial statements of the Company, its subsidiaries, the consolidated VIEs and VIEs’ subsidiaries for which the Company is the primary beneficiary. A subsidiary is an entity in which the Company, directly or indirectly, controls more than one half of the voting power, has the power to appoint or remove the majority of the members of the board of directors, to cast a majority of votes at the meeting of the board of directors or to govern the financial and operating policies of the investee under a statute or agreement among the shareholders or equity holders. A consolidated VIE is an entity in which the Company, or its subsidiaries, through Contractual Agreements, bears the risks of, and enjoys the rewards normally associated with, ownership of the entity, and therefore the Company or its subsidiaries are the primary beneficiary of the entity. All transactions and balances among the Company, its subsidiaries, the consolidated VIEs and VIEs’ subsidiaries have been eliminated upon consolidation. (c) Business combination and non-controlling The Company accounts for its business combinations using the acquisition method of accounting in accordance with Accounting Standards Codification (“ASC”) 805, Business Combinations non-controlling non-controlling In a business combination achieved in stages, the Company re-measures re-measurement When there is a change in ownership interests or a change in contractual arrangements that results in a loss of control of a subsidiary or consolidated VIE, the Company deconsolidates the subsidiary or consolidated VIE from the date control is lost. Any retained non-controlling For the Company’s consolidated subsidiaries, VIEs and VIEs’ subsidiaries, non-controlling Non-controlling (d) Use of estimates The preparation of the Company’s consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company believes that revenue recognition, sales returns, sales incentive, rebates, valuation of deferred tax assets, assessment for useful life and impairment of long-lived assets, allowance for doubtful accounts, valuation of available-for-sale Management bases the estimates on historical experience and on various other assumptions as discussed elsewhere to the consolidated financial statements that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. On an ongoing basis, management evaluates its estimates based on information that is currently available. Changes in circumstances, facts and experience may cause the Company to revise its estimates. Changes in estimates are recorded in the period in which they become known. Actual results could materially differ from these estimates. (e) Functional currency and foreign currency translation The Company’s reporting currency is Renminbi (“RMB”). The functional currency of the Company’s entities incorporated in Cayman Islands, British Virgin Islands and Hong Kong is the United States dollars (“US$”). The Company’s PRC subsidiaries, consolidated VIEs and VIEs’ subsidiaries determined their functional currency to be RMB. The determination of the respective functional currency is based on the criteria of ASC 830, Foreign Currency Matters Transactions denominated in other than the functional currencies are translated into the functional currency of the entity at the exchange rates prevailing on the transaction dates. Financial assets and liabilities denominated in other than the functional currency are translated at the balance sheet date exchange rate. The resulting exchange differences are included in the consolidated statements of comprehensive loss as foreign exchange related gains (losses), net. The financial statements of the Company are translated from the functional currency into RMB. Assets and liabilities denominated in foreign currencies are translated into RMB using the applicable exchange rates at the balance sheet date. Equity accounts other than earnings generated in current period are translated into RMB at the appropriate historical rates. Revenues, expenses, gains and losses are translated into RMB using the periodic average exchange rates. The resulting foreign currency translation adjustments are recorded in accumulated other comprehensive income (loss) as a component of shareholders’ equity. The exchange rates used for translation on March 31, 2020 and 2021 were US$1.00= RMB 7.0851 and RMB 6.5713, respectively, representing the index rates stipulated by the People’s Bank of China. (f) Convenience translation Translations of the consolidated balance sheets, the consolidated statements of comprehensive loss and the consolidated statements of cash flows from RMB into US$ as of and for the year ended March 31, 2021 are solely for the convenience of the readers and were calculated at the rate of US$1.00=RMB 6.5518, representing the certificated exchange rate published by the Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate on March 31, 2021, or at any other rate. (g) Fair value of financial instruments Accounting guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability. The established fair value hierarchy requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The three levels of inputs that may be used to measure fair value: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Observable, market-based inputs, other than quoted prices, in active markets for identical assets or liabilities. Level 3: Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. Accounting guidance also describes three main approaches to measuring the fair value of assets and liabilities: (1) market approach; (2) income approach and (3) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset. Financial assets and liabilities of the Company mainly consist of cash and cash equivalents, restricted cash, accounts receivable, amounts due from related parties, prepayments and other current assets, available-for-sale As of March 31, 2020 and 2021, except for available-for-sale non-current available-for-sale (h) Cash and cash equivalents Cash and cash equivalents include cash on hand and time deposits placed with banks and third party payment processors, which are unrestricted as to withdrawal or use, have original maturities of three months or less at the time of purchase and are readily convertible to known amounts of cash. (i) Short-term investments Short-term investments comprise primarily of (i) cash deposits at fixed rates with original maturities of greater than three months, but less than 12 months and; (ii) the investments issued by commercial banks or other financial institutions with a variable interest rate indexed to the performance of underlying assets within one year. As of March 31, 2021, RMB118.5 million short-term investments were used as collateral of RMB105.9 million short-term and long-term borrowings. (j) Accounts receivable, net Accounts receivable are presented net of allowance for doubtful accounts. The Company maintains an allowance for doubtful accounts which reflects its best estimate of amounts that potentially will not be collected. The Company determines the allowance for doubtful accounts on general basis taking into consideration various factors including but not limited to historical collection experience and credit-worthiness of the customers as well as the age of the individual receivables balance. Additionally, the Company makes specific bad debt provisions based on any specific knowledge the Company has acquired that might indicate that an account is uncollectible. The facts and circumstances of each account may require the Company to use substantial judgment in assessing its collectability. (k) Inventories Inventories are stated at the lower of cost and net realizable value. Cost elements of our inventories comprise the purchase price of products, vendor rebates, shipping charges to receive products from the suppliers when they are embedded in the purchase price. Cost is determined using the first-in first-out (l) Property and equipment, net Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the following estimated useful lives. The estimated useful lives are as follows: Useful years Warehouse equipment 3 - 5 years Furniture, computer and office equipment 3 - 5 years Vehicles 5 years Software 10 years Leasehold improvements Over the shorter of the expected life of leasehold improvements or the lease term Expenditures for maintenance and repairs are expensed as incurred. The gain or loss on the disposal of property and equipment is the difference between the net sales proceeds and the carrying amount of the relevant assets and is recognized in the consolidated statements of comprehensive loss. (m) Intangible assets, net Intangible assets purchased from third parties are initially recorded at cost. The Company performs valuation of the intangible assets arising from business combination to determine the relative fair value to be assigned to each asset acquired. The intangible assets are amortized using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of intangible assets are as follows: Useful years Trademark 10 years Dealership 10 years License 4.5 - 10 years The estimated life of amortized intangibles is reassessed if circumstances occur that indicate the life has changed. (n) Goodwill Goodwill represents the excess of the purchase price over the fair value of the identifiable assets and liabilities acquired in a business combination. Goodwill is not depreciated or amortized but is tested for impairment on an annual basis as of March 31, and in between annual tests when an event occurs or circumstances change that could indicate that the asset might be impaired. In accordance with the FASB guidance on “Testing of Goodwill for Impairment”, a company first has the option to assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company decides, as a result of its qualitative assessment, that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test is mandatory. Otherwise, no further testing is required. The quantitative impairment test consists of a comparison of the fair value of each reporting unit with its carrying amount, including goodwill. If the carrying amount of each reporting unit exceeds its fair value, an impairment loss equal to the difference between the implied fair value of the reporting unit’s goodwill and the carrying amount of goodwill will be recorded. Application of a goodwill impairment test requires significant management judgment, including the identification of reporting units, assigning assets and liabilities to reporting units, assigning goodwill to reporting units, and determining the fair value of each reporting unit. The judgment in estimating the fair value of reporting units includes estimating future cash flows, determining appropriate discount rates and making other assumptions. Changes in these estimates and assumptions could materially affect the determination of fair value for each reporting unit. (o) Long-term investments The Company’s investments include equity method investments and available-for-sale The Company applies the equity method of accounting to account for an equity investment, in common stock or in-substance Debt securities that the Company has the intent to hold the security for an indefinite period or may sell the security in response to the changes in economic conditions are classified as available-for-sale The Company continually reviews its investments to determine whether a decline in fair value to below the carrying value is other-than-temporary. The primary factors the Company considers in its determination are the duration and severity of the decline in fair value; the financial condition, operating performance and the prospects of the equity investee; and other company specific information such as recent financing rounds. If the decline in fair value is deemed to be other-than-temporary, the carrying value of the investment is written down to fair value. (p) Impairment of long-lived assets other than goodwill Long-lived assets are evaluated for impairment whenever events or changes in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying amount may not be fully recoverable or that the useful life is shorter than the Company had originally estimated. When these events occur, the Company evaluates the impairment by comparing carrying value of the assets to an estimate of future undiscounted cash flows expected to be generated from the use of the assets and their eventual disposition. If the sum of the expected future undiscounted cash flows is less than the carrying value of the assets, the Company recognizes an impairment loss based on the excess of the carrying value of the assets over the fair value of the assets. (q) Revenue recognition In May 2014, the FASB issued ASU No. 2014-09, 2014-09”) 2014-09 No. 2014-09 The Company adopted ASC 606 for all periods presented. Consistent with the criteria of Topic 606, the Company follows five steps for its revenue recognition: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Revenue arrangements with multiple performance obligations are divided into separate distinct goods or services. The Company allocates the transaction price to each performance obligation based on the relative standalone selling price of the goods or services provided. The Company’s revenues are primarily derived from (i) product sales and (ii) online marketing and information services and other service. When either party to a contract has performed, the Company presents the contract in the statement of financial position as a contract asset or a contract liabilities, depending on the relationship between the entity’s performance and the customer’s payment. A receivable is recorded when the Company has an unconditional right to consideration. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due. A contract asset is recorded when the Company has transferred products or services to the customer before payment is received or is due, and the Company’s right to consideration is conditional on future performance or other factors in the contract. No contract asset was recorded as of March 31, 2020 and 2021. The Company’s contract liabilities consist of payments received or awards to customers (in the form of Boqii Beans) related to unsatisfied performance obligations at the end of the period. As of April 1, 2019 and 2020, the Company’s total contract liabilities were RMB5.8 million and RMB7.7 million, respectively, of which RMB5.0 million and RMB7.7 million were recognized as revenue for the years ended March 31, 2020 and 2021. The Company’s total unearned revenue was RMB3.9 million as of March 31, 2021. Revenue is recorded net of value-added tax. Revenue recognition policies for each type of revenue steam are as follows: Sales of merchandise The Company primarily sells pet products through online stores to individual online customers. Besides online sales, the Company also sells products through offline channels to its business customers and pet stores across the country. The Company recognizes the product revenues from products sales on a gross basis as the Company is acting as a principal in these transactions. The Company has obtained control of the products before they are transferred to customers. The Company is primarily obligated in these transactions, is subject to inventory risk or has the ability to direct the use of inventory, and has latitude in establishing prices and selecting suppliers. Revenue is recognized when consumers physically accept the products after delivery, which is when the control of products is transferred, and is recorded net of return allowances and rebates to pet stores. The Company also enters into arrangement with its business partners to sell their products on the Company’s online stores. The Company considers the arrangement meet the indicators of consignment arrangement under ASC 606-10-55-80, Online marketing and information services and other revenue The Company provides online marketing and information services to third-party on the Company’s various channels and third-party platforms, including but not limited to advertising placements, organizing online and offline marketing campaigns featuring social media influencers and circulating marketing messages to end consumers. With respect to the Company’s marketing services, length of the periods over which services are provided are generally within months or less, revenue from such arrangements is recognized ratably over the service period, as the third-party simultaneously consumes the benefits when the advertisement is displayed or the campaign is ongoing. The Company also provides warehouse services. The warehouse services include warehousing, packaging, dispatching and other services. Revenue is primarily recognized when the services are rendered. (r) Sales returns The Company offers online consumers an unconditional right of return for a period of seven days upon receipt of products. Return allowances, which reduce revenue and cost of sales, are estimated by categories of return policies offered to online customers, based on historical data the Company has maintained, and subject to adjustments to the extent that actual returns differ or are expected to differ. (s) Sales incentives The Company grants certain units of Boqii Bean, from time to time, to its customers at its discretion in different situations. Boqii Beans are not redeemable for cash and can be used as a coupon for the customer’s future purchase on the Boqii Marketplace and Boqii.com. The value of ten units of Boqii Bean is equivalent to one RMB yuan before taking into account the impact of breakage. For the Boqii Beans that are granted with concurrent revenue transactions, the allocated transaction price based on its relative standalone selling price are recognized as reduction of the revenue and accrued for as contract liabilities. As customers redeem awards, the accrued liability is reduced correspondingly. For the Boqii Beans that are granted without concurrent revenue transactions, they are not accounted for when granted and are recognized as a reduction of revenue when they are applied in future sales. The Company also has a coupon program, through which the Company grants coupons to online customers when they make a successful purchase order, finish first registration on Boqii Marketplace or comment on products. When the coupon is granted concurrent with a revenue transaction, the Company accounts for the estimated cost of future usage of coupons as reduction of the revenue. When the coupon is not granted concurrent with a revenue transaction, they are not accounted for when they are granted and are recognized as a reduction of revenue when they are applied in future sales. (t) Cost of revenue Cost of revenue consist of cost of product sales of RMB599.2 million, RMB610.6 million and RMB820.3 million for the years ended March 31, 2019, 2020 and 2021, respectively, and cost of services of RMB0.3 million, RMB0.9 million and RMB3.4 million for the years ended March 31, 2019, 2020 and 2021, respectively. Cost of product sales comprise the purchase price of products, vendor rebates and inventory write-downs. Cost of products does not include other direct costs related to cost of product sales such as shipping and handling expense, payroll and benefits of logistic staff, logistic centers rental expenses and depreciation expenses. Cost of service consists of the advertising and promotion costs, employee wages and benefits in connection with the Company’s provision of marketing and information services including the fees that the Company paid to third party for advertising and promotion on various online and offline channels. (u) Vendor rebates The Company periodically receives consideration from certain vendors, representing rebates for products sold over a period of time. The Company accounts for the rebates received from its vendors as a reduction to the price it pays for the products purchased. Rebates are earned based on reaching minimum purchased thresholds for a specified period. When volume rebates can be reasonably estimated based on the Company’s past experience, current forecasts and purchase volume, a portion of the rebate is recognized as the Company makes progress towards the purchase threshold. (v) Fulfillment expenses Fulfillment costs primarily represent warehousing, shipping and handling expenses for dispatching and delivering products to consumers, employee wages and benefits for the relevant personnel, customs clearance expenses and other related transaction costs. (w) Sales and marketing expenses Sales and marketing expenses comprise primarily of advertising expenses, third-party platforms commission fee, employee wages, rental expenses and benefits for sales and marketing staff, depreciation expenses and other daily expenses which are related to the sales and marketing functions. Advertising expenses consist primarily of customer acquisition cost and costs for the promotion of corporate image and product marketing. The Company expenses all advertising costs as incurred and classifies these costs under sales and marketing expenses. For the years ended March 31, 2019, 2020 and 2021, the advertising expenses were RMB95.9 million, RMB69 million and RMB83 million, respectively. (x) General and administrative expenses General and administrative expenses consist of employee wages and benefits for corporate employees, research and development expenses and other expenses which are related to the general corporate functions, including accounting, finance, tax, legal and human resources, costs associated with use by these functions of facilities and equipment, such as depreciation expenses, rental and other general corporate related expenses. (y) Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use non-current ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate, which it calculates based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. The Company has elected to early adopt the following lease policies in conjunction with the adoption of ASU 2016-02 non-lease non-lease (z) Government grant The Company’s PRC based subsidiaries received government subsidies from certain local governments. The Company’s government subsidies consisted of specific subsidies and other subsidies. Specific subsidies are subsidies that the local government has provided for a specific purpose, such as product development and renewal of production facilities. Other subsidies are the subsidies that the local government has not specified its purpose for and are not tied to future trends or performance of the Company; receipt of such subsidy income is not contingent upon any further actions or performance of the Company and the amounts do not have to be refunded under any circumstances. The Company recorded specific purpose subsidies as advances payable when received. For specific subsidies, upon government acceptance of the related project development or asset acquisition, the specific purpose subsidies are recognized to reduce related cost of asset acquisition. Other subsidies are recognized as other income upon receipt as further performance by the Company is not required. (aa) Income taxes Current income taxes are recorded in accordance with the regulations of the relevant tax jurisdiction. The Company accounts for income taxes under the asset and liability method in accordance with ASC 740, Income Tax Uncertain tax positions The Company recognizes in its consolidated financial statements the benefit of a tax position if the tax position is “more likely than not” to prevail based on the facts and technical merits of the position. Tax positions that meet the “more likely than not” recognition threshold are measured at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. The Company estimates its liability for unrecognized tax benefits which are periodically assessed and may be affected by changing interpretations of laws, rulings by tax authorities, changes and/or developments with respect to tax audits, and expiration of the statute of limitations. The ultimate outcome for a particular tax position may not be determined with certainty prior to the conclusion of a tax audit and, in some cases, appeal or litigation process. The actual benefits ultimately realized may differ from the Company’s estimates. As each audit is concluded, adjustments, if any, are recorded in the Company’s consolidated financial statements in the period in which the audit is concluded. Additionally, in future periods, changes in facts, circumstances and new information may require the Company to adjust the recognition and measurement estimates with regard to individual tax positions. Changes in recognition and measurement estimates are recognized in the period in which the changes occur. As of March 31, 2020 and 2021, the Company did not have any significant unrecognized uncertain tax positions. (ab) Share-based compensation The Company follows ASC 718 to determine whether a share option should be classified and accounted for as a liability award or equity award. All grants of share-based awards to employees, management and nonemployees classified as equity awards are recognized in the financial statements based on their grant date fair values which are calculated using an option pricing model. Employees’ share-based compensation awards are measured at the grant date fair value of the awards and recognized as expenses (a) immediately at the grant date if no vesting conditions are required; or (b) for share-based awards granted with only service conditions, using the graded vesting method, net of estimated forfeitures, over the vesting period; or (c) for share-based awards granted with service conditions and the occurrence of an initial public offering (“IPO”) as performance condition, cumulative share-based compensation expenses for the options that have satisfied the service condition should be recorded upon the completion of the IPO, using the graded vesting method. Under ASC 718, the Company applies the Binominal option pricing model in determining the fair value of options granted. ASC 718 requires forfeiture rates to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. Share-based compensation expense is recorded net of estimated forfeitures such that expense is recorded only for those share-based awards that are expected to vest. (ac) Net loss per share Basic net loss per share is computed by dividing net loss attributable to holders of ordinary shares by the weighted average number of ordinary shares outstanding during the year using the two class method. Using the two class method, net profit/loss is allocated between ordinary shares and other participating securities (i.e. preferred shares) based on their participating rights. Diluted loss per share is calculated by dividing net loss attributable to ordinary shareholders as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalents shares outstanding during the year/period. Ordinary share equivalents consist of the ordinary shares issuable in connection with the Company’s convertible redeemable preferred shares using the if-converted (ad) Comprehensive loss Comprehensive loss is defined as the changes in shareholders’ deficit of the Company during a period transactions and other events and circumstances excluding transactions resulting from investments from shareholders, distributions to shareholders, accretions on convertible redeemable preferred shares and modification and extinguishment of convertible redeemable preferred shares. Comprehensive loss for the periods presented includes net loss and foreign currency translation adjustments. (ae) Segment reporting ASC 280, Segment Reporting Based on the criteria established by ASC 280, the Company’s chief operating decision maker (“CODM”) has been identified as the Chief Executive Officer, who reviews consolidated results when making decisions about allocating resources and assessing performance of the Company. As a whole and hence, the Company has only one reportable segment. The Company does not distinguish between markets or segments for the purpose of internal reporting. As the Company’s long-lived assets are substantially located in the PRC and substantially all the Company’s revenue are derived from within the PRC, no geographical segments are presented. (af) Recent accounting pronouncements The Company qualifies as an “emerging growth company”, or EGC, pursuant to the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. As an EGC, the Company does not need to comply with any new or revised financial accounting standards until such date that a private company is otherwise required to comply with such new or revised accounting standard

Business combinations

Business combinations	12 Months Ended
	Mar. 31, 2021
Business Combinations [Abstract]
Business combinations	3. Business combinations For the years ended March 31, 2019 and 2020, the Company has completed the below business combinations. The results of the acquired entities’ operations have been included in the Company’s consolidated financial statements since their respective dates of acquisition. (a) Nanjing Cuida Biotechnology Co. Ltd. (Cuida) Cuida is a company incorporated in Nanjing, the PRC and engages in selling veterinary drugs to offline pet stores and pet hospitals. On December 18, 2018, the Company acquired 70% equity interest of Cuida with total cash consideration of RMB6 million. The results of Cuida have been included in the consolidated financial statements of the Company since the acquisition date of December 18, 2018. As of March 31, 2019, the total unpaid cash consideration was RMB5.1 million, which was subsequently paid in March 2020. On the acquisition date, the allocation of the purchase price of the assets acquired and liabilities assumed based on their fair values was as follows. Fair value of the noncontrolling interests was estimated based on the equity value of Cuida derived by the discounted cash flow method after further considering a discount for lack of control: As of December 18, 2018 RMB Cash and cash equivalents 36 Accounts receivable, net 15 Inventory 783 Prepayments and other current assets 5,693 Amortizable intangible assets License 1,773 Total assets 8,300 Salary and welfare payable (4 ) Accrued liabilities and other current liabilities (246 ) Deferred tax liabilities (443 ) Total liabilities (693 ) Net assets acquired 7,607 Goodwill 494 Non-controlling (2,101 ) Total 6,000 As of December 18, 2018 RMB Total purchase price is comprised of: - cash consideration 6,000 The identifiable intangible asset is veterinary drugs license, which is amortized on a straight-line basis over 4.5 years. The acquired business contributed revenues of RMB1 million and losses of RMB0.08 million to the Company for the period from December 18, 2018 to March 31, 2019. The pro forma operating results for the Company, assuming the acquisition of Cuida occurred on April 1, 2017, represents the pro forma impact from April 1, 2017 to December 17, 2018. Year Ended March 31, 2019 RMB Net revenues 804,175 Net loss (231,712 ) (b) Xingmu Holding Limited (“Xingmu”, together with its subsidiaries and VIE, (“Xingmu Group”)) In August 2018, the Company acquired 14.5% equity interest of Nanjing Xingmu Biotechnology Co., Ltd. (“Nanjing Xingmu”), an offline veterinary drugs trading company incorporated in the PRC. The total purchase consideration was RMB10 million. According to the investment agreement, the Company was entitled to appoint a director to Nanjing Xingmu (out of total three board seats). The Company accounted this investment using equity method. In November 2019, Nanjing Xingmu’s then shareholders set up an overseas investment holding structure by establishing overseas holding companies and a PRC wholly owned subsidiary and entering into a series of contractual arrangements, through which Nanjing Xingmu became a consolidated VIE of Xingmu, an investment holding company incorporated in Cayman Islands (the “Reorganization”). In connection with the Reorganization, the Company acquired 51% equity interest of Xingmu by issuing 461,513 Series E convertible redeemable preferred shares of the Company and surrendering the Company’s previously held 14.5% equity interest in Nanjing Xingmu. After the transaction, the Company obtained control of Xingmu Group which consolidates Nanjing Xingmu. The Company accounted for this transaction as a step acquisition with the total purchase consideration of RMB44.1 million, which included the fair value of RMB33.4 million of the Company’s Series E convertible redeemable preferred shares issued, and the fair value of the previously held 14.5% equity interest of Nanjing Xingmu in an amount of RMB10.6 million. A gain of RMB0.5 million in relation to the revaluation of the previously held equity interests was recorded in other gains (losses), net in the consolidated statement of comprehensive loss for the year ended March 31, 2020. The fair value of the previously held equity interests was estimated based on the equity value of Nanjing Xingmu derived by the discounted cash flow method after further considering a discount for lack of control. On the acquisition date of November 1, 2019, the allocation of the purchase price of the assets acquired and liabilities assumed based on their fair values was as follows. Fair value of the noncontrolling interests was estimated based on the equity value of Xingmu Group derived by the discounted cash flow method after further considering a discount for lack of control: As of November 1, 2019 RMB Cash and cash equivalents 1,783 Accounts receivable, net 3,273 Inventory 9,445 Prepayments and other current assets 6,092 Property and equipment, net 91 Long-term investments 2,502 Amortizable intangible assets License 1,756 Dealership 31,717 Total assets 56,659 Short-term borrowings (2,200 ) Accounts payable (1,561 ) Salary and welfare payable (159 ) Accrued liabilities and other current liabilities (3,970 ) Deferred tax liabilities (8,368 ) Total liabilities (16,258 ) Net assets acquired 40,401 Goodwill 39,690 Non-controlling (36,023 ) Total 44,068 As of November 1, 2019 RMB Total purchase price is comprised of: - fair value of 14.5% previously held equity interests 10,628 - fair value of the Company’s Series E convertible redeemable preferred shares to achieve control 33,440 Fair value of total consideration 44,068 The intangible assets primarily consist of veterinary drugs license and dealership, which are amortized on a straight-line basis over 4.5 years and 10 years, respectively. The acquired business contributed revenues of RMB30.9 million and earnings of RMB2.0 million to the Company for the period from November 1, 2019 to March 31, 2020. The pro forma operating results for the Company, assuming the acquisition of Xingmu occurred on April 1, 2018 is as follows: Year Ended March 31, 2019 Year Ended March 31, 2020 RMB RMB Net revenues 850,932 802,249 Net loss (230,451 ) (176,070 )

Risks and Concentration

Risks and Concentration	12 Months Ended
	Mar. 31, 2021
Risks and Uncertainties [Abstract]
Risks and Concentration	4. Risks and Concentration (a) Foreign currency exchange rate risk In July 2005, the PRC government changed its decades-old (b) Interest rate risk Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company’s interest rate risk arises primarily from long-term borrowings. Borrowings issued at variable rates and fixed rates expose the Company to cash flow interest rate risk and fair value interest rate risk respectively. (c) Concentration of credit risk Financial instruments that potentially subject the Company to the concentration of credit risks consist of cash and cash equivalents, restricted cash, accounts receivable and amounts due from related parties. The maximum exposures of such assets to credit risk is their carrying amounts as of the balance sheet dates. The Company deposits its cash and cash equivalents and restricted cash with financial institutions located in jurisdictions where the subsidiaries are located. The Company believes that no significant credit risk exists as these financial institutions have high credit quality. Accounts receivable are typically unsecured and are derived from revenue earned through third-party consumers. The Company conducts credit evaluations of third-party customers and related parties, and generally does not require collateral or other security from its third-party customers and related parties. The Company establishes an allowance for doubtful accounts primarily based upon the age of the receivables and factors surrounding the credit risk of specific third-party customers and related parties. (d) Concentration of customers and suppliers Substantially all revenue was derived from customers located in China. There are no customers from whom revenues individually represent greater than 10% of the total revenues of the Company in any of the periods presented. For the year ended March 31, 2020, Royal Canin China Co., Ltd. and Boehringer Ingelheim Animal Health (Shanghai) Co., Ltd. contributed 24% and 14% of total purchases of the Company, respectively . For the year ended March 31, 2021, Royal Canin China Co., Ltd. and Boehringer Ingelheim Animal Health (Shanghai) Co., Ltd. contributed 19% and 7% of total purchases of the Company, respectively. The following table summarizes the supplier with greater than 10% of the accounts payable of the Company: Year Ended March 31, 2019 Year Ended March 31, 2020 Year Ended March 31, 2021 RMB RMB RMB Royal Canin China Co., Ltd. 14,320 13,331 15,616

Cash and cash equivalents

Cash and cash equivalents	12 Months Ended
	Mar. 31, 2021
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	5. Cash and cash equivalents Cash and cash equivalents represent cash on hand and demand deposits placed with banks and third party-payment processors, which are unrestricted as to withdrawal or use. Cash and cash equivalents balance as of March 31, 2020 and March 31, 2021 primarily consist of the following currencies: As of March 31, 2020 As of March 31, 2021 Amount RMB Amount RMB RMB 83,844 83,844 121,670 121,670 Hong Kong dollars 15 13 25 21 US$ 635 4,495 25,947 170,508 EUR — — 5 38 Total 88,352 292,237

Accounts receivable, net

Accounts receivable, net	12 Months Ended
	Mar. 31, 2021
Receivables [Abstract]
Accounts receivable, net	6. Accounts receivable, net Accounts receivable consist of the following : As of March 31, As of March 31, RMB RMB Accounts receivable - Product sales 44,558 37,429 Accounts receivable - Online marketing and information service and other service 785 8,559 Allowance of doubtful accounts (363 ) (256 ) Total 44,980 45,732 Movement of allowance of doubtful accounts As of March 31, As of March 31, As of March 31, RMB RMB RMB At beginning of year — 92 363 Addition/(reversal) 92 271 (107 ) At end of year 92 363 256

Inventories, net of inventory r

Inventories, net of inventory reserves	12 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Inventories, net of inventory reserves	7. Inventories, net of inventory reserves Inventories, net of inventory reserves consist of the following : As of March 31, As of March 31, RMB RMB Products 62,249 90,913 Packaging materials and others 807 638 Total inventories, net of inventory reserves 63,056 91,551

Prepayments and other current a

Prepayments and other current assets	12 Months Ended
	Mar. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepayments and other current assets	8. Prepayments and other current assets The prepayments and other current assets consist of the following: As of March 31, As of March 31, RMB RMB Loans receivable (a) 35,082 3,957 Prepayments for purchases of products (b) 16,152 53,209 Vendor rebate receivables (c) 10,486 8,723 Value-added tax (“VAT”) deductible (d) 9,818 10,672 Sales return assets 1,157 1,244 Deposits 774 1,456 Others 3,251 6,000 Total 76,720 85,261 (a) The balance represents loans receivable due from third parties. In January 2020, the Company entered into a four-month loan agreement with a third-party company for a principal amount of RMB1.0 million, bearing an interest rate of 6% per annum and the loan was repaid in May 2020. In May 2019, the Company entered into a four-month loan agreement with a third-party company for a principal amount of US$1.5 million (RMB10.8 million), bearing an interest rate of 5% per annum. In September 2019, the Company and the borrower agreed to extend the loan agreement for another eight months. In May 2019, the Company entered into an interest free loan agreement with one of its previously preferred shareholders for a principal amount of US$1.4 million (RMB9.8 million) with a term of 730 days, which was subsequently amended to 600 days on December 5, 2019, and the maturity date of the loan was shortened to December 2020. The Company accounted for the loan receivable by using effective interest rate method and difference of RMB0.2 million between the discounted present value of the loan receivable and the cash amount lent out was recorded as interest income loss for the year end March 31, 2020. The loan was early repaid in July, 2020. In June 2020, the Company entered into another interest free loan agreement with the shareholder for a principal amount of US$4.85 million (RMB33.0 million) with a term of three months. In February 2021, the Company entered into a share repurchase agreement with the shareholder. The Company repurchased and cancelled 521,924 shares of Class A ordinary shares held by the shareholder with a consideration amounting to the loan principal of US$4.85 million. In December 2018, the Company entered into an interest free facility loan agreement with a third-party company for a total loan facility up to RMB20 million with a term of 12 months. As of March 31, 2020 and 2021, the principal amount outstanding under this agreement was RMB11.4 million and RMB0.6 million, respectively. The loan was repaid in June 2021. In December 2018, the Company entered into a two-year In December 2018, the Company entered into a two-year In July 2020, the Company entered into a one-year In September 2020, the Company entered into a one-year From November 2020 to February 2021, the Company has entered into six one-year (b) Prepayments for purchases of products represent cash prepaid to the Company’s third party brand partners for the procurement of products. (c) Vendor rebate receivables represent the rebates to be received by the Company from its suppliers after certain levels of purchases are achieved. (d) VAT recoverable represents the balances that the Company can utilize to deduct its value-added tax liabilities within the next 12 months.

Property and equipment, net

Property and equipment, net	12 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Property and equipment, net	9. Property and equipment, net Property and equipment consist of the following: As of March 31, As of March 31, RMB RMB Cost: Warehouse equipment 2,426 2,513 Furniture, computer and office equipment 5,864 6,592 Vehicles 1,912 2,891 Leasehold improvement 5,555 10,056 Software 2,695 2,709 Total cost 18,452 24,761 Less: Accumulated depreciation (13,471 ) (16,375 ) Property and equipment, net 4,981 8,386 The total amounts charged to the consolidated statements of comprehensive loss for depreciation and amortization expenses amounted to approximately RMB3.00 million, RMB2.66 million and RMB3.08 million for the years ended March 31, 2019, 2020 and 2021, respectively.

Intangible assets, net

Intangible assets, net	12 Months Ended
	Mar. 31, 2021
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Intangible assets, net	10. Intangible assets, net Intangible assets of the Company were mainly as follows: As of March 31, As of March 31, RMB RMB Cost: Trademark 447 447 License (Note 3) 3,530 3,530 Dealership (Note 3) 31,717 31,717 Total cost 35,694 35,694 Less: Accumulated amortization (2,156 ) (6,157 ) Intangible assets, net 33,538 29,537 License and dealership resulting from the business combinations (Note 3) completed during the years ended March 31, 2019 and 2020 have been allocated to the single reporting unit of the Company. The total amount of intangible assets resulting from the business combinations were RMB33.47 million and RMB29.28 million as of March 31, 2020 and 2021, respectively. The total amortization expenses charged to the consolidated statements of comprehensive loss amounted to approximately RMB0.18 million, RMB1.92 million and RMB4.00 million for the years ended March 31, 2019, 2020 and 2021, respectively. The annual estimated amortization expense for intangible assets subject to amortization for the succeeding five years is as follows: As of March 31, 2022 2023 2024 2025 2026 Amortization expenses 4,001 4,001 3,770 3,342 3,209

Long-Term Investments

Long-Term Investments	12 Months Ended
	Mar. 31, 2021
Long-term Investments and Receivables, Net [Abstract]
Long-term investments	11. Long-term investments The Company’s long-term investments consist of the following: As of March 31, As of March 31, 2020 2021 RMB RMB Equity method investments 3,104 2,973 Available-for-sale 70,328 71,357 Total 73,432 74,330 Equity method investments The Company applies equity method in accounting for its investments in entities in which the Company has the ability to exercise significant influence but does not have control. As of March 31, 2020 and 2021, the carrying value of the equity method investments were RMB3.1 million and RMB3.0 million respectively, the change of which primarily relates to the equity loss recognized. Available-for-sale The following table summarizes the Company’s available-for-sale Cost Gross unrealized gains Gross unrealized losses Fair value Unlisted debt securities 60,000 10,328 — 70,328 The following table summarizes the Company’s available-for-sale Cost Gross unrealized gains Gross unrealized losses Fair value Unlisted debt securities 60,000 11,357 — 71,357 In October 2017, the Company purchased 7.2% shareholding of Qingdao Shuangan Biotechnology Co., Ltd (“Qingdao Shuangan”) with a cash consideration of RMB10 million. According to the investment agreement, the Company is entitled to demand redemption after 48 months from the transaction closing date. As of March 31, 2020 and 2021, based on the valuation results, the Company re-measured In October 2019, the Company purchased 23.64% shareholding of Beijing Petdog Technology Development Co., Ltd. (“Beijing Petdog”) with a cash consideration of RMB50 million. According to the investment agreement, the Company is entitled to demand redemption after 60 months from the transaction closing date. As of March 31, 2020 and 2021, based on the valuation results, the Company re-measured

Goodwill

Goodwill	12 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	12. Goodwill The goodwill of RMB40 million as of March 31, 2020 and 2021 represented the goodwill generated from the acquisition of Cuida and Xingmu (see Note 3). The businesses of Cuida and Xingmu were fully integrated into the Company after those acquisitions. As of March 31, 2020 and 2021, the Company performed a qualitative assessment by evaluating relevant events and circumstances that would affect the Company’s single reporting unit and did not note any indicator that it is more likely than not that the fair value of the Company’s reporting unit is less than its carrying amount, and therefore the Company’s goodwill was not impaired. The changes in the carrying amount of goodwill were as follows: Total RMB Balance as of March 31, 2019 Goodwill 494 Accumulated impairment loss — 494 Transaction during the year Additions (Note 3) 39,690 Balance as of March 31, 2020 Goodwill 40,184 Accumulated impairment loss — 40,184 Transaction during the year Additions — Balance as of March 31, 2021 Goodwill 40,184 Accumulated impairment loss — 40,184

Other non-current Assets

Other non-current Assets	12 Months Ended
	Mar. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other non-current Assets	13. Other non-current As of March 31, As of March 31, 2020 2021 RMB RMB Deposits (a) 3,076 3,767 Long-term loans receivable (b) — 344 Deferred initial public offering related costs 7,943 — 11,019 4,111 (a) Deposits mainly consisted of rental deposits and deposit for online stores operated on third party platforms, which will be collected after one year. (b) In December 2018, the Company entered into a two-year In December 2018, the Company entered into a two-year In October 2020, the Company entered into a two-year

Accrued liabilities and other c

Accrued liabilities and other current liabilities	12 Months Ended
	Mar. 31, 2021
Accrued Liabilities and Other Liabilities [Abstract]
Accrued liabilities and other current liabilities	14. Accrued liabilities and other current liabilities Accrued liabilities and other current liabilities consist of the following: As of March 31, As of March 31, 2020 2021 RMB RMB Logistics expenses payables 18,688 16,594 Accrued advertising expenses 611 228 Advances from customers (a) 7,825 3,534 Refund obligation of sales returns 1,345 1,543 Professional service fee accruals 5,046 3,449 Others 4,368 4,707 Total 37,883 30,055 (a) This balance represented the deposits placed from the Company’s customers for the purchases of the Company’s goods and services, and are refundable upon customer requests.

Leases

Leases	12 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Leases	15. Leases As of March 31, 2020 and 2021, the Company has operating leases recorded on its consolidated balance sheet for certain office spaces and facilities that expire on various dates through 2026. The Company does not plan to cancel the existing lease agreements for its existing facilities prior to their respective expiration dates. When determining the lease term, the Company considers options to extend or terminate the lease when it is reasonably certain that it will exercise or not exercise that option. All of the Company’s leases qualify as operating leases. As of March 31, As of March 31, 2020 2021 RMB RMB Assets Operating lease right-of-use 14,951 29,234 Liabilities Operating lease liabilities, current 7,969 8,063 Operating lease liabilities, non-current 5,375 19,997 Weighted average remaining lease term (years) 1.52 3.70 Weighted average discount rate 5.82 % 6.47 % Information related to operating lease activity during the years ended March 31, 2019, 2020 and 2021 are as follows: Year ended March 31, 2019 Year ended March 31, 2020 Year ended March 31, 2021 RMB RMB RMB Operating lease right-of-use 19,570 10,051 25,970 Operating lease rental expense Amortization of right-of-use 17,919 15,708 11,687 Interest of lease liabilities 1,636 1,353 1,596 19,555 17,061 13,283 Year ended March 31, 2019 Year ended March 31, 2020 Year ended March 31, 2021 RMB RMB RMB Operating lease payments (included in measurement of lease liabilities) 19,284 18,183 12,850 Maturities of lease liabilities were as follows: Year ended March 31, 2021 RMB For the year ending March 31, 2022 11,213 2023 6,589 2024 5,837 2025 6,568 2026 and thereafter 2,949 Total lease payments 33,156 Less: imputed interest (5,096 ) Total 28,060

Interest expense

Interest expense	12 Months Ended
	Mar. 31, 2021
Interest and Debt Expense [Abstract]
Interest expense	16. Interest expense Year ended March 31, 2019 Year ended March 31, 2020 Year ended March 31, 2021 RMB RMB RMB Amortization charges on promissory notes 17,077 56,290 21,611 Interest expense on borrowings 1,453 2,815 6,039 Others 124 163 — Total 18,654 59,268 27,650

Other gains (losses), net

Other gains (losses), net	12 Months Ended
	Mar. 31, 2021
Other Income and Expenses [Abstract]
Other gains (losses), net	17. Other gains (losses), net Year ended March 31, 2019 Year ended March 31, 2020 Year ended March 31, 2021 RMB RMB RMB Gain from the re-measurement — 481 — Foreign exchange losses, net (8,971 ) (3,787 ) (2,867 ) Gain on disposal of other debts (Note 22) — 10,095 6,846 Reimbursement from a depositary bank (a) — — 6,556 Others (843 ) 195 797 (9,814 ) 6,984 11,332 (a) In December 2020, the Company received a reimbursement of US$1.0M (equivalent to RMB6.6 million) from the depository for the establishment and maintenance of the ADS program.

Income taxes

Income taxes	12 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income taxes	18. Income taxes Cayman Islands Under the current tax laws of Cayman Islands, the Company and its subsidiaries incorporated in the Cayman Islands are not subject to tax on income or capital gain. Additionally, the Cayman Islands does not impose a withholding tax on payments of dividends to shareholders. Hong Kong Under the current Hong Kong Inland Revenue Ordinance, the Company’s subsidiaries incorporated in Hong Kong are subject to a two-tiered China On July 25, 2018, Boqii (Shanghai) Information Technology Co., Ltd. (“Shanghai Boqii”) was entitled to be “Software Enterprises”. According to the new CIT Law and relevant regulations, from the year of 2018, the entity could enjoy a tax holiday of 2-year 3-year Shanghai Boqii was also qualified as a “High and New Technology Enterprise (“HNTE”) on August 29, 2019, and is eligible to enjoy a preferential tax rate of 15% from 2019 to 2024 to the extent it has taxable income under the Enterprise Income Tax (“EIT”) Law, as long as it maintains the HNTE qualification and duly conducts relevant EIT filing procedures with the relevant tax authority. Shanghai Boqii can re-apply The Company’s other PRC subsidiaries, VIEs and VIEs’ subsidiaries are subject to the PRC general income tax rate of 25%. Reconciliations of the differences between the income tax expense of the Company and the PRC statutory EIT rate applicable to losses of the consolidated entities are as follows: Year ended March 31, 2019 Year ended March 31, 2020 Year ended March 31, 2021 RMB RMB RMB Loss before income tax (231,758 ) (175,925 ) (193,391 ) Income tax computed at respective applicable tax rate (57,940 ) (43,981 ) (48,348 ) Effect of different tax jurisdiction 25,553 19,507 14,272 Super deduction for research and development expenses (a) (5,969 ) (4,719 ) (2,632 ) Non-deductible 133 138 140 Change in valuation allowance 38,364 29,567 37,439 Total 141 512 871 (a) According to the relevant laws and regulations promulgated by the State Administration of Tax of the PRC effective from 2008 onwards, enterprises engaging in research and development activities are entitled to claim 150% of their qualified research and development expenses so incurred as tax deductible expenses when determining their assessable profits for the year (‘Super Deduction’). The additional deduction of 50% of qualified research and development expenses can only be claimed directly in the annual EIT filing and subject to the approval from the relevant tax authorities. Effective from 2018 onwards, enterprises engaging in research and development activities are entitled to claim 175% of their qualified research and development expenses so incurred as tax deductible expenses. The additional deduction of 75% of qualified research and development expenses can be directly claimed in the annual EIT filing. For the years end March 31, 2019, 2020 and 2021, the super deduction for research and development expenses amounted to RMB5.9 million, RMB4.7 million and RMB2.6 million, respectively. The provisions for income taxes for the years ended March 31, 2019, 2020 and 2021 differ from the amounts computed by applying the EIT primarily due to preferential tax rate enjoyed by certain subsidiaries and VIEs of the Company. The following table sets forth the effect of preferential tax on China operations: Year ended March 31, 2019 Year ended March 31, 2020 Year ended March 31, 2021 RMB RMB RMB Tax holiday effect (4,126 ) (5,471 ) 1,074 Basic and diluted net loss per share effect (0.20 ) (0.25 ) 0.02 Reconciliations between the effective income tax rate and the PRC statutory income tax rate are as follows: Year ended March 31, 2019 Year ended March 31, 2020 Year ended March 31, 2021 RMB RMB RMB PRC statutory income tax rates 25 % 25 % 25 % Effect on tax rates in different tax jurisdiction (11 %) (11 %) (7 %) Super deduction for research and development expenses 3 % 3 % 1 % Non-deductible 0 % 0 % 0 % Change in valuation allowance (17 %) (17 %) (19 %) Total 0 % 0 % 0 % Composition of income tax expense The current and deferred portions of income tax expense included in the consolidated statements of comprehensive loss are as follows: Year ended March 31, 2019 Year ended March 31, 2020 Year ended March 31, 2021 RMB RMB RMB Current income tax expense — 149 1,018 Deferred tax expense (141 ) (661 ) (1,889 ) Income tax credit, net (141 ) (512 ) (871 ) Deferred tax assets and deferred tax liabilities Deferred taxes were measured using the enacted tax rates for the periods in which they are expected to be reversed. The tax effects of temporary differences that give rise to the deferred tax asset and liabilities balances as of March 31, 2020 and 2021 are as follows: As of March 31, As of March 31, 2020 2021 RMB RMB Deferred tax assets: Net accumulated loss-carry forward 106,320 143,426 Deferred deductible advertising expense 1,780 940 Allowance 159 130 Contract liabilities 1,821 413 Accruals 2,459 5,069 Less: Valuation allowance (112,539 ) (149,978 ) Net deferred tax assets — — As of March 31, As of March 31, 2020 2021 RMB RMB Deferred tax liabilities: Recognition of intangible assets arising from asset acquisition and business combination (8,009 ) (6,119 ) Unrealized fair value change of the available-for-sale (2,582 ) (2,839 ) Net deferred tax liabilities (10,591 ) (8,958 ) As of March 31, 2020 and 2021, the PRC entities of the Company had tax loss carryforwards of approximately RMB425 million and RMB574 million respectively, which can be carried forward to offset taxable income. The carryforwards period for net operating losses under the EIT Law is five years. The net operating loss carry forward of the Company will expire in varying amounts between 2022 and 2026. Other than the expiration, there are no other limitations or restrictions upon the Company’s ability to use these operating loss carryforwards. Valuation allowance is provided against deferred tax assets when the Company determines that it is more likely than not that the deferred tax assets will not be utilized in the future. In making such determination, the Company considered factors including future taxable income exclusive of reversing temporary differences and tax loss carry forwards. If events occur in the future that allow the Company to realize part or all of its deferred income tax, an adjustment to the valuation allowances will result in a decrease in tax expense when those events occur. As of March 31, 2020 and 2021, valuation allowances of RMB112.5 million and RMB150.0 million were provided because it was more likely than not that the Company will not be able to utilize certain tax losses carry forwards and other deferred tax assets generated by its subsidiaries and VIEs. Movement of valuation allowance is as follows: As of March 31, As of March 31, 2020 2021 RMB RMB Beginning balance 82,972 112,539 Change of valuation allowance 29,567 37,439 Ending balance 112,539 149,978

Ordinary Share

Ordinary Share	12 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Ordinary Share	19. Ordinary Share As of March 31, 2020,the Company had 22,238,454 ordinary shares issued and outstanding. As of March 31, 2021, the Company had 54,505,108 Class A ordinary shares and 13,037,729 Class B ordinary shares issued and outstanding, respectively. Initial public offering In October 2020, the Company completed its IPO on the New York Stock Exchange of 7,000,000 American Depositary Shares (“ADS”) (including 1,050,000 ADSs sold upon the full exercise of the underwriters’ over-allotment option) (each representing 0.75 of one Class A ordinary share), for a total ordinary shares offering of 5,250,000 shares at a price of US$10.00 per ADS. The net proceeds raised from the IPO amounted to approximately US$64 million after deducting underwriting discounts and commissions and other offering expenses. Upon the completion of the IPO, all series of redeemable convertible preferred shares of the Company were converted and designated as Class A ordinary shares with a par value of US$0.001 each on a one-for-one one-for-one one-for-one one-for-one In respect of all matters subject to shareholders’ vote, each holder of Class A ordinary share is entitled to one and each holder of Class B ordinary share is entitled to twenty votes. In February 2021, the Company entered into a share repurchase agreement with one of its previously preferred shareholders. The Company repurchased and cancelled 521,924 shares of Class A ordinary shares held by the shareholder with a consideration amounting to US$4.8 million (which is the principal amount of the loan receivable from the shareholder).

Convertible redeemable preferre

Convertible redeemable preferred shares	12 Months Ended
	Mar. 31, 2021
Statement of Stockholders' Equity [Abstract]
Convertible redeemable preferred shares	20. Convertible redeemable preferred shares Series A convertible redeemable preferred shares (“Series A Preferred Shares”) On October 15, 2012, the Company entered into a shares purchase agreement with certain investors, pursuant to which 3,102,000 and 7,238,000 Series A Preferred Shares were issued on November 19, 2012 and April 3, 2013, respectively, for an aggregated consideration of US$11.0 million. The Company incurred issuance costs of RMB1.7 million (US$0.3 million) in connection with this offering. Series B convertible redeemable preferred shares (“Series B Preferred Shares”) On February 7, 2014, the Company entered into a shares purchase agreement with certain investors, pursuant to which 9,067,384 Series B Preferred Shares were issued on February 24, 2014 for an aggregated consideration of US$19.0 million. The Company incurred issuance costs of RMB1.9 million (US$0.3 million) in connection with this offering. Series C convertible redeemable preferred shares (“Series C Preferred Shares”) On May 3, 2015, the Company entered into a shares purchase agreement with certain investors, pursuant to which 5,518,101 Series C Preferred Shares were issued on May 13, 2015 for an aggregated consideration of US$25.5 million. The Company incurred issuance costs of RMB2.7 million (US$0.4 million) in connection with this offering. On July 7, 2015, the Company cancelled 865,585 Series C Preferred Shares previously issued to other investor for not receiving any consideration for these issued shares. Subsequently, on January 7, 2016, the Company re-issued re-issued re-issuance, Series C+ convertible redeemable preferred shares (“Series C+ Preferred Shares”) On January 26, 2016, the Company entered into a shares purchase agreement with certain investors, pursuant to which 552,005 Series C+ Preferred Shares were issued on January 26, 2016 for an aggregated consideration of US$3.8 million. Subsequently, on March 21, 2016, all 552,005 Series C+ Preferred Shares were cancelled as no consideration for these shares were received. On January 26, 2016, the Company issued a warrant to purchase up to 6,734,459 (as adjusted from time to time pursuant to the provisions of this warrant) Series C+ Preferred Shares to an investor at an exercise price equivalent to the conversion price of the Series C+ Preferred Shares in effect at the time of such exercise, amounting to an aggregate purchase price of up to US$46.2 million (the “CMB Warrant”). This warrant was issued in connection with an investment of RMB303.2 million (equivalent to US$46.2 million) made by the investor to one of the Company’s PRC consolidated VIEs, Guangcheng (Shanghai) Information Technology Co., Ltd. (“Guangcheng”), on January 26, 2016 (the “CMB investment”). The investor can convert the investment into Series C+ Preferred Shares of the Company by exercising the warrant. On March 21, 2016, the Company issued a warrant to purchase up to 552,005 (as adjusted from time to time pursuant to the provisions of this warrant) Series C+ Preferred Shares to an investor at an exercise price per share equal to the conversion price of the Series C+ Preferred Shares in effect at the time of the exercise, amounting to an aggregate purchase price of up to US$3.8 million (equivalent to RMB24.9 million). The investor can convert the investment into Series C+ Preferred Shares of the Company by exercising the warrant. The two warrants to purchase Series C+ Preferred Shares described above are collectively referred to as “Series C+ Warrants”. Each of the Series C+ Warrants is embedded in the respective investment instead of freestanding because it was (1) issued in connection with the investments, and (2) not separately exercisable without terminating the investment. The investment is considered to be accounted for as permanent equity because the Company would not be required to return the investment to the investor regardless of whether the warrant is exercised or not. The warrant, as an equity-linked instrument, is clearly and closely related to the investment which is an equity host, and thus does not need to be bifurcated and separately accounted for. Therefore, the combined instrument (investment and warrant) is accounted for as additional paid-in On March 31, 2020, all parties to the CMB Warrant and the CMB Investment entered into an agreement on the settlement of the CMB Warrant and the CMB Investment. According to this agreement: • The investor shall exercise the CMB Warrant at an exercise price of US$6.86 per share for 6,734,459 Series C+ Preferred Shares. • Guangcheng shall repay the CMB Investment to the investor two years after this agreement is signed. • The investor shall pay the exercise price of the CMB Warrant to the Company immediately after receiving the repayment of the CMB Investment from Guangcheng. On August 19, 2020, the CMB Warrant was exercised at an exercise price of US$6.86 per share for 6,734,459 Series C+ Preferred Share. Therefore, the Company recorded Series C+ Preferred Shares at the exercise date fair value amounting to RMB656.4 million and derecognized the permeant equity of CMB Warrant. The difference between the fair value of Series C+ Preferred Shares and the carrying value of the permeant equity was adjusts additional paid-in paid-in Series D convertible redeemable preferred shares (“Series D Preferred Shares”) On September 8, 2017, the Company entered into a shares purchase agreement with certain investors, pursuant to which 1,492,652 and 803,735 Series D Preferred Shares were issued on October 25, 2017 and November 13, 2017, respectively, for an aggregated consideration of US$20.0 million. The Company incurred issuance costs of RMB1.1 million (US$0.2 million) in connection with this offering. On January 30, 2018, the Company issued convertible promissory notes that are convertible into Series D Preferred Shares (“Series D Notes”). On August 3, 2018, the Company issued 229,639 Series D Preferred Shares upon the conversion of the Series D Notes. Series D-1 D-1 On June 19, 2018, the Company entered into a shares purchase agreement with certain investors, pursuant to which 1,089,265 Series D-1 D-1 On August 3, 2018, the Company issued a warrant to purchase up to 1,089,265 Series D-1 D-1 D-1 On March 31, 2020, the Company issued 1,089,265 Series D-1 D-1 Series D-2 D-2 On January 16, 2019, the Company issued a warrant to purchase up to 963,139 Series D-2 D-2 D-2 On January 16, 2019, the Company issued convertible promissory notes (“Series D-2 D-2 D-2 On March 23, 2020, the Company issued 219,664 Series D-2 D-2 D-2 On March 31, 2020, the Company issued 963,139 Series D-2 D-2 Series D-3 D-3 On June 16, 2019, the Company issued a warrant to purchase up to 154,395 Series D-3 D-3 D-3 D-3 D-3 D-3 Series E convertible redeemable preferred shares (“Series E Preferred Shares”) On June 17, 2019, the Company entered into a shares purchase agreement with an investor, pursuant to which 290,555 Series E Preferred Shares were issued on June 24, 2019 for an aggregated consideration of US$3 million. The Company incurred issuance costs of RMB0.1 million (US$ 21,244) in connection with this offering. On November 21, 2019, in connection with the step acquisition of Nanjing Xingmu (see Note 3), the Company issued 461,513 Series E Preferred Shares with a total purchase consideration amounting to US$4.8 million. On February 10, 2020, the Company entered into a shares purchase agreement with an investor, pursuant to which 290,555 Series E Preferred Shares were issued on February 17, 2020 for an aggregated consideration of US$3 million. The consideration is lower than the fair value of the preferred shares as of the date of closing, with the difference of RMB0.4 million being recorded as deemed dividend to Series E preferred shareholders. On March 6, 2020, the Company issued a warrant to purchase up to 205,767 Series E Preferred Shares at an exercise price of US$10.3251 per share (“Series E Warrant” and see Note 22(h)). On June 1, 2020, the Company issued 4,842,587 Series E Preferred Shares to an investor for an aggregated consideration of US$50 million. The consideration is lower than the fair value of the preferred shares as of the date of closing, with the difference of RMB12 million being recorded as deemed dividend to Series E preferred shareholders. The Series A, B, C, C+, D, D-1, D-2, D-3 Conversion rights Each Preferred Share may be converted at any time into ordinary shares at the option of the holders at the then applicable conversion price. The initial conversion ratio is 1:1, subject to adjustment in the event of (i) share splits or combinations, share dividends or distribution, other dividends, recapitalization and similar events, or (ii) issuance of ordinary shares (excluding certain events such as issuance of ordinary shares pursuant to a public offering) at a price per share less than the conversion price in effect immediately prior to such issuance. On May 13, 2015, the conversion prices of Series A and B Preferred Shares were increased from US$1.06 and US$2.10 to US$1.40 and US$2.22, respectively, due to some then-effective conversion price adjustment clauses. Other than these changes, no adjustment to conversion prices of the Preferred Shares issued has occurred so far. Each Preferred Share shall be automatically converted, based on the then applicable conversion price, into ordinary shares immediately upon the closing of an initial public offering of the Company’s ordinary shares with an offering price (net of underwriting commissions and expenses) that implies a market capitalization of the Company immediately prior to such offering of not less than US$800 million, and that results in gross cash proceeds to the Company of at least US$50 million (“Qualified IPO”, the criteria of which have been adjusted a number of times historically). The Company determined that there were no beneficial conversion features (“BCF”) identified for any of the Preferred Shares during any of the periods. In making this determination, the Company compared the fair value of the ordinary shares into which the Preferred Shares are convertible with the respective effective conversion price at the issuance date. In all instances, the effective conversion price was greater than the fair value of the ordinary shares. To the extent a conversion price adjustment occurs, as described above, the Company will reevaluate whether or not BCF should be recognized. Voting rights Each Preferred Share has voting rights equivalent to the number of ordinary shares to which it is convertible at the record date. The Preferred Shares shall vote separately as a class with respect to certain specified matters. Otherwise, the holders of the Preferred Shares and ordinary shares shall vote together as a single class. Dividend rights The holders of the Preferred Shares shall be entitled to receive dividends at the same rate as for the holders of the ordinary shares (calculated on an as converted basis), payable out of funds or assets when and as such funds or assets become legally available therefor on parity with each other and the holders of the Ordinary Shares, when, as, and if declared by the Board of Directors, with preference to Series E Preferred Shares, followed by Series D-3, D-2, D-1, Liquidation preference In the event of any liquidation (including deemed liquidation, such as change in control, etc.), dissolution or winding up of the Company, whether voluntary or involuntary, all assets and funds of the Company legally available for distribution (after satisfaction of all creditors’ claims and claims that may be preferred by law) shall be distributed in the following preference order: (1) Holders of the Series E Preferred Shares shall be entitled to receive a per share amount equal to 110% of the issue price of Series E Preferred Shares, respectively, plus all declared but unpaid dividends. (2) Holders of Series D-3 D-3 (3) Holders of Series D-2 D-2 (4) Holders of the Series D-1 D-1 (5) Holders of the Series D Preferred Shares shall be entitled to receive a per share amount equal to 140% of the issue price of Series D Preferred Shares, plus all declared but unpaid dividends. (6) Holders of the Series C+ Preferred Shares shall be entitled to receive a per share amount equal to 130% of the issue price of Series C+ Preferred Shares, plus all declared but unpaid dividends. (7) Holders of the Series C Preferred Shares shall be entitled to receive a per share amount equal to 140% of the issue price of Series C Preferred Shares, plus all declared but unpaid dividends. (8) Holders of the Series B Preferred Shares shall be entitled to receive a per share amount equal to 180% of the issue price of Series B Preferred Shares, plus all declared but unpaid dividends. (9) Holders of the Series A Preferred Shares shall be entitled to receive a per share amount equal to 180% of the issue price of Series A Preferred Shares, plus all declared but unpaid dividends. After the liquidation amounts of all series of the Preferred Shares have been paid in full, holders of the ordinary shares shall be entitled to receive an amount per share equal to US$0.2882 (as adjusted for any share splits, share dividends, combinations, recapitalizations or similar transactions) plus any declared but unpaid dividends thereon. After the liquidation amounts of all series of the Preferred Shares and ordinary shares have been paid in full, any remaining funds or assets of the Company legally available for distribution to shareholders shall be distributed ratably among the holders of the Preferred Shares, on an as-converted In the event of a deemed liquidation that implies a valuation of the Company of no less than US$653 million, any proceeds resulting from such deemed liquidation shall be distributed ratably among the holders of the Preferred Shares, on an as-converted Redemption right The Company shall redeem all or a portion of the Preferred Shares, at the option of the holders, if the Company triggers any redemption events. One redemption event is that the holders could redeem all or portion of the Preferred Shares, at the option of the holders, after the 5th anniversary of the issuance date of Series E Preferred Shares (“Optional Redemption Date”) if the Company has not achieved a Qualified IPO on or before the Optional Redemption Date. The Optional Redemption Date has been amended for a number of times historically. The price at which each Preferred Share shall be redeemed are summarized as follows: • Series A and B Preferred Shares – the higher of (1) the sum of 180% issue price and declared but unpaid dividends, or (2) fair market value of the Preferred Share. • All other series of the Preferred Shares – the higher of (1) the sum of issue price, interest calculated at 8% per year compound annually (calculated from the date specified in memorandum of association and articles of association) and any declared but unpaid dividends, or (2) fair market value of the Preferred Share. Upon redemption, the Company shall pay the redemption price of Series B, C, C+, D, D-1, D-2, D-3 Accounting of the Preferred Shares The Company classified the Preferred Shares in the mezzanine section of the Consolidated Balance Sheets because they were contingently redeemable upon the occurrence of an event outside of the Company’s control (e.g. the Company not achieving a Qualified IPO before the Optional Redemption Date). The Preferred Shares were determined to be mezzanine equity with no embedded feature to be bifurcated and no BCF to be recognized. The Preferred Shares are initially recorded at their respective issuance date fair value, net of issuance cost. Since the Preferred Shares become redeemable at the option of the holder at any time after the Optional Redemption Date, for each reporting period, the Company accretes the carrying amount of the Preferred Shares to the higher of (1) the fair market value of the Preferred Shares on the reporting date, or (2) the result of using effective interest rate method to accrete the Preferred Shares to the redemption prices on the Optional Redemption Date that are calculated with pre-determined RMB-121 million All classes of Preferred Shares of the Company were converted to ordinary shares upon completion of the IPO on October 2,2020. Modification of the Preferred Shares The Company assesses whether an amendment to the terms of its convertible redeemable preferred shares is an extinguishment or a modification using the fair value model. The Company considers that a significant change in fair value after the change of the terms to be substantive and thus result in extinguishment of the Preferred Shares. In contrast, a change in fair value which is not significant immediately after the change of the terms is considered non-substantive When an amendment is considered an extinguishment, the difference between the fair value of the amended preferred shares and the carrying amount of the original preferred shares (net of issuance costs) is treated as a deemed dividend to or from the preferred shareholders. During the reporting periods, there was no amendment that resulted in extinguishment of the Preferred Shares. When preferred shares are modified and such modification results in value transfer between preferred shareholders and ordinary shareholders, the value transferred is treated as a deemed dividend to or from the preferred shareholders. The Company’s Preferred Shares activities for the periods presented are summarized below: Series A Preferred Series B Preferred Series C Preferred Series C+ Preferred Series D Preferred Series D-1 Preferred Series D-2 Preferred Series E Preferred Number of Amount Number of Amount Number of Amount Number of Amount Number of Amount Number of Amount Number of Amount Number of Amount Balance as of March 31, 2018 10,340,000 287,629 9,067,384 321,636 5,518,101 275,986 — — 2,296,387 140,859 — — — — — — Issuance — — — — — — — — 229,639 13,662 1,089,265 68,138 — — — — Accretion on the Preferred Shares to redemption value — 137,301 — 141,924 — 94,883 — — — 13,367 — 5,075 — — — — Deemed dividend to preferred shareholders upon modification of Preferred Shares — — — — — — — — — 527 — 196 — — — — Balance as of March 31, 2019 10,340,000 424,930 9,067,384 463,560 5,518,101 370,869 — — 2,526,026 168,415 1,089,265 73,409 — — — — Issuance (Note a) — — — — — — — — — — 1,089,265 82,048 1,182,803 89,447 1,042,623 74,830 Accretion on the Preferred Shares to redemption value — 59,192 — 64,122 — 49,550 — — — 19,768 — 8,825 — 17 — 3,322 Deemed dividend to preferred shareholders (Note b) — — — — — — — — — — — — — — — 401 Balances as of March 31, 2020 10,340,000 484,122 9,067,384 527,682 5,518,101 420,419 — — 2,526,026 188,183 2,178,530 164,282 1,182,803 89,464 1,042,623 78,553 Balances as of March 31, 2020 10,340,000 484,122 9,067,384 527,682 5,518,101 420,419 — — 2,526,026 188,183 2,178,530 164,282 1,182,803 89,464 1,042,623 78,553 Issuance (Note a) — — — — — — 6,734,459 656,448 — — — — — — 4,842,587 353,893 Accretion on the Preferred Shares to redemption value — (22,677 ) — (23,345 ) — (88,954 ) — 6,360 — (7,179 ) — 577 — 2,850 — 11,495 Deemed dividend to preferred shareholders (Note b) — — — — — — — — — — — — — — — 12,039 Conversion of convertible redeemable preferred shares upon completion of the IPO (10,340,000 ) (461,445 ) (9,067,384 ) (504,337 ) (5,518,101 ) (331,465 ) (6,734,459 ) (662,808 ) (2,526,026 ) (181,004 ) (2,178,530 ) (164,859 ) (1,182,803 ) (92,314 ) (5,885,210 ) (455,980 ) Balances as of March 31, 2021 — — — — — — — — — — — — — — — — Note a: In March 2020, 112,648 Series D-2 D-2 D-2 D-2 D-1 D-1 D-2 D-2 Note b: As of March 31, 2020 and 2021, the deemed dividend to preferred shares of the Company was RMB0.4 million and RMB12 million, respectively.

Redeemable non-controlling inte

Redeemable non-controlling interests	12 Months Ended
	Mar. 31, 2021
Noncontrolling Interest [Abstract]
Redeemable non-controlling interests	21. Redeemable non-controlling Yoken Holding Limited (“Yoken”), a wholly owned subsidiary of the Company issued redeemable preferred shares amounting to RMB6 million to a third-party investor in October, 2020. The preferred shares are redeemable at holder’s option if Yoken fails to complete a qualified IPO in a pre-agreed period of time since its issuance with a redemption price measured by 10% interest per year. The preferred shares are therefore accounted for as redeemable non-controlling For the years ended March 31 2021, the Company recognized accretion of RMB0.1 million to the respective redemption value of the redeemable non-controlling interest over the period starting from issuance date with a corresponding increase to the accumulated deficit.

Borrowings, other debts and der

Borrowings, other debts and derivative liabilities	12 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Borrowings, other debts and derivative liabilities	22. Borrowings, other debts and derivative liabilities Short-term borrowings and long-term borrowings The following table presents short-term borrowings from commercial banks, other institutions and individuals as of March 31, 2020 and 2021. Short-term borrowings include borrowings with maturity terms shorter than one year: As of March 31, As of March 31, 2020 2021 RMB RMB Bank borrowings 32,738 85,566 Other borrowings 42,485 — Total short-term borrowings 75,223 85,566 The following table presents long-term borrowings from commercial banks, other institutions and individuals as of March 31, 2020 and 2021. Long-term borrowings include borrowings with maturity terms greater than one year: As of March 31, As of March 31, 2020 2021 RMB RMB Bank borrowings 48,191 68,075 Other borrowings 4,957 — Total long-term borrowings 53,148 68,075 Bank borrowings As of March 31, 2020 and 2021, the Company obtained short-term bank borrowings of RMB32.7 million and RMB85.6 million in aggregate, of which nil and RMB37.8 million were collateralized by short-term investments, respectively. The weighted average interest rate for the outstanding borrowings were approximately 5.04% and 4.52%, respectively. These short-term bank borrowings did not include any restrictive covenants. As of March 31, 2020 and 2021, the unused facility for the short-term borrowing were RMB100.3 million and RMB222.3 million, respectively. As of March 31, 2020 and 2021, the Company obtained long-term bank borrowings of RMB48.2 million and RMB68.1 million in aggregate, of which nil and RMB68.1 million were collateralized by short-term investments, respectively. The weighted average interest rate for the outstanding borrowings were approximately 6% and 4.15%, respectively. This long-term bank borrowing did not include any restrictive covenants. As of March 31, 2020 and 2021, the unused facility for the long-term borrowings were RMB4.3 million and RMB14 million, respectively. Other borrowings In October 2019, the Company entered into a three-month loan agreement with a third-party company for a principle amount of US$6.0 million (RMB 42.5 million), bearing an interest rate of 6.0% per annum. The loan was pledged by 1,940,000 ordinary shares held by the Company’s senior management personnel, Hao (Louis) Liang and Yingzhi (Lisa) Tang, as collaterals. In January 2020, the term of the borrowing was extended to ten months and was early repaid in May and June 2020. In May 2019, the Company entered into a two-year Future principal maturities of short-term borrowings and long-term borrowings as of March 31, 2021 are as followings: Year ended March 31, 2021 RMB For the year ending March 31, 2022 85,566 2023 68,075 Total 153,641 Other debts Other debts - current consist of the following: As of March 31, As of March 31, 2020 2021 RMB RMB Series D-3 76,252 — Other debts – non-current As of March 31, As of March 31, 2020 2021 RMB RMB Loan for Series C+ Warrant (Note 20) — 312,535 Loan for Series D-3 11,192 — Loan for Series D-3 41,824 — Loan from Chong Li (b) 94,758 100,842 Loan for Yoken Series A-1 18,000 19,915 Total 165,774 433,292 (a) Series D-1 D-1 On August 3, 2018, the Company issued a warrant to an investor to purchase up to 1,089,265 Series D-1 D-1 D-1 D-1 D-1 D-1 D-1 D-1 D-1 D-1 D-1 D-1 D-1 On December 3, 2019, all parties to the Series D-1 D-1 D-1 D-1 D-1 D-1 D-1 D-1 D-1 D-1 D-1 D-2 D-2 (b) Series D-2 D-2 On January 16, 2019, the Company issued a warrant to purchase up to 963,139 Series D-2 D-2 D-2 D-2 D-2 D-2 D-2 D-2 D-2 D-2 D-2 D-2 On December 27, 2019, all parties to the Series D-2 D-2 D-2 D-2 D-2 D-2 D-2 D-2 On March 31, 2020, the Company, Superb Origin International Limited (“Superb Origin”, an ordinary shareholder of the Company), Chong Li (the 100% equity owner of Superb Origin) and all parties to the Series D-1 D-1 D-2 D-2 • Series D-1 D-1 D-2 D-2 • The investor of Loan for Series D-1 D-2 D-1 D-1 • The Company entered into share purchase agreements with Superb Origin, pursuant to which 1,089,265 Series D-1 D-2 The Company determined that the above transactions executed on March 31, 2020 effectively converted Loan for Series D-1 D-2 D-1 D-2 D-1 D-2 D-1 D-1 D-2 D-2 D-1 D-2 The Company accounts for Loan from Chong Li as a long-term debt initially recognized in the amount of RMB95 million (which is the present value of the principal amount of RMB128 million) and subsequently measured at amortized cost. The Company also records a receivable for issuance of preferred shares in the amount of RMB95 million (which is the present value of the principal amount of RMB128 million) in mezzanine equity for the consideration of the Series D-1 D-2 D-1 D-2 (c) Series D-2 On January 16, 2019, the Company issued convertible promissory notes of US$1 million (“Series D-2 D-2 D-2 D-2 D-2 D-2 On March 23, 2020, all principal amount of Series D-2 D-2 (d) Series D-2 On January 16, 2019, the Company issued convertible promissory notes of US$1 million (“Series D-2 D-2 D-2 D-2 D-2 On December 16, 2019, the Company and the investor of the Series D-2 D-2 D-2 On March 23, 2020, all principal amount of Series D-2 D-2 (e) Series D-3 D-3 D-3 On June 16, 2019, the Company issued to an investor (1) a warrant to purchase up to 154,395 Series D-3 D-3 D-3 D-3 D-3 D-3 D-3 D-3 Loan for Series D-3 D-3 Guangcheng has the right to repay each of the loans with a simple interest of 10% per annum prior to their respective maturity dates (plus a 45-day D-3 On December 27, 2019, all parties to the Series D-3 D-3 D-3 D-3 D-3 D-3 D-3 D-3 D-3 D-3 D-3 D-3 D-3 D-3 D-3 In June 2020, the Company early repaid the loan for Series D-3 D-3 In July and October 2020, the Company repaid the loan for Series D-3 D-3 The difference between the total carrying value of the Loan for Series D-3 Warrant A and Loan for Series D-3 Warrant B, and the fair value of the conversion feature and the repaid amounts, being RMB4.9 million, was recognized as other gain (losses), net (Note 17) for the year ended March 31, 2021. (f) Series D-3 On May 27, 2019, the Company issued convertible promissory notes of US$10 million (“Series D-3 D-3 D-3 D-3 D-3 D-3 D-3 D-3 D-3 The Company determined that there was no BCF to be recognized as the fair value of the ordinary shares into which the Series D-3 The PICC Notes are recognized initially at fair value, net of issuance costs, and are subsequently measured at amortized cost. Any difference between the proceeds received (net of issuance costs) and the redemption value is recognized in the consolidated statements of comprehensive loss over the period of the PICC Notes using the effective interest method. As of March 31, 2020, the carrying value of Series D-3 On June 25, 2020, the Company and the investor of the Series D-3 D-3 D-3 D-3 (g) Yoken Series A-1 On March 2, 2020, Yoken Holding Limited (“Yoken”), a wholly owned subsidiary of the Company, entered into a share purchase agreement with three investors (“Yoken Series A-1 A-1 A-1 A-1 A-1 A-1 A-1 A-1 A-1 A-1 A-1 On October 23, 2020, one investor terminated and entered into a new share purchase agreement with Yoken, pursuant to which 120,000 Yoken Series A-1 A-1 A-1 A-1 A-1 (h) Series E Warrant To exchange the consultant service from a service provider, on March 6, 2020, the Company issued a warrant of Series E Preferred Shares of 205,767 shares at an exercise price of US$10.3251 per share (“Series E Warrant”). The fair value of the Series E Warrant is RMB2.5 million and is recorded as prepayments and other current assets. The exercise period of the Series E Warrant is from the warrant issuance date (March 6, 2020) to March 6, 2025. The Series E Warrant is classified as a derivative liability measured at fair value with any changes in fair value recognized currently in the income statement. (i) Forward exchange swap On March 8, the Company entered a forward exchange contract with certain financial institution. Pursuant to which, the financial institution agreed to purchase US$4 million from the Company in exchange of RMB26.5 million at a fixed foreign exchange rate of 6.6280. Such swap will be settled on December 10, 2021. As of March 31, 2021, the fair value loss of the foreign swap contract was RMB0.19 million, which was recorded as derivative liabilities with a loss of change in fair value. Accounting of conversion features The warrants issued in connection with Loan for Series D-1 D-2 D-3 D-3 A-1 The Company assessed the embedded warrants along with the conversion features in Series D Notes, Series D-2 D-2 For the initial recognition of each debt instrument that has a bifurcated derivative liability (i.e., embedded warrant or conversion feature), out of the total consideration received, the derivative liability is recognized at fair value and the remaining consideration (net of issuance costs) is then allocated to the host debt instrument. The derivative liability is subsequently carried at fair value with any changes in fair value recognized currently in the income statement. The host debt instrument is subsequently amortized using the effective interest rate method. Upon conversion of the host debt instrument into the Preferred Shares or debt repayment, both the host debt instrument and the respective derivative liability are subject to extinguishment accounting with a gain or loss recognized from the difference between the recoded values of both liabilities and the fair value of consideration given by the Company (i.e., the Preferred Shares or cash). The Company determined the fair value of derivative liabilities and concluded that as of March 31, 2020 and 2021, the fair values of the derivative liabilities are as follows: As of March 31, As of March 31, 2020 2021 RMB RMB Conversion feature of Yoken Series A-1 — 9,362 Conversion feature of Series D-3 2,377 — Conversion feature of Series D-3 9,473 — Series E Warrant (Note 22(h)) 2,501 444 Forward exchange swap (Note 22(i)) — 190 Total 14,351 9,996 Accounting of debt modifications The aforementioned amendments to Loan for Series D-1 D-2 D-2 D-2 D-3 D-3

Share-based compensation

Share-based compensation	12 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Share-based compensation	23. Share-based compensation On September 27, 2012, the Company adopted 2012 Global Share Plan (the “2012 Plan”) and reserved 1,061,500 ordinary shares for share options to be granted to the Company’s employees and non-employees Except for share options granted to certain senior management personnel during the years ended March 31, 2015 and 2016, which were immediately fully vested and exercisable once granted, other share options granted to employees and non-employees For the years ended March 31, 2020 and 2021, 915,097 and 998,000 share options were granted to the Participants respectively. In April 2019, certain management Participants of the Company exercised 1,299,954 share options with exercise price of US$0.001 per share. The following table sets forth the share options activity for the years ended March 31, 2020 and 2021: Number of shares Weighted average exercise price US$ Weighted average remaining contractual term Aggregate intrinsic value US$ Weighted fair value US$ Outstanding as of March 31, 2019 5,686,454 1.49 5.8610 34,717 1.68 Exercisable as of March 31, 2019 1,299,954 0.001 5.5679 9,878 1.83 Granted 915,097 4.03 — — 5.02 Exercised (1,299,954 ) 0.001 — — — Forfeited (444,625 ) 2.45 — — 1.89 Outstanding as of March 31, 2020 4,856,972 2.26 6.6680 39,472 2.72 Exercisable as of March 31, 2020 — — — — — Granted 998,000 4.13 — — 2.49 Forfeited (342,750 ) 3.49 — — 4.00 Outstanding as of March 31, 2021 5,512,222 3.36 6.32 29,360 3.28 Exercisable as of March 31, 2021 — — — — — The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the estimated fair value of the underlying shares of US$33,010,332, US$39,471,589 and US$29,359,582 at March 31, 2019, 2020 and 2021, respectively. As of March 31, 2020 and 2021, there were US$12,954,410 and US$3,212,747 of unrecognized share-based compensation expenses related to share options granted by the Company, which were expected to be recognized over a weighted-average vesting period of 6.7 and 6.3 years, respectively Options granted to Participants were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: Year ended March 31, 2020 Year ended March 31, 2021 Expected volatility 43.49% 44.41% Risk-free interest rate 0.87% 0.94% Exercise multiple 2.8/2.2 2.8/2.2 Expected dividend yield 0% 0% Contractual term (in years) 10 10 The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time horizon close to the expected term of the Company’s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the Company’s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price of when employees would decide to voluntarily exercise their vested options. As the Company did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. The expected dividend yield is zero as the Company has never declared or paid any cash dividends on its shares, and the Company does not anticipate any dividend payments in the foreseeable future. The expected term is the contract life of the option. For the Company’s share options granted to the Participants, the completion of a Qualified IPO is considered to be a performance condition of the awards. A Qualified IPO is not considered to be probable until it is completed. Under ASC 718, compensation cost should be accrued if it is probable that the performance condition will be achieved. As a result, no compensation expense will be recognized related to these options until the completion of a Qualified IPO, and hence no share-based compensation expense was recognized for the years ended March 31, 2020.Upon the completion of the IPO, the Company recorded RMB44.1 million of cumulative share-based compensation expenses for those options for which the vesting conditions have been satisfied as of such date. For the year ended March 31, 2021, additional RMB10.9 millions of share-based compensation expense was recorded. The fair value of options granted to the Participants for the years ended March 31, 2020 and 2021 was amounting to US$3.86 million and US$4.12million, respectively.

Employee benefits

Employee benefits	12 Months Ended
	Mar. 31, 2021
Compensation Related Costs [Abstract]
Employee benefits	24. Employee benefits The full-time employees of the Company’s subsidiaries and VIEs that are incorporated in the PRC are entitled to staff welfare benefits including medical insurance, basic pensions, unemployment insurance, work injury insurance, maternity insurance and housing funds. These companies are required to contribute to these benefits based on certain percentages of the employees’ salaries in accordance with the relevant regulations and charge the amount contributed to these benefits to the consolidated statements of comprehensive loss. The Company has no legal obligation for the benefits beyond the contribution made. The PRC government is responsible for the welfare and medical benefits and ultimate pension liability to these employees. The total amounts charged to the consolidated statements of comprehensive loss for such employee benefits amounted to RMB7 million, RMB7 million and RMB6 million for the years ended March 31, 2019, 2020 and 2021, respectively.

Fair value measurements

Fair value measurements	12 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair value measurements	25. Fair value measurements The Company measured its available-for-sale available-for-sale available-for-sale The following table summarizes the Company’s financial assets and liabilities measured and recorded at fair value on recurring basis as of March 31, 2020 and 2021: Fair value measurement at reporting date using Description Fair value as of Quoted price in Significant other Significant RMB RMB RMB RMB Assets: Available-for-sale 70,328 — — 70,328 Liabilities: Derivative liabilities 14,351 — — 14,351 Fair value measurement at reporting date using Description Fair value as of Quoted price in Significant other Significant RMB RMB RMB RMB Assets: Short-term investments 168,546 — 168,546 — Available-for-sale 71,357 — — 71,357 Total assets 239,903 — 168,546 71,357 Liabilities: Derivative liabilities 9,996 — 190 9,806 The roll forward of major Level 3 investments are as following: Derivative Available-for-sale Fair value of Level 3 investments as at March 31, 2018 1,333 13,767 New addition 32,099 — Conversion of Series D Notes (Note 20) (182 ) — Unrealized fair value change of the derivative liabilities 2,274 — Unrealized fair value change of the available-for-sale — 2,283 Fair value of Level 3 investments as at March 31, 2019 35,524 16,050 New addition 13,487 50,000 Conversion of Series D-1 (10,701 ) — Conversion of Series D-2 (10,614 ) — Unrealized fair value change of the derivative liabilities (13,345 ) — Unrealized fair value change of the available-for-sale — 4,278 Fair value of Level 3 investments as at March 31, 2020 14,351 70,328 New addition 9,391 — Disposal of Series D-3 (2,377 ) — Unrealized fair value change of the derivative liabilities (11,559 ) — Unrealized fair value change of the available-for-sale — 1,029 Fair value of Level 3 investments as at March 31, 2021 9,806 71,357 The Company determined the fair value of their investments by using income approach and equity allocation model. The determination of the fair value was based on estimates, judgments and information of other comparable public companies. The significant unobservable inputs adopted in the valuation as of March 31, 2020 and 2021: As of March 31, As of March 31, 2020 2021 Weighted average cost of capital 15%, 16.5% 15%,16.5% Lack of marketability discount 17%, 23% 17%,23% Risk-free rate 1.86%, 2.24% 2.88%,2.87% Expected volatility 39.86%, 48.13% 41.79%,42.26% Probability Liquidation scenario: 40% Redemption scenario: 40% IPO scenario: 20% Liquidation scenario: 40% Redemption scenario: 40% IPO scenario: 20% The significant unobservable inputs used in the fair value measurement of the fair value of the investments include weighted average cost of capital, lack of marketability discount, risk-free rate, expected volatility and probabilities of different scenarios. Significant increases in weighted average cost of capital, lack of marketability discount and risk-free rate would result in a significantly lower fair value measurement. Significant decreases in expected volatility would result in a significantly lower fair value measurement. If the probabilities of redemption and liquidation scenarios are assumed to keep equal, significant increases in the probability of IPO scenario would result in a significantly lower fair value measurement. The Company determined the fair value of their derivative liabilities by using binominal model. The determination of the fair value was based on estimates, judgments and information of other comparable public companies. The significant unobservable inputs adopted in the valuation as of March 31, 2020 and 2021 are as follows: As of March 31, As of March 31, 2020 2021 Spot price (US$) 8.24~10.74 5.57,7.19 Risk-free rate 0.19% 0.00%,0.9% Expected volatility 55.14% 41.05%,52.33%, Expected expiry years (in years) 0.50 0.50,4.56 The significant unobservable inputs used in the fair value measurement of the derivative liabilities include spot price, risk-free rate, expected volatility and expected expiry years. Significant decreases in spot price, risk-free rate, expected volatility and expected expiry years would result in a significantly lower fair value measurement.

Net loss per share

Net loss per share	12 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Net Loss per share	26. Net loss per share Basic loss per share and diluted loss per share have been calculated in accordance with ASC 260 on computation of earnings per share for the years ended March 31, 2019, 2020 and 2021, respectively, as follows: Year Ended March 31, 2019 Year Ended March 31, 2020 Year Ended March 31, 2021 RMB RMB RMB Numerator: Net loss attributable to Boqii Holding Limited (234,241 ) (179,024 ) (194,444 ) Accretion on the Preferred Shares to redemption value (Note 20) (392,550 ) (204,796 ) 120,873 Accretion on the Redeemable non-controlling — — (138 ) Deemed dividend to preferred shareholders (723 ) (1,142 ) (12,547 ) Net loss attributable to ordinary shareholders (625,514 ) (384,962 ) (86,256 ) Denominator: Weighted average number of ordinary shares used in computing net loss per share, Basic and diluted (Note (a)) 22,238,454 22,238,454 66,953,610 Net loss per share attributable to ordinary shareholders: Basic and diluted (28.22 ) (17.31 ) (1.29 ) Note (a): Options exercisable for a minimal exercise price (the “Penny Stock”) are included in the denominator of basic loss per share calculation once there are no further vesting conditions or contingencies associated with them, as they are considered issuable shares. Basic net loss per share is computed using the weighted average number of ordinary shares outstanding and the Penny Stock during the period. Diluted net loss per share is computed using the weighted average number of ordinary shares and dilutive potential ordinary shares outstanding and the Penny Stock during the period. For the years ended March 31, 2019, 2020 and 2021, respectively, assumed conversion of the Preferred Shares have not been reflected in the dilutive calculations pursuant to ASC 260, “Earnings Per Share,” due to the anti-dilutive effect. For the years ended March 31 2021, assumed share options have not been reflected in the dilutive calculations pursuant to ASC 260, “Earnings Per Share,” due to the anti-dilutive effect. The following ordinary shares equivalent were excluded from the computation of diluted net loss per ordinary share for the periods presented because including them would have had an anti-dilutive effect: Year Ended March 31, 2019 Year Ended March 31, 2020 Year Ended March 31, 2021 RMB RMB RMB Preferred Shares — weighted average 25,083,831 26,072,893 — Share options - weighted average — — 2,585,103

Related party transactions

Related party transactions	12 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Related party transactions	27. Related party transactions The table below sets forth the major related parties and their relationships with the Company as of March 31, 2019, 2020 and 2021: Name of related parties Relationship with the Company Nanjing Xingmu An equity investee of the Company before November 1, 2019 Nanjing Animal Pharmaceutical An equity investee of the Company Shanghai Yichong An equity investee of the Company Wuhan Chunzhijin An equity investee of the Company Beijing Petdog An available-for-sale Yingzhi (Lisa) Tang A senior management of the Company Di (Jackie) Chen A senior management of the Company Ying (Christina) Zhang A senior management of the Company Fei Wang A senior management of the Company Yan Jiang A senior management of the Company Details of related party transactions and balances as of March 31, 2020 and 2021 are as follows: The Company believes that the terms of the agreements with the related parties are comparable to the terms in arm’s-length Transactions with related parties Year Ended March 31, 2019 Year Ended March 31, 2020 Year Ended March 31, 2021 RMB RMB RMB Sales of goods Beijing Petdog — 2,316 — Year Ended March 31, 2019 Year Ended March 31, 2020 Year Ended March 31, 2021 RMB RMB RMB Online marketing and information services Beijing Petdog — 315 410 Year Ended March 31, 2019 Year Ended March 31, 2020 Year Ended March 31, 2021 RMB RMB RMB Purchase of merchandise Nanjing Xingmu 2,533 751 — Nanjing Animal Pharmaceutical — 45 250 2,533 796 250 Year Ended March 31, 2019 Year Ended March 31, 2020 Year Ended March 31, 2021 RMB RMB RMB Loans granted to related parties Nanjing Animal Pharmaceutical (a) — 1,000 500 Wuhan Chunzhijin (b) — — 5,690 Yan Jiang 17,848 — 200 Ying (Christina) Zhang — 152 — Di (Jackie) Chen — 785 — Fei Wang (c) — — 500 17,848 1,937 6,890 In December 2019, Nanjing Xingmu entered into a twelve-month interest free loan agreement with Nanjing Agricultural Pharmaceutical for a principal amount of RMB1 million. This loan was early repaid in May 2020. In June 2020, Nanjing Xingmu entered into another twelve-month interest free loan agreement with Nanjing Agricultural Pharmaceutical for a principal amount of RMB0.5 million. As of March 31, 2021, the outstanding principal amount under this agreement was RMB0.5 million. (a) From April 2020 to January 2021, the Company entered into several interest free loans with Wuhan Chunzhijin for a total principal of RMB5.7 million. (b) In January 2021, the Company entered into a one-year loan agreement with Fei Wang, for a principal amount of RMB0.5 million, bearing an interest rate of 4% per annum. This Loan was pledged by 515,000 stock options owned by Fei Wang. Year Ended March 31, 2019 Year Ended March 31, 2020 Year Ended March 31, 2021 RMB RMB RMB Staff advances Yingzhi (Lisa) Tang — — 10 Di (Jackie) Chen 528 6 — 528 6 10 Advances provided to related parties Nanjing Animal Pharmaceutical — — 2,073 Wuhan Chunzhijin 2,720 3,350 — 2,720 3,350 2,073 Loans granted from related parties Yingzhi (Lisa) Tang (a) 5,014 1,450 — Di (Jackie) Chen (b) — 1,250 — Yan Jiang (c) — 9,000 — 5,014 11,700 — (a) In September 2019, the Company obtained a two-year In November 2018, Yingzhi (Lisa) Tang advanced RMB4 million to the Company, which was repaid by the Company in the same month. In July 2018, the Company obtained a forty-month loan of US$0.15 million (RMB1 million) from Yingzhi (Lisa) Tang, bearing an interest rate of 6.0% per annum. The loan was early repaid in January 2021. (b) In October 2019, Di (Jackie) Chen advanced RMB1.25 million to the Company, which was repaid by the Company in the same month. (c) In September 2019, the Company obtained a two-year Amounts due from related parties As of March 31, As of March 31, As of March 31, RMB RMB RMB Trade receivables from related parties Beijing Petdog — 1,564 — Prepayments to related parties Nanjing Animal Pharmaceutical — — 2,023 Nanjing Xingmu 138 — — 138 — 2,023 As of March 31, As of March 31, As of March 31, RMB RMB RMB Other receivables from related parties Wuhan Chunzhijin 3,795 2,481 7,295 Loans to related parties Nanjing Animal Pharmaceutical — 1,000 500 Yingzhi (Lisa) Tang — — 10 Yan Jiang — — 200 Di (Jackie) Chen (a) — 785 785 Ying (Christina) Zhang — 152 152 Fei Wang (b) — — 500 — 1,937 2,147 (a) In December 2019, the Company entered into a twelve-month interest free loan agreement with, Di (Jackie) Chen, for a principal amount of RMB0.7 million. In December 2020, the loan contract was renewed for another one year. (b) In January 2021, the Company entered into a one-year loan agreement with Fei Wang, for a principal amount of RMB0.5 million, bearing an interest rate of 4% per annum. This Loan was pledged by 515,000 stock options owned by Fei Wang. Amounts due to related parties As of March 31, As of March 31, As of March 31, RMB RMB RMB Trade payables to related parties Nanjing Animal Pharmaceutical — 45 874 As of March 31, As of March 31, As of March 31, RMB RMB RMB Advances from related parties Beijing Petdog — — 36 Wuhan Chunzhijin 150 — — 150 — 36 Long-term loan from related parties Yingzhi (Lisa) Tang (a) 1,015 2,521 — Yan Jiang (b) — 9,000 — 1,015 11,521 — (a) In July 2018, the Company entered into a forty-month loan agreement with Yingzhi (Lisa) Tang, for a principal amount of US$0.15 million (RMB1.0 million), bearing an interest rate of 6% per annum. The loan was early repaid in January 2021. In September 2019, the Company entered into another two-year (b) The balance as of December 31, 2019 represented a two-year

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	28. Commitments and contingencies (a) Capital commitments The Company’s capital commitments primarily relate to commitments on leasehold improvement and purchase of equipment. As of March 31, 2020 and 2021, no capital commitment was related to leasehold improvement and purchase of equipment. (b) Contingencies The Company is subject to legal proceedings and regulatory actions in the ordinary course of business. The results of such proceedings cannot be predicted with certainty, but the Company does not anticipate that the final outcome arising out of any such matter will have a material adverse effect on our consolidated financial position, cash flows or results of operations on an individual basis or in the aggregate. As of March 31, 2020 and 2021, the Company is not a party to any material legal or administrative proceedings.

Subsequent events

Subsequent events	12 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent events	29. Subsequent events The Company has evaluated the subsequent events through the date of issuance of the financial statements.

Restricted net assets

Restricted net assets	12 Months Ended
	Mar. 31, 2021
Receivables [Abstract]
Restricted net assets	30. Restricted net assets The Company’s ability to pay dividends may depend on the Company receiving distributions of funds from its PRC subsidiaries. Relevant PRC statutory laws and regulations permit payments of dividends by the Company’s PRC subsidiaries only out of their retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the consolidated financial statements prepared in accordance with US GAAP differ from those reflected in the statutory financial statements of the Company’s PRC subsidiary. In accordance with the Company law of the PRC, a domestic enterprise is required to provide statutory reserves of at least 10% of its annual after-tax For the years ended March 31, 2019, 2020 and 2021, appropriation to statutory reserves was made because two PRC subsidiaries had generated profits for these periods. As a result of these PRC laws and regulations subject to the limit discussed above that require annual appropriations of 10% of after-tax Foreign exchange and other regulations in the PRC further restrict the Company’s PRC subsidiaries from transferring funds to the Company in the form of dividends, loans and advances. Since the Company has a consolidated shareholders’ deficit, its net asset base for purposes of calculating the proportionate share of restricted net assets of consolidated subsidiaries should be zero. Therefore, the restrictions placed on the net assets of the Company’s PRC subsidiaries with positive equity would result in the 25 percent threshold being exceeded and a corresponding requirement to provide parent company financial information (see Note 31).

Condensed financial information

Condensed financial information of the parent company	12 Months Ended
	Mar. 31, 2021
Condensed Financial Information Disclosure [Abstract]
Condensed financial information of the parent company	31. Condensed financial information of the parent company The Company performed a test on the restricted net assets of consolidated subsidiaries in accordance with Securities and Exchange Commission Regulation S-X Rule 4-08 The subsidiaries did not pay any dividends to the Company for the periods presented. For the purpose of presenting parent company only financial information, the Company records its investments in its subsidiaries under the equity method of accounting. Such investments are presented on the separate condensed balance sheets of the Company as “Investments (deficit) in subsidiaries” and the loss of the subsidiaries is presented as “share of losses of subsidiaries”. Certain information and footnote disclosures generally included in financial statements prepared in accordance with US GAAP have been condensed and omitted. The footnote disclosures contain supplemental information relating to the operations of the Company, as such, these statements should be read in conjunction with the notes to the consolidated financial statements of the Company. The parent company did not have significant capital and other commitments, long-term obligations, other long-term debt, or guarantees as of March 31, 2020 and 2021. Balance sheets As of March 31, As of March 31, 2020 2021 RMB RMB US$ (Note 2(f)) ASSETS Current assets: Cash and cash equivalents 1,145 18,285 2,791 Prepayments and other current assets 686,819 1,208,128 184,396 Total current assets 687,964 1,226,413 187,187 Non-current Other non-current 7,943 344 53 Total non-current 7,943 344 53 Total assets 695,907 1,226,757 187,240 LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS’ DEFICIT Current liabilities Short-term borrowings 42,485 — — Accrued liabilities and other current liabilities 12,126 5,017 766 Other debts, current 76,252 — — Derivative liabilities 14,816 444 68 Total current liabilities 145,679 5,461 834 Non-current Long-term borrowings 4,957 — — Negative carrying amount of subsidiaries 690,121 1,138,622 173,788 Total non-current 695,078 1,138,622 173,788 Total liabilities 840,757 1,144,083 174,622 Mezzanine equity: Series A convertible redeemable preferred shares (US$ 0.001 par value; 11,000,000 shares authorized, 10,340,000 and nil shares issued and outstanding as of March 31, 2020 and 2021, respectively) 484,122 — — Series B convertible redeemable preferred shares (US$ 0.001 par value; 10,000,000 shares authorized, 9,067,384 and nil shares issued and outstanding as of March 31, 2020 and 2021, respectively) 527,682 — — Series C convertible redeemable preferred shares (US$ 0.001 par value; 6,000,000 shares authorized, 5,518,101 and nil shares issued and outstanding as of March 31, 2020 and 2021, respectively) 420,419 — — Series D convertible redeemable preferred shares (US$ 0.001 par value; 3,000,000 shares authorized, 2,526,026 and nil shares issued and outstanding as of March 31, 2020 and 2021, respectively) 188,183 — — Series D-1 164,282 — — Series D-2 89,464 — — Series E convertible redeemable preferred shares (US$ 0.001 par value; 3,000,000 and 7,000,000 shares authorized, 1,042,623 and nil shares issued and outstanding as of March 31, 2020 and 2021, respectively) 78,553 — — Receivable for issuance of preferred shares (94,758 ) — — Total mezzanine equity 1,857,947 — — As of March 31, 2020 2021 RMB RMB US$ (Note 2(f)) Stockholders’ deficit: Ordinary Shares (US$0.001 par value;153,000,000 ordinary shares authorized and 22,238,454 issued and outstanding as of March 31, 2020; nil shares issued and outstanding as of March 31, 2021) 139 — — Class A ordinary shares (US$0.001 par value; nil shares authorized, issued and outstanding shares as of March 31, 2020; 129,500,000 shares authorized, 54,505,108 shares issued and outstanding as of March 31, 2021) — 364 56 Class B ordinary shares (US$0.001 par value; nil shares authorized, issued and outstanding shares as of March 31, 2020; 15,000,000 shares authorized, 13,037,729 shares issued and outstanding as of March 31, 2021) — 82 12 Statutory reserves 2,627 3,047 465 Additional paid-in — 3,272,612 499,498 Accumulated other comprehensive loss 11,204 (20,172 ) (3,079 ) Accumulated deficit (2,016,758 ) (2,759,882 ) (421,240 ) Receivable for issuance of ordinary shares (9 ) (413,377 ) (63,094 ) Total shareholders’ deficit (2,002,797 ) 82,674 12,618 Total liabilities, mezzanine equity and shareholders’ deficit 695,907 1,226,757 187,240 Statements of comprehensive loss Year Ended March 31, 2019 2020 2021 RMB RMB RMB US$ (Note 2(f)) Sales and marketing expenses — — (12,875 ) (1,965 ) General and administrative expenses (812 ) (4,631 ) (14,050 ) (2,144 ) Total operating expenses (812 ) (4,631 ) (26,925 ) (4,109 ) Loss from operations (812 ) (4,631 ) (26,925 ) (4,109 ) Interest income — — 15,416 2,353 Interest expense (5,624 ) (12,578 ) — — Share of losses of subsidiaries (225,531 ) (134,660 ) (191,458 ) (29,221 ) Other (expense)/income, net — (40,500 ) (3,008 ) (459 ) Fair value change of derivative liabilities (2,274 ) 13,345 11,531 1,760 Net loss attributable to Boqii Holding Limited (234,241 ) (179,024 ) (194,444 ) (29,676 ) Less: Accretion on the Preferred Shares to redemption value (392,550 ) (204,796 ) 120,873 18,449 Less: Accretion on redeemable non-controlling — — (138 ) (21 ) Less: Deemed contribution from preferred shareholders (723 ) (1,142 ) (12,547 ) (1,915 ) Net loss attributable to Boqii Holding Limited’s ordinary shareholders (627,514 ) (384,962 ) (86,256 ) (13,163 ) Net loss (234,241 ) (179,024 ) (194,444 ) (29,676 ) Other comprehensive loss: Foreign currency translation adjustment, net of nil tax 3,808 2,021 (32,148 ) (4,907 ) Unrealized securities holding gains 1,711 3,209 772 118 Total comprehensive loss (228,722 ) (173,794 ) (225,820 ) (34,465 ) Statements of cash flows Year Ended March 31, 2019 2020 2021 RMB RMB RMB US$ (Note 2(f)) Net cash used in operating activities — — (47,806 ) (7,297 ) Net cash used in investing activities (99,221 ) (184,354 ) (588,953 ) (89,892 ) Net cash provided by financing activities 81,206 155,712 660,366 100,792 Effects of foreign exchange rate changes on cash and cash equivalents 18,010 29,778 (6,465 ) (987 ) Net increase (decrease) in cash and cash equivalents (5 ) 1,136 17,140 2,616 Cash and cash equivalents at beginning of the year 14 9 1,145 175 Cash and cash equivalents at end of the year 9 1,145 18,285 2,791

Principal Accounting Policies (

Principal Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of preparation	(a) Basis of preparation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). Significant accounting policies followed by the Company in the preparation of the accompanying consolidated financial statements are summarized below.
Basis of consolidation	(b) Basis of consolidation The Company’s consolidated financial statements include the financial statements of the Company, its subsidiaries, the consolidated VIEs and VIEs’ subsidiaries for which the Company is the primary beneficiary. A subsidiary is an entity in which the Company, directly or indirectly, controls more than one half of the voting power, has the power to appoint or remove the majority of the members of the board of directors, to cast a majority of votes at the meeting of the board of directors or to govern the financial and operating policies of the investee under a statute or agreement among the shareholders or equity holders. A consolidated VIE is an entity in which the Company, or its subsidiaries, through Contractual Agreements, bears the risks of, and enjoys the rewards normally associated with, ownership of the entity, and therefore the Company or its subsidiaries are the primary beneficiary of the entity. All transactions and balances among the Company, its subsidiaries, the consolidated VIEs and VIEs’ subsidiaries have been eliminated upon consolidation.
Business combination and non-controlling interests	(c) Business combination and non-controlling The Company accounts for its business combinations using the acquisition method of accounting in accordance with Accounting Standards Codification (“ASC”) 805, Business Combinations non-controlling non-controlling In a business combination achieved in stages, the Company re-measures re-measurement When there is a change in ownership interests or a change in contractual arrangements that results in a loss of control of a subsidiary or consolidated VIE, the Company deconsolidates the subsidiary or consolidated VIE from the date control is lost. Any retained non-controlling For the Company’s consolidated subsidiaries, VIEs and VIEs’ subsidiaries, non-controlling Non-controlling
Use of estimates	(d) Use of estimates The preparation of the Company’s consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company believes that revenue recognition, sales returns, sales incentive, rebates, valuation of deferred tax assets, assessment for useful life and impairment of long-lived assets, allowance for doubtful accounts, valuation of available-for-sale Management bases the estimates on historical experience and on various other assumptions as discussed elsewhere to the consolidated financial statements that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. On an ongoing basis, management evaluates its estimates based on information that is currently available. Changes in circumstances, facts and experience may cause the Company to revise its estimates. Changes in estimates are recorded in the period in which they become known. Actual results could materially differ from these estimates.
Functional currency and foreign currency translation	(e) Functional currency and foreign currency translation The Company’s reporting currency is Renminbi (“RMB”). The functional currency of the Company’s entities incorporated in Cayman Islands, British Virgin Islands and Hong Kong is the United States dollars (“US$”). The Company’s PRC subsidiaries, consolidated VIEs and VIEs’ subsidiaries determined their functional currency to be RMB. The determination of the respective functional currency is based on the criteria of ASC 830, Foreign Currency Matters Transactions denominated in other than the functional currencies are translated into the functional currency of the entity at the exchange rates prevailing on the transaction dates. Financial assets and liabilities denominated in other than the functional currency are translated at the balance sheet date exchange rate. The resulting exchange differences are included in the consolidated statements of comprehensive loss as foreign exchange related gains (losses), net. The financial statements of the Company are translated from the functional currency into RMB. Assets and liabilities denominated in foreign currencies are translated into RMB using the applicable exchange rates at the balance sheet date. Equity accounts other than earnings generated in current period are translated into RMB at the appropriate historical rates. Revenues, expenses, gains and losses are translated into RMB using the periodic average exchange rates. The resulting foreign currency translation adjustments are recorded in accumulated other comprehensive income (loss) as a component of shareholders’ equity. The exchange rates used for translation on March 31, 2020 and 2021 were US$1.00= RMB 7.0851 and RMB 6.5713, respectively, representing the index rates stipulated by the People’s Bank of China.
Convenience translation	(f) Convenience translation Translations of the consolidated balance sheets, the consolidated statements of comprehensive loss and the consolidated statements of cash flows from RMB into US$ as of and for the year ended March 31, 2021 are solely for the convenience of the readers and were calculated at the rate of US$1.00=RMB 6.5518, representing the certificated exchange rate published by the Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate on March 31, 2021, or at any other rate.
Fair value of financial instruments	(g) Fair value of financial instruments Accounting guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability. The established fair value hierarchy requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The three levels of inputs that may be used to measure fair value: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Observable, market-based inputs, other than quoted prices, in active markets for identical assets or liabilities. Level 3: Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. Accounting guidance also describes three main approaches to measuring the fair value of assets and liabilities: (1) market approach; (2) income approach and (3) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset. Financial assets and liabilities of the Company mainly consist of cash and cash equivalents, restricted cash, accounts receivable, amounts due from related parties, prepayments and other current assets, available-for-sale As of March 31, 2020 and 2021, except for available-for-sale non-current available-for-sale
Cash and cash equivalents	(h) Cash and cash equivalents Cash and cash equivalents include cash on hand and time deposits placed with banks and third party payment processors, which are unrestricted as to withdrawal or use, have original maturities of three months or less at the time of purchase and are readily convertible to known amounts of cash.
Short-term investments	(i) Short-term investments Short-term investments comprise primarily of (i) cash deposits at fixed rates with original maturities of greater than three months, but less than 12 months and; (ii) the investments issued by commercial banks or other financial institutions with a variable interest rate indexed to the performance of underlying assets within one year. As of March 31, 2021, RMB118.5 million short-term investments were used as collateral of RMB105.9 million short-term and long-term borrowings.
Accounts receivable, net	(j) Accounts receivable, net Accounts receivable are presented net of allowance for doubtful accounts. The Company maintains an allowance for doubtful accounts which reflects its best estimate of amounts that potentially will not be collected. The Company determines the allowance for doubtful accounts on general basis taking into consideration various factors including but not limited to historical collection experience and credit-worthiness of the customers as well as the age of the individual receivables balance. Additionally, the Company makes specific bad debt provisions based on any specific knowledge the Company has acquired that might indicate that an account is uncollectible. The facts and circumstances of each account may require the Company to use substantial judgment in assessing its collectability.
Inventories	(k) Inventories Inventories are stated at the lower of cost and net realizable value. Cost elements of our inventories comprise the purchase price of products, vendor rebates, shipping charges to receive products from the suppliers when they are embedded in the purchase price. Cost is determined using the first-in first-out
Property and equipment, net	(l) Property and equipment, net Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the following estimated useful lives. The estimated useful lives are as follows: Useful years Warehouse equipment 3 - 5 years Furniture, computer and office equipment 3 - 5 years Vehicles 5 years Software 10 years Leasehold improvements Over the shorter of the expected life of leasehold improvements or the lease term Expenditures for maintenance and repairs are expensed as incurred. The gain or loss on the disposal of property and equipment is the difference between the net sales proceeds and the carrying amount of the relevant assets and is recognized in the consolidated statements of comprehensive loss.
Intangible assets, net	(m) Intangible assets, net Intangible assets purchased from third parties are initially recorded at cost. The Company performs valuation of the intangible assets arising from business combination to determine the relative fair value to be assigned to each asset acquired. The intangible assets are amortized using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of intangible assets are as follows: Useful years Trademark 10 years Dealership 10 years License 4.5 - 10 years The estimated life of amortized intangibles is reassessed if circumstances occur that indicate the life has changed.
Goodwill	(n) Goodwill Goodwill represents the excess of the purchase price over the fair value of the identifiable assets and liabilities acquired in a business combination. Goodwill is not depreciated or amortized but is tested for impairment on an annual basis as of March 31, and in between annual tests when an event occurs or circumstances change that could indicate that the asset might be impaired. In accordance with the FASB guidance on “Testing of Goodwill for Impairment”, a company first has the option to assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company decides, as a result of its qualitative assessment, that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test is mandatory. Otherwise, no further testing is required. The quantitative impairment test consists of a comparison of the fair value of each reporting unit with its carrying amount, including goodwill. If the carrying amount of each reporting unit exceeds its fair value, an impairment loss equal to the difference between the implied fair value of the reporting unit’s goodwill and the carrying amount of goodwill will be recorded. Application of a goodwill impairment test requires significant management judgment, including the identification of reporting units, assigning assets and liabilities to reporting units, assigning goodwill to reporting units, and determining the fair value of each reporting unit. The judgment in estimating the fair value of reporting units includes estimating future cash flows, determining appropriate discount rates and making other assumptions. Changes in these estimates and assumptions could materially affect the determination of fair value for each reporting unit.
Long-term investments	(o) Long-term investments The Company’s investments include equity method investments and available-for-sale The Company applies the equity method of accounting to account for an equity investment, in common stock or in-substance Debt securities that the Company has the intent to hold the security for an indefinite period or may sell the security in response to the changes in economic conditions are classified as available-for-sale The Company continually reviews its investments to determine whether a decline in fair value to below the carrying value is other-than-temporary. The primary factors the Company considers in its determination are the duration and severity of the decline in fair value; the financial condition, operating performance and the prospects of the equity investee; and other company specific information such as recent financing rounds. If the decline in fair value is deemed to be other-than-temporary, the carrying value of the investment is written down to fair value.
Impairment of long-lived assets other than goodwill	(p) Impairment of long-lived assets other than goodwill Long-lived assets are evaluated for impairment whenever events or changes in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying amount may not be fully recoverable or that the useful life is shorter than the Company had originally estimated. When these events occur, the Company evaluates the impairment by comparing carrying value of the assets to an estimate of future undiscounted cash flows expected to be generated from the use of the assets and their eventual disposition. If the sum of the expected future undiscounted cash flows is less than the carrying value of the assets, the Company recognizes an impairment loss based on the excess of the carrying value of the assets over the fair value of the assets.
Revenue recognition	(q) Revenue recognition In May 2014, the FASB issued ASU No. 2014-09, 2014-09”) 2014-09 No. 2014-09 The Company adopted ASC 606 for all periods presented. Consistent with the criteria of Topic 606, the Company follows five steps for its revenue recognition: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Revenue arrangements with multiple performance obligations are divided into separate distinct goods or services. The Company allocates the transaction price to each performance obligation based on the relative standalone selling price of the goods or services provided. The Company’s revenues are primarily derived from (i) product sales and (ii) online marketing and information services and other service. When either party to a contract has performed, the Company presents the contract in the statement of financial position as a contract asset or a contract liabilities, depending on the relationship between the entity’s performance and the customer’s payment. A receivable is recorded when the Company has an unconditional right to consideration. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due. A contract asset is recorded when the Company has transferred products or services to the customer before payment is received or is due, and the Company’s right to consideration is conditional on future performance or other factors in the contract. No contract asset was recorded as of March 31, 2020 and 2021. The Company’s contract liabilities consist of payments received or awards to customers (in the form of Boqii Beans) related to unsatisfied performance obligations at the end of the period. As of April 1, 2019 and 2020, the Company’s total contract liabilities were RMB5.8 million and RMB7.7 million, respectively, of which RMB5.0 million and RMB7.7 million were recognized as revenue for the years ended March 31, 2020 and 2021. The Company’s total unearned revenue was RMB3.9 million as of March 31, 2021. Revenue is recorded net of value-added tax. Revenue recognition policies for each type of revenue steam are as follows: Sales of merchandise The Company primarily sells pet products through online stores to individual online customers. Besides online sales, the Company also sells products through offline channels to its business customers and pet stores across the country. The Company recognizes the product revenues from products sales on a gross basis as the Company is acting as a principal in these transactions. The Company has obtained control of the products before they are transferred to customers. The Company is primarily obligated in these transactions, is subject to inventory risk or has the ability to direct the use of inventory, and has latitude in establishing prices and selecting suppliers. Revenue is recognized when consumers physically accept the products after delivery, which is when the control of products is transferred, and is recorded net of return allowances and rebates to pet stores. The Company also enters into arrangement with its business partners to sell their products on the Company’s online stores. The Company considers the arrangement meet the indicators of consignment arrangement under ASC 606-10-55-80, Online marketing and information services and other revenue The Company provides online marketing and information services to third-party on the Company’s various channels and third-party platforms, including but not limited to advertising placements, organizing online and offline marketing campaigns featuring social media influencers and circulating marketing messages to end consumers. With respect to the Company’s marketing services, length of the periods over which services are provided are generally within months or less, revenue from such arrangements is recognized ratably over the service period, as the third-party simultaneously consumes the benefits when the advertisement is displayed or the campaign is ongoing. The Company also provides warehouse services. The warehouse services include warehousing, packaging, dispatching and other services. Revenue is primarily recognized when the services are rendered.
Sales returns	(r) Sales returns The Company offers online consumers an unconditional right of return for a period of seven days upon receipt of products. Return allowances, which reduce revenue and cost of sales, are estimated by categories of return policies offered to online customers, based on historical data the Company has maintained, and subject to adjustments to the extent that actual returns differ or are expected to differ.
Sales incentives	(s) Sales incentives The Company grants certain units of Boqii Bean, from time to time, to its customers at its discretion in different situations. Boqii Beans are not redeemable for cash and can be used as a coupon for the customer’s future purchase on the Boqii Marketplace and Boqii.com. The value of ten units of Boqii Bean is equivalent to one RMB yuan before taking into account the impact of breakage. For the Boqii Beans that are granted with concurrent revenue transactions, the allocated transaction price based on its relative standalone selling price are recognized as reduction of the revenue and accrued for as contract liabilities. As customers redeem awards, the accrued liability is reduced correspondingly. For the Boqii Beans that are granted without concurrent revenue transactions, they are not accounted for when granted and are recognized as a reduction of revenue when they are applied in future sales. The Company also has a coupon program, through which the Company grants coupons to online customers when they make a successful purchase order, finish first registration on Boqii Marketplace or comment on products. When the coupon is granted concurrent with a revenue transaction, the Company accounts for the estimated cost of future usage of coupons as reduction of the revenue. When the coupon is not granted concurrent with a revenue transaction, they are not accounted for when they are granted and are recognized as a reduction of revenue when they are applied in future sales.
Cost of revenue	(t) Cost of revenue Cost of revenue consist of cost of product sales of RMB599.2 million, RMB610.6 million and RMB820.3 million for the years ended March 31, 2019, 2020 and 2021, respectively, and cost of services of RMB0.3 million, RMB0.9 million and RMB3.4 million for the years ended March 31, 2019, 2020 and 2021, respectively. Cost of product sales comprise the purchase price of products, vendor rebates and inventory write-downs. Cost of products does not include other direct costs related to cost of product sales such as shipping and handling expense, payroll and benefits of logistic staff, logistic centers rental expenses and depreciation expenses. Cost of service consists of the advertising and promotion costs, employee wages and benefits in connection with the Company’s provision of marketing and information services including the fees that the Company paid to third party for advertising and promotion on various online and offline channels.
Vendor rebates	(u) Vendor rebates The Company periodically receives consideration from certain vendors, representing rebates for products sold over a period of time. The Company accounts for the rebates received from its vendors as a reduction to the price it pays for the products purchased. Rebates are earned based on reaching minimum purchased thresholds for a specified period. When volume rebates can be reasonably estimated based on the Company’s past experience, current forecasts and purchase volume, a portion of the rebate is recognized as the Company makes progress towards the purchase threshold.
Fulfillment expenses	(v) Fulfillment expenses Fulfillment costs primarily represent warehousing, shipping and handling expenses for dispatching and delivering products to consumers, employee wages and benefits for the relevant personnel, customs clearance expenses and other related transaction costs.
Sales and marketing expenses	(w) Sales and marketing expenses Sales and marketing expenses comprise primarily of advertising expenses, third-party platforms commission fee, employee wages, rental expenses and benefits for sales and marketing staff, depreciation expenses and other daily expenses which are related to the sales and marketing functions. Advertising expenses consist primarily of customer acquisition cost and costs for the promotion of corporate image and product marketing. The Company expenses all advertising costs as incurred and classifies these costs under sales and marketing expenses. For the years ended March 31, 2019, 2020 and 2021, the advertising expenses were RMB95.9 million, RMB69 million and RMB83 million, respectively.
General and administrative expenses	(x) General and administrative expenses General and administrative expenses consist of employee wages and benefits for corporate employees, research and development expenses and other expenses which are related to the general corporate functions, including accounting, finance, tax, legal and human resources, costs associated with use by these functions of facilities and equipment, such as depreciation expenses, rental and other general corporate related expenses.
Leases	(y) Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use non-current ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate, which it calculates based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. The Company has elected to early adopt the following lease policies in conjunction with the adoption of ASU 2016-02 non-lease non-lease
Government grant	(z) Government grant The Company’s PRC based subsidiaries received government subsidies from certain local governments. The Company’s government subsidies consisted of specific subsidies and other subsidies. Specific subsidies are subsidies that the local government has provided for a specific purpose, such as product development and renewal of production facilities. Other subsidies are the subsidies that the local government has not specified its purpose for and are not tied to future trends or performance of the Company; receipt of such subsidy income is not contingent upon any further actions or performance of the Company and the amounts do not have to be refunded under any circumstances. The Company recorded specific purpose subsidies as advances payable when received. For specific subsidies, upon government acceptance of the related project development or asset acquisition, the specific purpose subsidies are recognized to reduce related cost of asset acquisition. Other subsidies are recognized as other income upon receipt as further performance by the Company is not required.
Income taxes	(aa) Income taxes Current income taxes are recorded in accordance with the regulations of the relevant tax jurisdiction. The Company accounts for income taxes under the asset and liability method in accordance with ASC 740, Income Tax Uncertain tax positions The Company recognizes in its consolidated financial statements the benefit of a tax position if the tax position is “more likely than not” to prevail based on the facts and technical merits of the position. Tax positions that meet the “more likely than not” recognition threshold are measured at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. The Company estimates its liability for unrecognized tax benefits which are periodically assessed and may be affected by changing interpretations of laws, rulings by tax authorities, changes and/or developments with respect to tax audits, and expiration of the statute of limitations. The ultimate outcome for a particular tax position may not be determined with certainty prior to the conclusion of a tax audit and, in some cases, appeal or litigation process. The actual benefits ultimately realized may differ from the Company’s estimates. As each audit is concluded, adjustments, if any, are recorded in the Company’s consolidated financial statements in the period in which the audit is concluded. Additionally, in future periods, changes in facts, circumstances and new information may require the Company to adjust the recognition and measurement estimates with regard to individual tax positions. Changes in recognition and measurement estimates are recognized in the period in which the changes occur. As of March 31, 2020 and 2021, the Company did not have any significant unrecognized uncertain tax positions.
Share-based compensation	(ab) Share-based compensation The Company follows ASC 718 to determine whether a share option should be classified and accounted for as a liability award or equity award. All grants of share-based awards to employees, management and nonemployees classified as equity awards are recognized in the financial statements based on their grant date fair values which are calculated using an option pricing model. Employees’ share-based compensation awards are measured at the grant date fair value of the awards and recognized as expenses (a) immediately at the grant date if no vesting conditions are required; or (b) for share-based awards granted with only service conditions, using the graded vesting method, net of estimated forfeitures, over the vesting period; or (c) for share-based awards granted with service conditions and the occurrence of an initial public offering (“IPO”) as performance condition, cumulative share-based compensation expenses for the options that have satisfied the service condition should be recorded upon the completion of the IPO, using the graded vesting method. Under ASC 718, the Company applies the Binominal option pricing model in determining the fair value of options granted. ASC 718 requires forfeiture rates to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. Share-based compensation expense is recorded net of estimated forfeitures such that expense is recorded only for those share-based awards that are expected to vest.
Net loss per share	(ac) Net loss per share Basic net loss per share is computed by dividing net loss attributable to holders of ordinary shares by the weighted average number of ordinary shares outstanding during the year using the two class method. Using the two class method, net profit/loss is allocated between ordinary shares and other participating securities (i.e. preferred shares) based on their participating rights. Diluted loss per share is calculated by dividing net loss attributable to ordinary shareholders as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalents shares outstanding during the year/period. Ordinary share equivalents consist of the ordinary shares issuable in connection with the Company’s convertible redeemable preferred shares using the if-converted
Comprehensive loss	(ad) Comprehensive loss Comprehensive loss is defined as the changes in shareholders’ deficit of the Company during a period transactions and other events and circumstances excluding transactions resulting from investments from shareholders, distributions to shareholders, accretions on convertible redeemable preferred shares and modification and extinguishment of convertible redeemable preferred shares. Comprehensive loss for the periods presented includes net loss and foreign currency translation adjustments.
Segment reporting	(ae) Segment reporting ASC 280, Segment Reporting Based on the criteria established by ASC 280, the Company’s chief operating decision maker (“CODM”) has been identified as the Chief Executive Officer, who reviews consolidated results when making decisions about allocating resources and assessing performance of the Company. As a whole and hence, the Company has only one reportable segment. The Company does not distinguish between markets or segments for the purpose of internal reporting. As the Company’s long-lived assets are substantially located in the PRC and substantially all the Company’s revenue are derived from within the PRC, no geographical segments are presented.
Recent accounting pronouncements	(af) Recent accounting pronouncements The Company qualifies as an “emerging growth company”, or EGC, pursuant to the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. As an EGC, the Company does not need to comply with any new or revised financial accounting standards until such date that a private company is otherwise required to comply with such new or revised accounting standards. The Company adopts the following standards based on extended transition period provided to private companies or early adopts as necessary as permitted by the respective standards. New and amended standards not yet adopted by the Company: In June 2016, the FASB issued ASU 2016-13, 2016-13 2016-13 In December 2019, the FASB issued ASU 2019-12—Income 2019-12 2019-12 2019-12. In January 2020, the FASB issued ASU 2020-01 815-10-15-141(a) 2020-01.

Organization and principal ac_2

Organization and principal activities (Tables)	12 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Details of the Subsidiaries, VIEs and VIE's Subsidiaries	As of March 31, 2021, the Company’s principal subsidiaries, consolidated VIEs and major VIEs’ subsidiaries are as follows: Name of subsidiaries and VIE Place of incorporation Date of incorporation or acquisition Percentage of direct or indirect Principal activities Subsidiaries: Boqii Corporation Limited (“Boqii Corporation”) Hong Kong July 2012 100% Investment holding Boqii International Limited Hong Kong August 2016 100% Investment holding Xingmu International Limited British Virgin Islands August 2019 51% Investment holding Xingmu HK Limited Hong Kong November 2019 51% Investment holding Nanjing Xinmu Information Technology Co., Ltd. (“Xingmu WFOE”) Nanjing, the PRC November 2019 51% Technology development and sales of merchandise Xincheng (Shanghai) Information Technology Co., Ltd. (“Shanghai Xincheng”) Shanghai, the PRC November 2012 100% Technology development and sales of merchandise Shanghai Yiqin Pets Products Co., Ltd. Shanghai, the PRC February 2013 100% Technology development and sales of merchandise Consolidated VIEs Guangcheng (Shanghai) Information Technology Co., Ltd. Shanghai, the PRC November 2012 100% Operates the Company’s own online e-commerce Nanjing Xingmu Biotechnology Co., Ltd. Nanjing, the PRC November 2019 51% Biotechnology research and development Subsidiaries of VIEs Boqii (Shanghai) Information Technology Co., Ltd. Shanghai, the PRC August 2014 90% Technology development Tianjing Guangcheng Information Technology Co., Ltd. Tianjin, the PRC June 2017 100% Sales of merchandise Nanjing Cuida Biotechnology Co. Ltd.(“Cuida”) Nanjing, the PRC April 2017 70% Biotechnology extension services Taizhou Xingmu Biotechnology Co., Ltd. Taizhou, the PRC November 2019 80% Biotechnology research and development
Schedule of Variable Interest Entities	The following table set forth the assets, liabilities, results of operations and changes in cash, cash equivalents and restricted cash of the consolidated VIEs and their subsidiaries taken as a whole, which were included in the Company’s consolidated financial statements with intercompany transactions eliminated (RMB in thousands): As of March 31, 2020 2021 RMB RMB Cash and cash equivalents 36,977 17,886 Accounts receivable, net 36,682 63,331 Amounts due from related parties 4,752 11,466 Inventories, net 38,400 11,349 Prepayments and other current assets 47,215 45,098 Property and equipment, net 4,933 8,372 Intangible assets 1,315 909 Operating lease right-of-use 13,565 27,736 Goodwill 494 494 Long-term investments 73,432 74,330 Other non-current 1,004 2,433 Total assets 258,769 263,404 As of March 31, 2020 2021 RMB RMB Short-term borrowings 2,761 3,484 Accounts payable 331,760 439,879 Amounts due to related parties, current 45 910 Salary and welfare payable 3,789 4,851 Accrued liabilities and other current liabilities 116,516 225,709 Contract liabilities 7,621 3,706 Operating lease liabilities, current 6,652 6,058 Deferred tax liabilities 2,593 1,852 Operating lease liabilities, non-current 5,375 19,997 Long-term 982 872 Other debts, non-current 147,774 415,122 Amounts due to related parties, non-current 10,450 — Total liabilities 636,318 1,122,440 Year Ended March 31, 2019 2020 2021 RMB RMB RMB Total revenues 761,121 672,093 783,892 Cost of revenues (557,275 ) (509,168 ) (670,319 ) Net loss 150,002 61,805 166,502 Net cash used in operating activities (108,063 ) 22,099 88,703 Net cash used in investing activities (12,722 ) (43,435 ) (37,214 ) Net cash provided by financing activities 118,070 44,228 (70,434 ) Effects of foreign exchange rate changes on cash and cash equivalents 3,826 (8,268 ) (146 ) Net increase in cash and cash equivalents 1,111 14,624 (19,091 ) Cash and cash equivalents at beginning of the year 21,242 22,353 36,977 Cash and cash equivalents at end of the year 22,353 36,977 17,886

Principal Accounting Policies_2

Principal Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Schedule of Property Plant and Equipment & Useful Lives	The estimated useful lives are as follows: Useful years Warehouse equipment 3 - 5 years Furniture, computer and office equipment 3 - 5 years Vehicles 5 years Software 10 years Leasehold improvements Over the shorter of the expected life of leasehold improvements or the lease term
Schedule of Finite Lived Intangible Assets Useful Lives	The estimated useful lives of intangible assets are as follows: Useful years Trademark 10 years Dealership 10 years License 4.5 - 10 years

Business combinations (Tables)

Business combinations (Tables)	12 Months Ended
	Mar. 31, 2021
NanjingCuidaBiotechnology Co Ltd [Member]
Business Acquisition [Line Items]
Summary of Identified Assets Acquired and Liabilities Assumed	Fair value of the noncontrolling interests was estimated based on the equity value of Cuida derived by the discounted cash flow method after further considering a discount for lack of control: As of December 18, 2018 RMB Cash and cash equivalents 36 Accounts receivable, net 15 Inventory 783 Prepayments and other current assets 5,693 Amortizable intangible assets License 1,773 Total assets 8,300 Salary and welfare payable (4 ) Accrued liabilities and other current liabilities (246 ) Deferred tax liabilities (443 ) Total liabilities (693 ) Net assets acquired 7,607 Goodwill 494 Non-controlling (2,101 ) Total 6,000 As of December 18, 2018 RMB Total purchase price is comprised of: - cash consideration 6,000
Summary of Business Acquisition, Pro Forma Information	The pro forma operating results for the Company, assuming the acquisition of Cuida occurred on April 1, 2017, represents the pro forma impact from April 1, 2017 to December 17, 2018. Year Ended March 31, 2019 RMB Net revenues 804,175 Net loss (231,712 )
Xingmu Group [Member]
Business Acquisition [Line Items]
Summary of Identified Assets Acquired and Liabilities Assumed	Fair value of the noncontrolling interests was estimated based on the equity value of Xingmu Group derived by the discounted cash flow method after further considering a discount for lack of control: As of November 1, 2019 RMB Cash and cash equivalents 1,783 Accounts receivable, net 3,273 Inventory 9,445 Prepayments and other current assets 6,092 Property and equipment, net 91 Long-term investments 2,502 Amortizable intangible assets License 1,756 Dealership 31,717 Total assets 56,659 Short-term borrowings (2,200 ) Accounts payable (1,561 ) Salary and welfare payable (159 ) Accrued liabilities and other current liabilities (3,970 ) Deferred tax liabilities (8,368 ) Total liabilities (16,258 ) Net assets acquired 40,401 Goodwill 39,690 Non-controlling (36,023 ) Total 44,068 As of November 1, 2019 RMB Total purchase price is comprised of: - fair value of 14.5% previously held equity interests 10,628 - fair value of the Company’s Series E convertible redeemable preferred shares to achieve control 33,440 Fair value of total consideration 44,068
Summary of Business Acquisition, Pro Forma Information	The pro forma operating results for the Company, assuming the acquisition of Xingmu occurred on April 1, 2018 is as follows: Year Ended March 31, 2019 Year Ended March 31, 2020 RMB RMB Net revenues 850,932 802,249 Net loss (230,451 ) (176,070 )

Risks and Concentration (Tables

Risks and Concentration (Tables)	12 Months Ended
	Mar. 31, 2021
Risks and Uncertainties [Abstract]
Schedules of Concentration of Risk, By Risk Factor	The following table summarizes the supplier with greater than 10% of the accounts payable of the Company: Year Ended March 31, 2019 Year Ended March 31, 2020 Year Ended March 31, 2021 RMB RMB RMB Royal Canin China Co., Ltd. 14,320 13,331 15,616

Cash and cash equivalents (Tabl

Cash and cash equivalents (Tables)	12 Months Ended
	Mar. 31, 2021
Cash and Cash Equivalents [Abstract]
Schedule of Cash and Cash Equivalents	Cash and cash equivalents represent cash on hand and demand deposits placed with banks and third party-payment processors, which are unrestricted as to withdrawal or use. Cash and cash equivalents balance as of March 31, 2020 and March 31, 2021 primarily consist of the following currencies: As of March 31, 2020 As of March 31, 2021 Amount RMB Amount RMB RMB 83,844 83,844 121,670 121,670 Hong Kong dollars 15 13 25 21 US$ 635 4,495 25,947 170,508 EUR — — 5 38 Total 88,352 292,237

Accounts receivable, net (Table

Accounts receivable, net (Tables)	12 Months Ended
	Mar. 31, 2021
Receivables [Abstract]
Summary of Accounts Receivable Net	Accounts receivable consist of the following : As of March 31, As of March 31, RMB RMB Accounts receivable - Product sales 44,558 37,429 Accounts receivable - Online marketing and information service and other service 785 8,559 Allowance of doubtful accounts (363 ) (256 ) Total 44,980 45,732
Summary of Movement of Allowance of Doubtful Accounts	Movement of allowance of doubtful accounts As of March 31, As of March 31, As of March 31, RMB RMB RMB At beginning of year — 92 363 Addition/(reversal) 92 271 (107 ) At end of year 92 363 256

Inventories, net of inventory_2

Inventories, net of inventory reserves (Tables)	12 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Summary of Inventories, Net of Inventory Reserves	Inventories, net of inventory reserves consist of the following : As of March 31, As of March 31, RMB RMB Products 62,249 90,913 Packaging materials and others 807 638 Total inventories, net of inventory reserves 63,056 91,551

Prepayments and other current_2

Prepayments and other current assets (Tables)	12 Months Ended
	Mar. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Summary of Prepayments and Other Current Assets	The prepayments and other current assets consist of the following: As of March 31, As of March 31, RMB RMB Loans receivable (a) 35,082 3,957 Prepayments for purchases of products (b) 16,152 53,209 Vendor rebate receivables (c) 10,486 8,723 Value-added tax (“VAT”) deductible (d) 9,818 10,672 Sales return assets 1,157 1,244 Deposits 774 1,456 Others 3,251 6,000 Total 76,720 85,261 (a) The balance represents loans receivable due from third parties. In January 2020, the Company entered into a four-month loan agreement with a third-party company for a principal amount of RMB1.0 million, bearing an interest rate of 6% per annum and the loan was repaid in May 2020. In May 2019, the Company entered into a four-month loan agreement with a third-party company for a principal amount of US$1.5 million (RMB10.8 million), bearing an interest rate of 5% per annum. In September 2019, the Company and the borrower agreed to extend the loan agreement for another eight months. In May 2019, the Company entered into an interest free loan agreement with one of its previously preferred shareholders for a principal amount of US$1.4 million (RMB9.8 million) with a term of 730 days, which was subsequently amended to 600 days on December 5, 2019, and the maturity date of the loan was shortened to December 2020. The Company accounted for the loan receivable by using effective interest rate method and difference of RMB0.2 million between the discounted present value of the loan receivable and the cash amount lent out was recorded as interest income loss for the year end March 31, 2020. The loan was early repaid in July, 2020. In June 2020, the Company entered into another interest free loan agreement with the shareholder for a principal amount of US$4.85 million (RMB33.0 million) with a term of three months. In February 2021, the Company entered into a share repurchase agreement with the shareholder. The Company repurchased and cancelled 521,924 shares of Class A ordinary shares held by the shareholder with a consideration amounting to the loan principal of US$4.85 million. In December 2018, the Company entered into an interest free facility loan agreement with a third-party company for a total loan facility up to RMB20 million with a term of 12 months. As of March 31, 2020 and 2021, the principal amount outstanding under this agreement was RMB11.4 million and RMB0.6 million, respectively. The loan was repaid in June 2021. In December 2018, the Company entered into a two-year In December 2018, the Company entered into a two-year In July 2020, the Company entered into a one-year In September 2020, the Company entered into a one-year From November 2020 to February 2021, the Company has entered into six one-year (b) Prepayments for purchases of products represent cash prepaid to the Company’s third party brand partners for the procurement of products. (c) Vendor rebate receivables represent the rebates to be received by the Company from its suppliers after certain levels of purchases are achieved. (d) VAT recoverable represents the balances that the Company can utilize to deduct its value-added tax liabilities within the next 12 months.

Property and equipment, net (T

Property and equipment, net (Tables)	12 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Summary of Property, Plant and Equipment's	Property and equipment consist of the following: As of March 31, As of March 31, RMB RMB Cost: Warehouse equipment 2,426 2,513 Furniture, computer and office equipment 5,864 6,592 Vehicles 1,912 2,891 Leasehold improvement 5,555 10,056 Software 2,695 2,709 Total cost 18,452 24,761 Less: Accumulated depreciation (13,471 ) (16,375 ) Property and equipment, net 4,981 8,386

Intangible assets, net (Tables)

Intangible assets, net (Tables)	12 Months Ended
	Mar. 31, 2021
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Schedule of Intangible Assets	Intangible assets of the Company were mainly as follows: As of March 31, As of March 31, RMB RMB Cost: Trademark 447 447 License (Note 3) 3,530 3,530 Dealership (Note 3) 31,717 31,717 Total cost 35,694 35,694 Less: Accumulated amortization (2,156 ) (6,157 ) Intangible assets, net 33,538 29,537
Schedule of Annual Estimated Amortization Expense for Intangible Assets	The annual estimated amortization expense for intangible assets subject to amortization for the succeeding five years is as follows: As of March 31, 2022 2023 2024 2025 2026 Amortization expenses 4,001 4,001 3,770 3,342 3,209

Long-Term Investments (Tables)

Long-Term Investments (Tables)	12 Months Ended
	Mar. 31, 2021
Long-term Investments and Receivables, Net [Abstract]
Summary of Long-Term Investment	The Company’s long-term investments consist of the following: As of March 31, As of March 31, 2020 2021 RMB RMB Equity method investments 3,104 2,973 Available-for-sale 70,328 71,357 Total 73,432 74,330
Summary of Available-For-Sale Debt Investments	The following table summarizes the Company’s available-for-sale Cost Gross unrealized gains Gross unrealized losses Fair value Unlisted debt securities 60,000 10,328 — 70,328 The following table summarizes the Company’s available-for-sale Cost Gross unrealized gains Gross unrealized losses Fair value Unlisted debt securities 60,000 11,357 — 71,357

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes in the Carrying Amount of Goodwill	The changes in the carrying amount of goodwill were as follows: Total RMB Balance as of March 31, 2019 Goodwill 494 Accumulated impairment loss — 494 Transaction during the year Additions (Note 3) 39,690 Balance as of March 31, 2020 Goodwill 40,184 Accumulated impairment loss — 40,184 Transaction during the year Additions — Balance as of March 31, 2021 Goodwill 40,184 Accumulated impairment loss — 40,184

Other non-current Assets (Table

Other non-current Assets (Tables)	12 Months Ended
	Mar. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Non-current Assets	As of March 31, As of March 31, 2020 2021 RMB RMB Deposits (a) 3,076 3,767 Long-term loans receivable (b) — 344 Deferred initial public offering related costs 7,943 — 11,019 4,111 (a) Deposits mainly consisted of rental deposits and deposit for online stores operated on third party platforms, which will be collected after one year. (b) In December 2018, the Company entered into a two-year

Accrued liabilities and other_2

Accrued liabilities and other current liabilities (Tables)	12 Months Ended
	Mar. 31, 2021
Accrued Liabilities and Other Liabilities [Abstract]
Schedule of Accrued Liabilities and Other Current Liabilities	Accrued liabilities and other current liabilities consist of the following: As of March 31, As of March 31, 2020 2021 RMB RMB Logistics expenses payables 18,688 16,594 Accrued advertising expenses 611 228 Advances from customers (a) 7,825 3,534 Refund obligation of sales returns 1,345 1,543 Professional service fee accruals 5,046 3,449 Others 4,368 4,707 Total 37,883 30,055 (a) This balance represented the deposits placed from the Company’s customers for the purchases of the Company’s goods and services, and are refundable upon customer requests.

Leases (Tables)

Leases (Tables)	12 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Summary of Operating Leases	As of March 31, As of March 31, 2020 2021 RMB RMB Assets Operating lease right-of-use 14,951 29,234 Liabilities Operating lease liabilities, current 7,969 8,063 Operating lease liabilities, non-current 5,375 19,997 Weighted average remaining lease term (years) 1.52 3.70 Weighted average discount rate 5.82 % 6.47 %
Summary of Operating Lease Activity	Information related to operating lease activity during the years ended March 31, 2019, 2020 and 2021 are as follows: Year ended March 31, 2019 Year ended March 31, 2020 Year ended March 31, 2021 RMB RMB RMB Operating lease right-of-use 19,570 10,051 25,970 Operating lease rental expense Amortization of right-of-use 17,919 15,708 11,687 Interest of lease liabilities 1,636 1,353 1,596 19,555 17,061 13,283 Year ended March 31, 2019 Year ended March 31, 2020 Year ended March 31, 2021 RMB RMB RMB Operating lease payments (included in measurement of lease liabilities) 19,284 18,183 12,850
Summary of Maturities of Lease Liabilities	Maturities of lease liabilities were as follows: Year ended March 31, 2021 RMB For the year ending March 31, 2022 11,213 2023 6,589 2024 5,837 2025 6,568 2026 and thereafter 2,949 Total lease payments 33,156 Less: imputed interest (5,096 ) Total 28,060

Interest expense (Tables)

Interest expense (Tables)	12 Months Ended
	Mar. 31, 2021
Interest and Debt Expense [Abstract]
Summary of Interest Expense	Year ended March 31, 2019 Year ended March 31, 2020 Year ended March 31, 2021 RMB RMB RMB Amortization charges on promissory notes 17,077 56,290 21,611 Interest expense on borrowings 1,453 2,815 6,039 Others 124 163 — Total 18,654 59,268 27,650

Other gains (losses), net (Tabl

Other gains (losses), net (Tables)	12 Months Ended
	Mar. 31, 2021
Other Income and Expenses [Abstract]
Summary of Other (Losses), Net	Year ended March 31, 2019 Year ended March 31, 2020 Year ended March 31, 2021 RMB RMB RMB Gain from the re-measurement — 481 — Foreign exchange losses, net (8,971 ) (3,787 ) (2,867 ) Gain on disposal of other debts (Note 22) — 10,095 6,846 Reimbursement from a depositary bank (a) — — 6,556 Others (843 ) 195 797 (9,814 ) 6,984 11,332 (a) In December 2020, the Company received a reimbursement of US$1.0M (equivalent to RMB6.6 million) from the depository for the establishment and maintenance of the ADS program.

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	Reconciliations of the differences between the income tax expense of the Company and the PRC statutory EIT rate applicable to losses of the consolidated entities are as follows: Year ended March 31, 2019 Year ended March 31, 2020 Year ended March 31, 2021 RMB RMB RMB Loss before income tax (231,758 ) (175,925 ) (193,391 ) Income tax computed at respective applicable tax rate (57,940 ) (43,981 ) (48,348 ) Effect of different tax jurisdiction 25,553 19,507 14,272 Super deduction for research and development expenses (a) (5,969 ) (4,719 ) (2,632 ) Non-deductible 133 138 140 Change in valuation allowance 38,364 29,567 37,439 Total 141 512 871 Reconciliations between the effective income tax rate and the PRC statutory income tax rate are as follows: Year ended March 31, 2019 Year ended March 31, 2020 Year ended March 31, 2021 RMB RMB RMB PRC statutory income tax rates 25 % 25 % 25 % Effect on tax rates in different tax jurisdiction (11 %) (11 %) (7 %) Super deduction for research and development expenses 3 % 3 % 1 % Non-deductible 0 % 0 % 0 % Change in valuation allowance (17 %) (17 %) (19 %) Total 0 % 0 % 0 %
Summary of Income Tax Holiday	The following table sets forth the effect of preferential tax on China operations: Year ended March 31, 2019 Year ended March 31, 2020 Year ended March 31, 2021 RMB RMB RMB Tax holiday effect (4,126 ) (5,471 ) 1,074 Basic and diluted net loss per share effect (0.20 ) (0.25 ) 0.02
Schedule of Components of Income Tax Expense (Benefit)	The current and deferred portions of income tax expense included in the consolidated statements of comprehensive loss are as follows: Year ended March 31, 2019 Year ended March 31, 2020 Year ended March 31, 2021 RMB RMB RMB Current income tax expense — 149 1,018 Deferred tax expense (141 ) (661 ) (1,889 ) Income tax credit, net (141 ) (512 ) (871 )
Schedule of Deferred Tax Assets And Tax Liabilities	Deferred taxes were measured using the enacted tax rates for the periods in which they are expected to be reversed. The tax effects of temporary differences that give rise to the deferred tax asset and liabilities balances as of March 31, 2020 and 2021 are as follows: As of March 31, As of March 31, 2020 2021 RMB RMB Deferred tax assets: Net accumulated loss-carry forward 106,320 143,426 Deferred deductible advertising expense 1,780 940 Allowance 159 130 Contract liabilities 1,821 413 Accruals 2,459 5,069 Less: Valuation allowance (112,539 ) (149,978 ) Net deferred tax assets — — As of March 31, As of March 31, 2020 2021 RMB RMB Deferred tax liabilities: Recognition of intangible assets arising from asset acquisition and business combination (8,009 ) (6,119 ) Unrealized fair value change of the available-for-sale (2,582 ) (2,839 ) Net deferred tax liabilities (10,591 ) (8,958 )
Summary of Valuation Allowance	Movement of valuation allowance is as follows: As of March 31, As of March 31, 2020 2021 RMB RMB Beginning balance 82,972 112,539 Change of valuation allowance 29,567 37,439 Ending balance 112,539 149,978

Convertible redeemable prefer_2

Convertible redeemable preferred shares (Tables)	12 Months Ended
	Mar. 31, 2021
Statement of Stockholders' Equity [Abstract]
Summary of Preferred Shares Activities for the Periods as Summarized	The Company’s Preferred Shares activities for the periods presented are summarized below: Series A Preferred Series B Preferred Series C Preferred Series C+ Preferred Series D Preferred Series D-1 Preferred Series D-2 Preferred Series E Preferred Number of Amount Number of Amount Number of Amount Number of Amount Number of Amount Number of Amount Number of Amount Number of Amount Balance as of March 31, 2018 10,340,000 287,629 9,067,384 321,636 5,518,101 275,986 — — 2,296,387 140,859 — — — — — — Issuance — — — — — — — — 229,639 13,662 1,089,265 68,138 — — — — Accretion on the Preferred Shares to redemption value — 137,301 — 141,924 — 94,883 — — — 13,367 — 5,075 — — — — Deemed dividend to preferred shareholders upon modification of Preferred Shares — — — — — — — — — 527 — 196 — — — — Balance as of March 31, 2019 10,340,000 424,930 9,067,384 463,560 5,518,101 370,869 — — 2,526,026 168,415 1,089,265 73,409 — — — — Issuance (Note a) — — — — — — — — — — 1,089,265 82,048 1,182,803 89,447 1,042,623 74,830 Accretion on the Preferred Shares to redemption value — 59,192 — 64,122 — 49,550 — — — 19,768 — 8,825 — 17 — 3,322 Deemed dividend to preferred shareholders (Note b) — — — — — — — — — — — — — — — 401 Balances as of March 31, 2020 10,340,000 484,122 9,067,384 527,682 5,518,101 420,419 — — 2,526,026 188,183 2,178,530 164,282 1,182,803 89,464 1,042,623 78,553 Balances as of March 31, 2020 10,340,000 484,122 9,067,384 527,682 5,518,101 420,419 — — 2,526,026 188,183 2,178,530 164,282 1,182,803 89,464 1,042,623 78,553 Issuance (Note a) — — — — — — 6,734,459 656,448 — — — — — — 4,842,587 353,893 Accretion on the Preferred Shares to redemption value — (22,677 ) — (23,345 ) — (88,954 ) — 6,360 — (7,179 ) — 577 — 2,850 — 11,495 Deemed dividend to preferred shareholders (Note b) — — — — — — — — — — — — — — — 12,039 Conversion of convertible redeemable preferred shares upon completion of the IPO (10,340,000 ) (461,445 ) (9,067,384 ) (504,337 ) (5,518,101 ) (331,465 ) (6,734,459 ) (662,808 ) (2,526,026 ) (181,004 ) (2,178,530 ) (164,859 ) (1,182,803 ) (92,314 ) (5,885,210 ) (455,980 ) Balances as of March 31, 2021 — — — — — — — — — — — — — — — — Note a: In March 2020, 112,648 Series D-2 D-2 D-2 D-2 D-1 D-1 D-2 D-2 Note b: As of March 31, 2020 and 2021, the deemed dividend to preferred shares of the Company was RMB0.4 million and RMB12 million, respectively.

Borrowings, other debts and d_2

Borrowings, other debts and derivative liabilities (Tables)	12 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Summary of Short-term Debt	The following table presents short-term borrowings from commercial banks, other institutions and individuals as of March 31, 2020 and 2021. Short-term borrowings include borrowings with maturity terms shorter than one year: As of March 31, As of March 31, 2020 2021 RMB RMB Bank borrowings 32,738 85,566 Other borrowings 42,485 — Total short-term borrowings 75,223 85,566
Summary of Long-term Debt Instruments	The following table presents long-term borrowings from commercial banks, other institutions and individuals as of March 31, 2020 and 2021. Long-term borrowings include borrowings with maturity terms greater than one year: As of March 31, As of March 31, 2020 2021 RMB RMB Bank borrowings 48,191 68,075 Other borrowings 4,957 — Total long-term borrowings 53,148 68,075
Summary of Maturities of Long-term Debt	Future principal maturities of short-term borrowings and long-term borrowings as of March 31, 2021 are as followings: Year ended March 31, 2021 RMB For the year ending March 31, 2022 85,566 2023 68,075 Total 153,641
Summary of Other Short Term Debt	Other debts - current consist of the following: As of March 31, As of March 31, 2020 2021 RMB RMB Series D-3 76,252 —
Summary of Other Long Term Debt	Other debts – non-current As of March 31, As of March 31, 2020 2021 RMB RMB Loan for Series C+ Warrant (Note 20) — 312,535 Loan for Series D-3 11,192 — Loan for Series D-3 41,824 — Loan from Chong Li (b) 94,758 100,842 Loan for Yoken Series A-1 18,000 19,915 Total 165,774 433,292
Summary of Fair Value of Derivative Liabilities	The Company determined the fair value of derivative liabilities and concluded that as of March 31, 2020 and 2021, the fair values of the derivative liabilities are as follows: As of March 31, As of March 31, 2020 2021 RMB RMB Conversion feature of Yoken Series A-1 — 9,362 Conversion feature of Series D-3 2,377 — Conversion feature of Series D-3 9,473 — Series E Warrant (Note 22(h)) 2,501 444 Forward exchange swap (Note 22(i)) — 190 Total 14,351 9,996

Share-based compensation (Table

Share-based compensation (Tables)	12 Months Ended
	Mar. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Summary of Stock Option Activity	The following table sets forth the share options activity for the years ended March 31, 2020 and 2021: Number of shares Weighted average exercise price US$ Weighted average remaining contractual term Aggregate intrinsic value US$ Weighted fair value US$ Outstanding as of March 31, 2019 5,686,454 1.49 5.8610 34,717 1.68 Exercisable as of March 31, 2019 1,299,954 0.001 5.5679 9,878 1.83 Granted 915,097 4.03 — — 5.02 Exercised (1,299,954 ) 0.001 — — — Forfeited (444,625 ) 2.45 — — 1.89 Outstanding as of March 31, 2020 4,856,972 2.26 6.6680 39,472 2.72 Exercisable as of March 31, 2020 — — — — — Granted 998,000 4.13 — — 2.49 Forfeited (342,750 ) 3.49 — — 4.00 Outstanding as of March 31, 2021 5,512,222 3.36 6.32 29,360 3.28 Exercisable as of March 31, 2021 — — — — —
Employees and Non Employees [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Summary of Options Measured At Fair Value, Valuation Assumptions	Options granted to Participants were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: Year ended March 31, 2020 Year ended March 31, 2021 Expected volatility 43.49% 44.41% Risk-free interest rate 0.87% 0.94% Exercise multiple 2.8/2.2 2.8/2.2 Expected dividend yield 0% 0% Contractual term (in years) 10 10

Fair value measurements (Tables

Fair value measurements (Tables)	12 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Summary of Company's Financial Assets and Liabilities	The following table summarizes the Company’s financial assets and liabilities measured and recorded at fair value on recurring basis as of March 31, 2020 and 2021: Fair value measurement at reporting date using Description Fair value as of Quoted price in Significant other Significant RMB RMB RMB RMB Assets: Available-for-sale 70,328 — — 70,328 Liabilities: Derivative liabilities 14,351 — — 14,351 Fair value measurement at reporting date using Description Fair value as of Quoted price in Significant other Significant RMB RMB RMB RMB Assets: Short-term investments 168,546 — 168,546 — Available-for-sale 71,357 — — 71,357 Total assets 239,903 — 168,546 71,357 Liabilities: Derivative liabilities 9,996 — 190 9,806
Summary of Roll Forward of Major Level 3 Investments	The roll forward of major Level 3 investments are as following: Derivative Available-for-sale Fair value of Level 3 investments as at March 31, 2018 1,333 13,767 New addition 32,099 — Conversion of Series D Notes (Note 20) (182 ) — Unrealized fair value change of the derivative liabilities 2,274 — Unrealized fair value change of the available-for-sale — 2,283 Fair value of Level 3 investments as at March 31, 2019 35,524 16,050 New addition 13,487 50,000 Conversion of Series D-1 (10,701 ) — Conversion of Series D-2 (10,614 ) — Unrealized fair value change of the derivative liabilities (13,345 ) — Unrealized fair value change of the available-for-sale — 4,278 Fair value of Level 3 investments as at March 31, 2020 14,351 70,328 New addition 9,391 — Disposal of Series D-3 (2,377 ) — Unrealized fair value change of the derivative liabilities (11,559 ) — Unrealized fair value change of the available-for-sale — 1,029 Fair value of Level 3 investments as at March 31, 2021 9,806 71,357
Summary of Significant Unobservable Inputs	The Company determined the fair value of their investments by using income approach and equity allocation model. The determination of the fair value was based on estimates, judgments and information of other comparable public companies. The significant unobservable inputs adopted in the valuation as of March 31, 2020 and 2021: As of March 31, As of March 31, 2020 2021 Weighted average cost of capital 15%, 16.5% 15%,16.5% Lack of marketability discount 17%, 23% 17%,23% Risk-free rate 1.86%, 2.24% 2.88%,2.87% Expected volatility 39.86%, 48.13% 41.79%,42.26% Probability Liquidation scenario: 40% Redemption scenario: 40% IPO scenario: 20% Liquidation scenario: 40% Redemption scenario: 40% IPO scenario: 20%

Net loss per share (Tables)

Net loss per share (Tables)	12 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	Basic loss per share and diluted loss per share have been calculated in accordance with ASC 260 on computation of earnings per share for the years ended March 31, 2019, 2020 and 2021, respectively, as follows: Year Ended March 31, 2019 Year Ended March 31, 2020 Year Ended March 31, 2021 RMB RMB RMB Numerator: Net loss attributable to Boqii Holding Limited (234,241 ) (179,024 ) (194,444 ) Accretion on the Preferred Shares to redemption value (Note 20) (392,550 ) (204,796 ) 120,873 Accretion on the Redeemable non-controlling — — (138 ) Deemed dividend to preferred shareholders (723 ) (1,142 ) (12,547 ) Net loss attributable to ordinary shareholders (625,514 ) (384,962 ) (86,256 ) Denominator: Weighted average number of ordinary shares used in computing net loss per share, Basic and diluted (Note (a)) 22,238,454 22,238,454 66,953,610 Net loss per share attributable to ordinary shareholders: Basic and diluted (28.22 ) (17.31 ) (1.29 )
Schedule of Antidilutive Securities Excluded From Computation Of Earnings Per Share	The following ordinary shares equivalent were excluded from the computation of diluted net loss per ordinary share for the periods presented because including them would have had an anti-dilutive effect: Year Ended March 31, 2019 Year Ended March 31, 2020 Year Ended March 31, 2021 RMB RMB RMB Preferred Shares — weighted average 25,083,831 26,072,893 — Share options - weighted average — — 2,585,103

Related party transactions (Tab

Related party transactions (Tables)	12 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Summary of Major Related Parties And Their Relationships With The Company	The table below sets forth the major related parties and their relationships with the Company as of March 31, 2019, 2020 and 2021: Name of related parties Relationship with the Company Nanjing Xingmu An equity investee of the Company before November 1, 2019 Nanjing Animal Pharmaceutical An equity investee of the Company Shanghai Yichong An equity investee of the Company Wuhan Chunzhijin An equity investee of the Company Beijing Petdog An available-for-sale Yingzhi (Lisa) Tang A senior management of the Company Di (Jackie) Chen A senior management of the Company Ying (Christina) Zhang A senior management of the Company Fei Wang A senior management of the Company Yan Jiang A senior management of the Company
Summary of Related Party Transactions And Balances	The Company believes that the terms of the agreements with the related parties are comparable to the terms in arm’s-length Transactions with related parties Year Ended March 31, 2019 Year Ended March 31, 2020 Year Ended March 31, 2021 RMB RMB RMB Sales of goods Beijing Petdog — 2,316 — Year Ended March 31, 2019 Year Ended March 31, 2020 Year Ended March 31, 2021 RMB RMB RMB Online marketing and information services Beijing Petdog — 315 410 Year Ended March 31, 2019 Year Ended March 31, 2020 Year Ended March 31, 2021 RMB RMB RMB Purchase of merchandise Nanjing Xingmu 2,533 751 — Nanjing Animal Pharmaceutical — 45 250 2,533 796 250 Year Ended March 31, 2019 Year Ended March 31, 2020 Year Ended March 31, 2021 RMB RMB RMB Loans granted to related parties Nanjing Animal Pharmaceutical (a) — 1,000 500 Wuhan Chunzhijin (b) — — 5,690 Yan Jiang 17,848 — 200 Ying (Christina) Zhang — 152 — Di (Jackie) Chen — 785 — Fei Wang (c) — — 500 17,848 1,937 6,890
Summary of Related Party Transactions	Year Ended March 31, 2019 Year Ended March 31, 2020 Year Ended March 31, 2021 RMB RMB RMB Staff advances Yingzhi (Lisa) Tang — — 10 Di (Jackie) Chen 528 6 — 528 6 10 Advances provided to related parties Nanjing Animal Pharmaceutical — — 2,073 Wuhan Chunzhijin 2,720 3,350 — 2,720 3,350 2,073 Loans granted from related parties Yingzhi (Lisa) Tang (a) 5,014 1,450 — Di (Jackie) Chen (b) — 1,250 — Yan Jiang (c) — 9,000 — 5,014 11,700 — (a) In September 2019, the Company obtained a two-year In November 2018, Yingzhi (Lisa) Tang advanced RMB4 million to the Company, which was repaid by the Company in the same month. In July 2018, the Company obtained a forty-month loan of US$0.15 million (RMB1 million) from Yingzhi (Lisa) Tang, bearing an interest rate of 6.0% per annum. The loan was early repaid in January 2021. (b) In October 2019, Di (Jackie) Chen advanced RMB1.25 million to the Company, which was repaid by the Company in the same month. (c) In September 2019, the Company obtained a two-year
Summary of Transactions Due From Related Parties	Amounts due from related parties As of March 31, As of March 31, As of March 31, RMB RMB RMB Trade receivables from related parties Beijing Petdog — 1,564 — Prepayments to related parties Nanjing Animal Pharmaceutical — — 2,023 Nanjing Xingmu 138 — — 138 — 2,023 As of March 31, As of March 31, As of March 31, RMB RMB RMB Other receivables from related parties Wuhan Chunzhijin 3,795 2,481 7,295 Loans to related parties Nanjing Animal Pharmaceutical — 1,000 500 Yingzhi (Lisa) Tang — — 10 Yan Jiang — — 200 Di (Jackie) Chen (a) — 785 785 Ying (Christina) Zhang — 152 152 Fei Wang (b) — — 500 — 1,937 2,147 (a) In December 2019, the Company entered into a twelve-month interest free loan agreement with, Di (Jackie) Chen, for a principal amount of RMB0.7 million. In December 2020, the loan contract was renewed for another one year. (b) In January 2021, the Company entered into a one-year loan agreement with Fei Wang, for a principal amount of RMB0.5 million, bearing an interest rate of 4% per annum. This Loan was pledged by 515,000 stock options owned by Fei Wang.
Summary of Transactions Due To related parties	Amounts due to related parties As of March 31, As of March 31, As of March 31, RMB RMB RMB Trade payables to related parties Nanjing Animal Pharmaceutical — 45 874 As of March 31, As of March 31, As of March 31, RMB RMB RMB Advances from related parties Beijing Petdog — — 36 Wuhan Chunzhijin 150 — — 150 — 36 Long-term loan from related parties Yingzhi (Lisa) Tang (a) 1,015 2,521 — Yan Jiang (b) — 9,000 — 1,015 11,521 — (a) In July 2018, the Company entered into a forty-month loan agreement with Yingzhi (Lisa) Tang, for a principal amount of US$0.15 million (RMB1.0 million), bearing an interest rate of 6% per annum. The loan was early repaid in January 2021. In September 2019, the Company entered into another two-year (b) The balance as of December 31, 2019 represented a two-year

Condensed financial informati_2

Condensed financial information of the parent company (Tables)	12 Months Ended
	Mar. 31, 2021
Condensed Financial Information Disclosure [Abstract]
Summary of Condensed Balance Sheet Statements	Balance sheets As of March 31, As of March 31, 2020 2021 RMB RMB US$ (Note 2(f)) ASSETS Current assets: Cash and cash equivalents 1,145 18,285 2,791 Prepayments and other current assets 686,819 1,208,128 184,396 Total current assets 687,964 1,226,413 187,187 Non-current Other non-current 7,943 344 53 Total non-current 7,943 344 53 Total assets 695,907 1,226,757 187,240 LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS’ DEFICIT Current liabilities Short-term borrowings 42,485 — — Accrued liabilities and other current liabilities 12,126 5,017 766 Other debts, current 76,252 — — Derivative liabilities 14,816 444 68 Total current liabilities 145,679 5,461 834 Non-current Long-term borrowings 4,957 — — Negative carrying amount of subsidiaries 690,121 1,138,622 173,788 Total non-current 695,078 1,138,622 173,788 Total liabilities 840,757 1,144,083 174,622 Mezzanine equity: Series A convertible redeemable preferred shares (US$ 0.001 par value; 11,000,000 shares authorized, 10,340,000 and nil shares issued and outstanding as of March 31, 2020 and 2021, respectively) 484,122 — — Series B convertible redeemable preferred shares (US$ 0.001 par value; 10,000,000 shares authorized, 9,067,384 and nil shares issued and outstanding as of March 31, 2020 and 2021, respectively) 527,682 — — Series C convertible redeemable preferred shares (US$ 0.001 par value; 6,000,000 shares authorized, 5,518,101 and nil shares issued and outstanding as of March 31, 2020 and 2021, respectively) 420,419 — — Series D convertible redeemable preferred shares (US$ 0.001 par value; 3,000,000 shares authorized, 2,526,026 and nil shares issued and outstanding as of March 31, 2020 and 2021, respectively) 188,183 — — Series D-1 164,282 — — Series D-2 89,464 — — Series E convertible redeemable preferred shares (US$ 0.001 par value; 3,000,000 and 7,000,000 shares authorized, 1,042,623 and nil shares issued and outstanding as of March 31, 2020 and 2021, respectively) 78,553 — — Receivable for issuance of preferred shares (94,758 ) — — Total mezzanine equity 1,857,947 — — As of March 31, 2020 2021 RMB RMB US$ (Note 2(f)) Stockholders’ deficit: Ordinary Shares (US$0.001 par value;153,000,000 ordinary shares authorized and 22,238,454 issued and outstanding as of March 31, 2020; nil shares issued and outstanding as of March 31, 2021) 139 — — Class A ordinary shares (US$0.001 par value; nil shares authorized, issued and outstanding shares as of March 31, 2020; 129,500,000 shares authorized, 54,505,108 shares issued and outstanding as of March 31, 2021) — 364 56 Class B ordinary shares (US$0.001 par value; nil shares authorized, issued and outstanding shares as of March 31, 2020; 15,000,000 shares authorized, 13,037,729 shares issued and outstanding as of March 31, 2021) — 82 12 Statutory reserves 2,627 3,047 465 Additional paid-in — 3,272,612 499,498 Accumulated other comprehensive loss 11,204 (20,172 ) (3,079 ) Accumulated deficit (2,016,758 ) (2,759,882 ) (421,240 ) Receivable for issuance of ordinary shares (9 ) (413,377 ) (63,094 ) Total shareholders’ deficit (2,002,797 ) 82,674 12,618 Total liabilities, mezzanine equity and shareholders’ deficit 695,907 1,226,757 187,240
Summary of Statements of Comprehensive Loss	Statements of comprehensive loss Year Ended March 31, 2019 2020 2021 RMB RMB RMB US$ (Note 2(f)) Sales and marketing expenses — — (12,875 ) (1,965 ) General and administrative expenses (812 ) (4,631 ) (14,050 ) (2,144 ) Total operating expenses (812 ) (4,631 ) (26,925 ) (4,109 ) Loss from operations (812 ) (4,631 ) (26,925 ) (4,109 ) Interest income — — 15,416 2,353 Interest expense (5,624 ) (12,578 ) — — Share of losses of subsidiaries (225,531 ) (134,660 ) (191,458 ) (29,221 ) Other (expense)/income, net — (40,500 ) (3,008 ) (459 ) Fair value change of derivative liabilities (2,274 ) 13,345 11,531 1,760 Net loss attributable to Boqii Holding Limited (234,241 ) (179,024 ) (194,444 ) (29,676 ) Less: Accretion on the Preferred Shares to redemption value (392,550 ) (204,796 ) 120,873 18,449 Less: Accretion on redeemable non-controlling — — (138 ) (21 ) Less: Deemed contribution from preferred shareholders (723 ) (1,142 ) (12,547 ) (1,915 ) Net loss attributable to Boqii Holding Limited’s ordinary shareholders (627,514 ) (384,962 ) (86,256 ) (13,163 ) Net loss (234,241 ) (179,024 ) (194,444 ) (29,676 ) Other comprehensive loss: Foreign currency translation adjustment, net of nil tax 3,808 2,021 (32,148 ) (4,907 ) Unrealized securities holding gains 1,711 3,209 772 118 Total comprehensive loss (228,722 ) (173,794 ) (225,820 ) (34,465 )
Summary of Condensed Cash Flow Statements	Statements of cash flows Year Ended March 31, 2019 2020 2021 RMB RMB RMB US$ (Note 2(f)) Net cash used in operating activities — — (47,806 ) (7,297 ) Net cash used in investing activities (99,221 ) (184,354 ) (588,953 ) (89,892 ) Net cash provided by financing activities 81,206 155,712 660,366 100,792 Effects of foreign exchange rate changes on cash and cash equivalents 18,010 29,778 (6,465 ) (987 ) Net increase (decrease) in cash and cash equivalents (5 ) 1,136 17,140 2,616 Cash and cash equivalents at beginning of the year 14 9 1,145 175 Cash and cash equivalents at end of the year 9 1,145 18,285 2,791

Organization and principal ac_3

Organization and principal activities - Schedule of Details of the Subsidiaries, VIEs and VIE's Subsidiaries (Detail)	12 Months Ended
	Mar. 31, 2021
Guangcheng (Shanghai) Information Technology Co., Ltd. [Member]
Schedule Of Subsidiaries And Variable Interest Entities [Line Items]
Place of incorporation	Shanghai, the PRC
Date of incorporation or acquisition	Nov. 30, 2012
Percentage of direct or indirect	100.00%
Principal activities	Operates the Company’s own online e-commerce platform
Nanjing Xingmu Biotechnology Co., Ltd. [Member]
Schedule Of Subsidiaries And Variable Interest Entities [Line Items]
Place of incorporation	Nanjing, the PRC
Date of incorporation or acquisition	Nov. 30, 2019
Percentage of direct or indirect	51.00%
Principal activities	Biotechnology research and development
Boqii (Shanghai) Information Technology Co., Ltd. [Member]
Schedule Of Subsidiaries And Variable Interest Entities [Line Items]
Place of incorporation	Shanghai, the PRC
Date of incorporation or acquisition	Aug. 31, 2014
Percentage of direct or indirect	90.00%
Principal activities	Technology development
Tianjing Guangcheng Information Technology Co., Ltd. [Member]
Schedule Of Subsidiaries And Variable Interest Entities [Line Items]
Place of incorporation	Tianjin, the PRC
Date of incorporation or acquisition	Jun. 30, 2017
Percentage of direct or indirect	100.00%
Principal activities	Sales of merchandise
Nanjing Cuida Biotechnology Co. Ltd.("Cuida") [Member]
Schedule Of Subsidiaries And Variable Interest Entities [Line Items]
Place of incorporation	Nanjing, the PRC
Date of incorporation or acquisition	Apr. 30, 2017
Percentage of direct or indirect	70.00%
Principal activities	Biotechnology extension services
Taizhou Xingmu Biotechnology Co., Ltd. [Member]
Schedule Of Subsidiaries And Variable Interest Entities [Line Items]
Place of incorporation	Taizhou, the PRC
Date of incorporation or acquisition	Nov. 30, 2019
Percentage of direct or indirect	80.00%
Principal activities	Biotechnology research and development
Boqii Corporation Limited ("Boqii Corporation") [Member]
Schedule Of Subsidiaries And Variable Interest Entities [Line Items]
Place of incorporation	Hong Kong
Date of incorporation or acquisition	Jul. 31, 2012
Percentage of direct or indirect	100.00%
Principal activities	Investment holding
Boqii International Limited [Member]
Schedule Of Subsidiaries And Variable Interest Entities [Line Items]
Place of incorporation	Hong Kong
Date of incorporation or acquisition	Aug. 31, 2016
Percentage of direct or indirect	100.00%
Principal activities	Investment holding
Xingmu International Limited [Member]
Schedule Of Subsidiaries And Variable Interest Entities [Line Items]
Place of incorporation	British Virgin Islands
Date of incorporation or acquisition	Aug. 31, 2019
Percentage of direct or indirect	51.00%
Principal activities	Investment holding
Xingmu HK Limited [Member]
Schedule Of Subsidiaries And Variable Interest Entities [Line Items]
Place of incorporation	Hong Kong
Date of incorporation or acquisition	Nov. 30, 2019
Percentage of direct or indirect	51.00%
Principal activities	Investment holding
Nanjing Xinmu Information Technology Co., Ltd. ("Xingmu WFOE") [Member]
Schedule Of Subsidiaries And Variable Interest Entities [Line Items]
Place of incorporation	Nanjing, the PRC
Date of incorporation or acquisition	Nov. 30, 2019
Percentage of direct or indirect	51.00%
Principal activities	Technology development and sales of merchandise
Xincheng (Shanghai) Information Technology Co., Ltd. ("Shanghai Xincheng") [Member]
Schedule Of Subsidiaries And Variable Interest Entities [Line Items]
Place of incorporation	Shanghai, the PRC
Date of incorporation or acquisition	Nov. 30, 2012
Percentage of direct or indirect	100.00%
Principal activities	Technology development and sales of merchandise
Shanghai Yiqin Pets Products Co., Ltd. [Member]
Schedule Of Subsidiaries And Variable Interest Entities [Line Items]
Place of incorporation	Shanghai, the PRC
Date of incorporation or acquisition	Feb. 28, 2013
Percentage of direct or indirect	100.00%
Principal activities	Technology development and sales of merchandise

Organization and principal ac_4

Organization and principal activities - Schedule of Variable Interest Entities (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)	Mar. 31, 2019CNY (¥)	Mar. 31, 2021CNY (¥)
Variable Interest Entity [Line Items]
Cash and cash equivalents	$ 44,605		¥ 88,352		¥ 292,237
Accounts receivable, net	6,980		44,980		45,732
Amounts due from related parties	1,750		5,982		11,465
Inventories, net	13,974		63,056		91,551
Prepayments and other current assets	13,013		76,720		85,261
Property and equipment, net	1,280		4,981		8,386
Intangible assets	4,508		33,538		29,537
Operating lease right-of-use assets	4,462		14,951		29,234
Goodwill	6,133		40,184	¥ 494	40,184
Long-term investments	11,345		73,432		74,330
Other non-current asset	627		11,019		4,111
Total assets	134,402		457,195		880,574
Short-term borrowings	13,061		75,223		85,566
Accounts payable	10,966		88,005		71,848
Amounts due to related parties, current	139		45		910
Salary and welfare payable	963		4,465		6,309
Accrued liabilities and other current liabilities	4,587		37,883		30,055
Contract liabilities	590		7,702		3,866
Operating lease liabilities, current					28,060
Deferred tax liabilities	1,367		10,591		8,958
Operating lease liabilities, non-current	3,052		5,375		19,997
Long-term debt	10,390		53,148		68,075
Other debts, non-current	66,133		165,774		433,292
Amounts due to related parties, non-current			11,521
Total liabilities	114,005		558,304		746,935
Total Revenues	154,307	¥ 1,010,985	770,237	803,831
Cost of revenue	(125,719)	(823,686)	(611,470)	(599,477)
Net loss	(29,489)	(193,216)	(175,933)	(231,526)
Net cash used in operating activities	(37,772)	(247,486)	(165,912)	(206,224)
Net cash used in investing activities	(28,147)	(184,417)	(75,056)	(22,562)
Net cash provided by financing activities	98,979	648,491	295,032	199,313
Cash and cash equivalents at beginning of the year		88,352
Cash and cash equivalents at end of the year	$ 44,605	292,237	88,352
Variable Interest Entity, Primary Beneficiary [Member] | Nonrecourse [Member]
Variable Interest Entity [Line Items]
Cash and cash equivalents			36,977	22,353	17,886
Accounts receivable, net			36,682		63,331
Amounts due from related parties			4,752		11,466
Inventories, net			38,400		11,349
Prepayments and other current assets			47,215		45,098
Property and equipment, net			4,933		8,372
Intangible assets			1,315		909
Operating lease right-of-use assets			13,565		27,736
Goodwill			494		494
Long-term investments			73,432		74,330
Other non-current asset			1,004		2,433
Total assets			258,769		263,404
Short-term borrowings			2,761		3,484
Accounts payable			331,760		439,879
Amounts due to related parties, current			45		910
Salary and welfare payable			3,789		4,851
Accrued liabilities and other current liabilities			116,516		225,709
Contract liabilities			7,621		3,706
Operating lease liabilities, current			6,652		6,058
Deferred tax liabilities			2,593		1,852
Operating lease liabilities, non-current			5,375		19,997
Long-term debt			982		872
Other debts, non-current			147,774		415,122
Amounts due to related parties, non-current			10,450		0
Total liabilities			636,318		¥ 1,122,440
Total Revenues		783,892	672,093	761,121
Cost of revenue		(670,319)	(509,168)	(557,275)
Net loss		166,502	61,805	150,002
Net cash used in operating activities		88,703	22,099	(108,063)
Net cash used in investing activities		(37,214)	(43,435)	(12,722)
Net cash provided by financing activities		(70,434)	44,228	118,070
Effects of foreign exchange rate changes on cash and cash equivalents		(146)	(8,268)	3,826
Net increase (decrease) in cash and cash equivalents		(19,091)	14,624	1,111
Cash and cash equivalents at beginning of the year		36,977	22,353	21,242
Cash and cash equivalents at end of the year		¥ 17,886	¥ 36,977	¥ 22,353

Organization and principal ac_5

Organization and principal activities - Additional Information (Detail) - CNY (¥)	Mar. 31, 2021	Mar. 31, 2020
Variable Interest Entity, Primary Beneficiary [Member] | Nonrecourse [Member]
Organization And Principal Activities [Line Items]
Total registered capital	¥ 52,000,000	¥ 52,000,000
Contractual Arrangements [Member]
Organization And Principal Activities [Line Items]
Percentage of Maximum entity interests acquirable In variable Interest Entity Under PRC law	100.00%
Loan Agreements [Member] | Repayment of Loan [Member]
Organization And Principal Activities [Line Items]
Third party claim against nominee shareholders	¥ 500,000
Intellectual Property License Agreements [Member]
Organization And Principal Activities [Line Items]
Number of Business days in which agreement amount is to paid from relevant quarter	15 days
Term of agreement	10 years
Extended term	10 years
Period of prior written notice required to terminate the agreement	90 days
Equity Interest Pledge Agreements [Member]
Organization And Principal Activities [Line Items]
Percentage of equity interest pledged by nominal shareholders	100.00%

Principal Accounting Policies -

Principal Accounting Policies - Additional Information (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)	Mar. 31, 2019CNY (¥)	Apr. 01, 2020CNY (¥)	Apr. 01, 2019CNY (¥)
Principal Accounting Policies [Line Items]
Contract with Customer, Asset		¥ 0	¥ 0
Contract with Customer, Liability					¥ 7,700	¥ 5,800
Contract with Customer, Liability, Revenue Recognized		7,700	5,000
Unearned Revenue		3,900
Cost of Revenue	$ 125,719	823,686	611,470	¥ 599,477
Advertising Expense		83,000	69,000	95,900
Short-term Investments [Member]
Principal Accounting Policies [Line Items]
Short-term investments used as collateral		118,500
Short-term and long-term borrowings collateralized by short-term investments		105,900
Cost of product sales [Member]
Principal Accounting Policies [Line Items]
Cost of Revenue		820,300	610,600	599,200
Cost of services [Member]
Principal Accounting Policies [Line Items]
Cost of Revenue		¥ 3,400	¥ 900	¥ 300
CNY [Member]
Principal Accounting Policies [Line Items]
Foreign Currency Exchange Rate		6.5713	7.0851
Convenience translation exchange rate		6.5518

Principal Accounting Policies_3

Principal Accounting Policies - Schedule of Property Plant And Equipment Useful Lives (Detail)	12 Months Ended
	Mar. 31, 2021
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	Over the shorter of the expected life of leasehold improvements or the lease term
Maximum [Member] | Warehouse Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Maximum [Member] | Furniture, Computer And Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Minimum [Member] | Warehouse Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Minimum [Member] | Furniture, Computer And Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years

Principal Accounting Policies_4

Principal Accounting Policies - Schedule of Finite Lived Intangible Assets Useful Lives (Detail)	12 Months Ended
	Mar. 31, 2021
Trademark [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years
Dealership [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years
License [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	4 years 6 months
License [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years

Business combinations - Summary

Business combinations - Summary of Identified Assets Acquired and Liabilities Assumed (Detail) - CNY (¥) ¥ in Thousands	Nov. 01, 2019	Dec. 18, 2018
Nanjing Cuida Biotechnology Co Ltd [Member]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Cash and cash equivalents		¥ 36
Accounts receivable, net		15
Inventory		783
Prepayments and other current assets		5,693
License		1,773
Total assets		8,300
Salary and welfare payable		(4)
Accrued liabilities and other current liabilities		(246)
Deferred tax liabilities		(443)
Total liabilities		(693)
Net assets acquired		7,607
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net		494
Non-controlling interests		(2,101)
Total		6,000
Total purchase price is comprised of:
- cash consideration		6,000
Fair value of total consideration		¥ 6,000
Xingmu Group [Member]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Cash and cash equivalents	¥ 1,783
Accounts receivable, net	3,273
Inventory	9,445
Prepayments and other current assets	6,092
Property and equipment, net	91
Long-term investments	2,502
License	1,756
Dealership	31,717
Total assets	56,659
Short-term borrowings	(2,200)
Accounts payable	(1,561)
Salary and welfare payable	(159)
Accrued liabilities and other current liabilities	(3,970)
Deferred tax liabilities	(8,368)
Total liabilities	(16,258)
Net assets acquired	40,401
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	39,690
Non-controlling interests	(36,023)
Total	44,068
Total purchase price is comprised of:
- fair value of 14.5% previously held equity interests	10,628
- fair value of the Company's Series E convertible redeemable preferred shares to achieve control	33,440
Fair value of total consideration	¥ 44,068

Business combinations - Summa_2

Business combinations - Summary of Identified Assets Acquired and Liabilities Assumed (Detail) (Parenthetical)	Nov. 01, 2019	Aug. 31, 2018
Xingmu Group [Member]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Business Combination, Step Acquisition, Equity Interest in Acquire, Percentage	14.50%	14.50%

Business combinations - Summa_3

Business combinations - Summary of Business Acquisition, Pro Forma Information (Detail) - CNY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Nanjing Cuida Biotechnology Co Ltd [Member]
Business Acquisition Pro Forma Information [Line Items]
Net revenues		¥ 804,175
Net loss		(231,712)
Xingmu Group [Member]
Business Acquisition Pro Forma Information [Line Items]
Net revenues	¥ 802,249	850,932
Net loss	¥ (176,070)	¥ (230,451)

Business combinations - Additio

Business combinations - Additional Information (Detail) - CNY (¥) ¥ in Thousands	Nov. 30, 2019	Nov. 01, 2019	Dec. 18, 2018	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2020	Mar. 31, 2019	Aug. 31, 2018
Nanjing Cuida Biotechnology Co Ltd [Member]
Business Acquisition, Percentage of Voting Interests Acquired			70.00%
Unpaid cash consideration				¥ 5,100			¥ 5,100
Finite-Lived Intangible Asset, Useful Life							4 years 6 months
Business Combination, Pro Forma Information, Revenue of Acquire since Acquisition Date				1,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquire since Acquisition Date				¥ 80
Business Combination, Consideration Transferred			¥ 6,000
Xingmu Group [Member]
Business Combination, Pro Forma Information, Revenue of Acquire since Acquisition Date					¥ 30,900
Business Combination, Pro Forma Information, Earnings or Loss of Acquire since Acquisition Date					¥ 2,000
Business Combination, Step Acquisition, Equity Interest in Acquire, Including Subsequent Acquisition, Percentage		51.00%
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		461,513
Business Combination, Step Acquisition, Equity Interest in Acquire, Percentage		14.50%						14.50%
Business Combination, Consideration Transferred		¥ 44,068
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned		33,440
Business Combination, Step Acquisition, Equity Interest in Acquire, Fair Value		¥ 10,628
Xingmu Group [Member] | Veterinary Drugs License [Member]
Finite-Lived Intangible Asset, Useful Life						4 years 6 months
Xingmu Group [Member] | Veterinary Drugs Dealership [Member]
Finite-Lived Intangible Asset, Useful Life						10 years
Nanjing Xingmu [Member]
Business Combination, Consideration Transferred	¥ 44,100
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned	33,400
Business Combination, Step Acquisition, Equity Interest in Acquire, Fair Value	¥ 10,600

Risks and Concentration - Addit

Risks and Concentration - Additional Information (Detail)	Jul. 05, 2005	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Revenue Benchmark [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage			10.00%
Number of Customers			0
Revenue Benchmark [Member] | Royal Canin China Co., Ltd [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage		19.00%	24.00%
Revenue Benchmark [Member] | Boehringer Ingelheim Animal Health (Shanghai) Co., Ltd [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage		7.00%	14.00%
CNY [Member]
Concentration Risk [Line Items]
Foreign Currency increase (decrease) percentage	20.00%			1.20%	5.70%

Risks and Concentration - Sched

Risks and Concentration - Schedules of Concentration of Risk, By Risk Factor (Detail) ¥ in Thousands, $ in Thousands	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)	Mar. 31, 2019CNY (¥)
Concentration Risk [Line Items]
Accounts payable	$ 10,966	¥ 71,848	¥ 88,005
Royal Canin China Co., Ltd [Member]
Concentration Risk [Line Items]
Accounts payable		¥ 15,616	¥ 13,331	¥ 14,320

Cash and cash equivalents - Sch

Cash and cash equivalents - Schedule of Cash And Cash Equivalents (Detail) ¥ in Thousands, $ in Thousands	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)
RMB
Cash and cash equivalents	$ 44,605	¥ 292,237	¥ 88,352
Cash Equivalents [Member]
RMB
Cash and cash equivalents		292,237	88,352
CNY [Member] | Cash [Member]
RMB
Cash and cash equivalents		121,670	83,844
CNY [Member] | Cash Equivalents [Member]
RMB
Cash and cash equivalents		121,670	83,844
Hong Kong dollars [Member] | Cash [Member]
RMB
Cash and cash equivalents		25	15
Hong Kong dollars [Member] | Cash Equivalents [Member]
RMB
Cash and cash equivalents		21	13
USD [Member] | Cash [Member]
RMB
Cash and cash equivalents		25,947	635
USD [Member] | Cash Equivalents [Member]
RMB
Cash and cash equivalents		170,508	¥ 4,495
EUR [Member] | Cash [Member]
RMB
Cash and cash equivalents		5
EUR [Member] | Cash Equivalents [Member]
RMB
Cash and cash equivalents		¥ 38

Accounts receivable, net - Summ

Accounts receivable, net - Summary of Accounts Receivable Net (Detail) ¥ in Thousands, $ in Thousands	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance of doubtful accounts		¥ (256)	¥ (363)
Total	$ 6,980	45,732	44,980
Product Sales [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable		37,429	44,558
Online Marketing And Information Services And Other Revenue [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable		¥ 8,559	¥ 785

Accounts receivable, net - Su_2

Accounts receivable, net - Summary of Movement of Allowance of Doubtful Accounts (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)	Mar. 31, 2019CNY (¥)
Accounts, Notes, Loans and Financing Receivable [Line Items]
At beginning of year		¥ 363	¥ 92
Addition/(reversal)	$ (16)	(107)	271	¥ 92
At end of year		¥ 256	¥ 363	¥ 92

Inventories, net of inventory_3

Inventories, net of inventory reserves - Summary of Inventories, Net of Inventory Reserves (Detail) ¥ in Thousands, $ in Thousands	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)
Inventory [Line Items]
Inventory, Net	$ 13,974	¥ 91,551	¥ 63,056
Products [Member]
Inventory [Line Items]
Inventory, Net		90,913	62,249
Packaging materials and others [Member]
Inventory [Line Items]
Inventory, Net		¥ 638	¥ 807

Prepayments and other current_3

Prepayments and other current assets - Summary of Prepayments and Other Current Assets (Detail) ¥ in Thousands, $ in Thousands	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)
Prepaid Expense and Other Assets, Current [Abstract]
Loans receivable		¥ 3,957	¥ 35,082
Prepayments for purchases of products		53,209	16,152
Vendor rebate receivables		8,723	10,486
Value-added tax ("VAT") deductible		10,672	9,818
Sales return assets		1,244	1,157
Deposits		1,456	774
Others		6,000	3,251
Total	$ 13,013	¥ 85,261	¥ 76,720

Prepayments and other current_4

Prepayments and other current assets - Additional Information (Detail) ¥ in Thousands, $ in Thousands

Dec. 05, 2019

Feb. 28, 2021USD ($)shares

Sep. 30, 2020CNY (¥)

Jul. 31, 2020CNY (¥)

Jun. 30, 2020USD ($)

Jan. 31, 2020CNY (¥)

Sep. 30, 2019

May 31, 2019USD ($)

Dec. 31, 2018CNY (¥)

Feb. 28, 2021CNY (¥)

Mar. 31, 2021USD ($)

Mar. 31, 2021CNY (¥)

Mar. 31, 2020CNY (¥)

Mar. 31, 2019CNY (¥)

Oct. 31, 2020CNY (¥)

Jun. 30, 2020CNY (¥)

May 31, 2019CNY (¥)

Prepayments And Other Current Assets [Line Items]

Stock repurchased during period, value

¥ 31,386

Repayments of debt

$ 11,295

74,000

¥ 43,533

¥ 65,798

Financing receivable, after allowance for credit loss, current

3,957

35,082

Long-term Debt

153,641

Proceeds from collection of loans receivable

¥ 600

$ 6,836

44,790

12,013

¥ 2,500

Interest Free Loan Agreement [Member]

Prepayments And Other Current Assets [Line Items]

Debt instrument, term

600 days

3 months

730 days

Debt instrument, face amount

$ 4,850

$ 1,400

¥ 20,000

1,000

¥ 33,000

¥ 9,800

Loans receivable discounted present value

200

Stock repurchased during period, shares | shares

521,924

Stock repurchased during period, value | $

$ 4,850

Long-term Debt

¥ 600

11,400

Four Month Agreement [Member]

Prepayments And Other Current Assets [Line Items]

Debt instrument, term

4 months

8 months

4 months

Debt instrument, face amount

¥ 1,000

$ 1,500

¥ 10,800

Debt instrument, interest rate, stated percentage

6.00%

5.00%

5.00%

Two Year Loan Agreement One [Member]

Prepayments And Other Current Assets [Line Items]

Debt instrument, term

2 years

Debt instrument, face amount

¥ 1,460

Debt instrument, interest rate, stated percentage

6.00%

Repayments of debt

¥ 700

¥ 800

Financing receivable, after allowance for credit loss, current

¥ 800

Two Year Loan Agreement Two [Member]

Prepayments And Other Current Assets [Line Items]

Debt instrument, term

2 years

Debt instrument, face amount

¥ 1,500

Debt instrument, interest rate, stated percentage

6.00%

One Year Loan Agreement [Member]

Prepayments And Other Current Assets [Line Items]

Debt instrument, term

1 year

Debt instrument, face amount

¥ 650

Debt instrument, interest rate, stated percentage

4.00%

Six One Year Loan Agreements [Member]

Prepayments And Other Current Assets [Line Items]

Debt instrument, face amount

2,600

Six One Year Loan Agreements [Member] | Three Percent Interest Loan [Member]

Prepayments And Other Current Assets [Line Items]

Debt instrument, face amount

¥ 1,600

Debt instrument, interest rate, stated percentage

3.00%

One Year Interest Free Loan Agreement [Member]

Prepayments And Other Current Assets [Line Items]

Debt instrument, term

1 year

Debt instrument, face amount

¥ 120

Property and equipment, net - S

Property and equipment, net - Summary of Property, Plant and Equipment's (Detail) ¥ in Thousands, $ in Thousands	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross		¥ 24,761	¥ 18,452
Less: Accumulated depreciation		(16,375)	(13,471)
Property and equipment, net	$ 1,280	8,386	4,981
Warehouse Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross		2,513	2,426
Furniture, Computer And Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross		6,592	5,864
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross		2,891	1,912
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross		10,056	5,555
Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross		¥ 2,709	¥ 2,695

Property and equipment, net -

Property and equipment, net - Additional Information (Detail) - CNY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation	¥ 3,080	¥ 2,660	¥ 3,000

Intangible assets, net - Schedu

Intangible assets, net - Schedule of Intangible Assets (Detail) ¥ in Thousands, $ in Thousands	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross		¥ 35,694	¥ 35,694
Less: Accumulated amortization		(6,157)	(2,156)
Intangible assets	$ 4,508	29,537	33,538
Trademark [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross		447	447
License [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross		3,530	3,530
Dealership [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross		¥ 31,717	¥ 31,717

Intangible assets, net - Sche_2

Intangible assets, net - Schedule of Annual Estimated Amortization Expense for Intangible Assets (Detail) ¥ in Thousands	Mar. 31, 2021CNY (¥)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2022	¥ 4,001
2023	4,001
2024	3,770
2025	3,342
2026	¥ 3,209

Intangible assets, net - Additi

Intangible assets, net - Additional Information (Detail) - CNY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Intangible assets resulting from the business combinations	¥ 29,280	¥ 33,470
Amortization expenses	¥ 4,000	¥ 1,920	¥ 180

Long-Term Investments - Summary

Long-Term Investments - Summary of Long-Term Investment (Detail) ¥ in Thousands, $ in Thousands	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)
Long-term Investments [Abstract]
Equity method investments		¥ 2,973	¥ 3,104
Available-for-sale investments		71,357	70,328
Total	$ 11,345	¥ 74,330	¥ 73,432

Long-Term Investments - Summa_2

Long-Term Investments - Summary of Available-For-Sale Debt Investments (Detail) - CNY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Debt Securities, Available-for-sale [Abstract]
Cost	¥ 60,000	¥ 60,000
Gross unrealized gains	11,357	10,328
Gross unrealized losses	0	0
Fair value	¥ 71,357	¥ 70,328

Long-Term Investments - Additio

Long-Term Investments - Additional Information (Detail) - CNY (¥) ¥ in Thousands	1 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2017	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Long term Investments and Receivables Net [Line Items]
Carrying value of equity method investments			¥ 2,973	¥ 3,104
Cash consideration				50,000	¥ 10,745
Qingdao Shuangan Biotechnology Co Ltd [Member]
Long term Investments and Receivables Net [Line Items]
Equity method investment ownership percentage		7.20%
Cash consideration		¥ 10,000
Redemption of investment period		48 months
Investment re-measured at fair value			17,300	17,000
Unrealized Securities holding gain, Net of tax			20	1,000
Beijing Petdog Technology Development Co Ltd [Member]
Long term Investments and Receivables Net [Line Items]
Equity method investment ownership percentage	23.64%
Cash consideration	¥ 50,000
Redemption of investment period	60 months
Investment re-measured at fair value			54,000	53,300
Unrealized Securities holding gain, Net of tax			¥ 750	¥ 2,300

Goodwill - Schedule of Changes

Goodwill - Schedule of Changes in the Carrying Amount of Goodwill (Detail) ¥ in Thousands, $ in Thousands	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)	Mar. 31, 2019CNY (¥)
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill		¥ 40,184	¥ 40,184	¥ 494
Accumulated impairment loss		0	0	0
Total	$ 6,133	40,184	40,184	¥ 494
Additions		¥ 0	¥ 39,690

Goodwill - Additional Informati

Goodwill - Additional Information (Detail) - CNY (¥) ¥ in Millions	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cuida and Xingmu [Member]
Indefinite-lived Intangible Assets [Line Items]
Goodwill generated from the acquisition	¥ 40	¥ 40

Other non-current Assets - Sche

Other non-current Assets - Schedule of Other Non-current Assets (Detail) ¥ in Thousands, $ in Thousands	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)
Other Assets, Noncurrent Disclosure [Abstract]
Deposits		¥ 3,767	¥ 3,076
Long-term loans receivable		344	0
Deferred initial public offering related costs		0	7,943
Total	$ 627	¥ 4,111	¥ 11,019

Other non-current Assets - Sc_2

Other non-current Assets - Schedule of Other Non-current Assets (Parenthetical) (Detail) - CNY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2018
Other Assets Noncurrent Disclosure [Line Items]
Principal amount outstanding	¥ 3,957	¥ 35,082
Loan Agreement With Third Party [Member]
Other Assets Noncurrent Disclosure [Line Items]
Loan Agreement Term with a third party			2 years
Principal amount of loan			¥ 1,500
Interest rate on loan			6.00%
Early repayment of loan	2020-08
Loan Agreement With Third Party [Member] | Prepayment and Other Current Assets [Member]
Other Assets Noncurrent Disclosure [Line Items]
Principal amount outstanding		¥ 1,500

Other non-current Assets - Addi

Other non-current Assets - Additional Information (Detail) - CNY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2021	Oct. 31, 2020	Mar. 31, 2020	Dec. 31, 2018
Other Assets Noncurrent Disclosure [Line Items]
Principal amount outstanding	¥ 3,957		¥ 35,082
Loan Agreement With Third Party One [Member]
Other Assets Noncurrent Disclosure [Line Items]
Loan Agreement Term with a third party				2 years
Principal amount of loan				¥ 1,460
Interest rate on loan				6.00%
Early repayment of loan	2020-10
Loan Agreement With Third Party One [Member] | Prepayment and Other Current Assets [Member]
Other Assets Noncurrent Disclosure [Line Items]
Principal amount outstanding			¥ 1,460
Interest Free Loan Agreement With Third Party [Member]
Other Assets Noncurrent Disclosure [Line Items]
Loan Agreement Term with a third party		2 years
Principal amount of loan		¥ 300
Principal amount outstanding	¥ 300

Accrued liabilities and other_3

Accrued liabilities and other current liabilities - Schedule of Accrued Liabilities and Other Current Liabilities (Detail) ¥ in Thousands, $ in Thousands	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)
Accrued Liabilities and Other Liabilities [Abstract]
Logistics expenses payables		¥ 16,594	¥ 18,688
Accrued advertising expenses		228	611
Advances from customers		3,534	7,825
Refund obligation of sales returns		1,543	1,345
Professional service fee accruals		3,449	5,046
Others		4,707	4,368
Total	$ 4,587	¥ 30,055	¥ 37,883

Leases - Summary of Operating L

Leases - Summary of Operating Leases (Detail) ¥ in Thousands, $ in Thousands	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)
Assets
Operating lease right-of-use assets	$ 4,462	¥ 29,234	¥ 14,951
Liabilities
Operating lease liabilities, current	1,231	8,063	7,969
Operating lease liabilities, non-current	$ 3,052	¥ 19,997	¥ 5,375
Weighted average remaining lease term (years)	3 years 8 months 12 days	3 years 8 months 12 days	1 year 6 months 7 days
Weighted average discount rate	6.47%	6.47%	5.82%

Leases - Summary of Operating_2

Leases - Summary of Operating Lease Activity (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)	Mar. 31, 2019CNY (¥)
Leases [Abstract]
Operating lease right-of-use assets obtained in exchange for lease obligations	$ 3,964	¥ 25,970	¥ 10,051	¥ 19,570
Amortization of right-of-use assets		11,687	15,708	17,919
Interest of lease liabilities		1,596	1,353	1,636
Operating lease, expense		13,283	17,061	19,555
Operating lease payments (included in measurement of lease liabilities)		¥ 12,850	¥ 18,183	¥ 19,284

Leases - Summary of Maturities

Leases - Summary of Maturities of Lease Liabilities (Detail) ¥ in Thousands	Mar. 31, 2021CNY (¥)
Leases [Abstract]
2022	¥ 11,213
2023	6,589
2024	5,837
2025	6,568
2026 and thereafter	2,949
Total lease payments	33,156
Less: imputed interest	(5,096)
Total	¥ 28,060

Interest expense - Summary of I

Interest expense - Summary of Interest Expense (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)	Mar. 31, 2019CNY (¥)
Interest and Debt Expense [Abstract]
Amortization charges on promissory notes		¥ 21,611	¥ 56,290	¥ 17,077
Interest expense on borrowings		6,039	2,815	1,453
Others			163	124
Total	$ 4,220	¥ 27,650	¥ 59,268	¥ 18,654

Other gains (losses), net - Sum

Other gains (losses), net - Summary of Other (Losses), Net (Detail) - CNY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Other gains (losses), net [Abstract]
Gain from the re-measurement of the previously held equity interests to the fair value in the business acquisition	¥ 0	¥ 481	¥ 0
Foreign exchange losses, net	(2,867)	(3,787)	(8,971)
Gain on disposal of other debts	6,846	10,095	0
Reimbursement from a depositary bank	6,556	0	0
Others	797	195	(843)
Total	¥ 11,332	¥ 6,984	¥ (9,814)

Other gains (losses), net - S_2

Other gains (losses), net - Summary of Other (Losses), Net (Parenthetical) (Detail) - 1 months ended Dec. 31, 2020 ¥ in Millions, $ in Millions	USD ($)	CNY (¥)
Other gains (losses), net [Abstract]
Reimbursement depositary received	$ 1	¥ 6.6

Income taxes - Schedule of Effe

Income taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)	Mar. 31, 2019CNY (¥)
Income Tax Disclosure [Abstract]
Loss before income tax	$ (29,516)	¥ (193,391)	¥ (175,925)	¥ (231,758)
Income tax computed at respective applicable tax rate		(48,348)	(43,981)	(57,940)
Effect of different tax jurisdiction		14,272	19,507	25,553
Super deduction for research and development expenses (a)		(2,632)	(4,719)	(5,969)
Non-deductible expenses		140	138	133
Change in valuation allowance		37,439	29,567	38,364
Total	$ 133	¥ 871	¥ 512	¥ 141
PRC statutory income tax rates	25.00%	25.00%	25.00%	25.00%
Effect on tax rates in different tax jurisdiction	(7.00%)	(7.00%)	(11.00%)	(11.00%)
Super deduction for research and development expenses	1.00%	1.00%	3.00%	3.00%
Non-deductible expenses	0.00%	0.00%	0.00%	0.00%
Change in valuation allowance	(19.00%)	(19.00%)	(17.00%)	(17.00%)
Total	0.00%	0.00%	0.00%	0.00%

Income taxes - Schedule of Ef_2

Income taxes - Schedule of Effective Income Tax Rate Reconciliation (Parenthetical) (Detail) - CNY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Super deduction for research and development expenses	¥ 2,632	¥ 4,719	¥ 5,969
Tax Year 2008 [Member]
Effective income tax rate reconciliation non-deductible expense research and development percentage	150.00%
Effective income tax rate reconciliation non-deductible expense research and development additional deduction percentage	50.00%
Tax Year 2018 [Member]
Effective income tax rate reconciliation non-deductible expense research and development percentage	175.00%
Effective income tax rate reconciliation non-deductible expense research and development additional deduction percentage	75.00%

Income taxes - Summary of Inco

Income taxes - Summary of Income Tax Holiday (Detail) - CNY (¥) ¥ / shares in Units, ¥ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Tax holiday effect	¥ 1,074	¥ (5,471)	¥ (4,126)
Basic and diluted net loss per share effect	¥ 0.02	¥ (0.25)	¥ (0.20)

Income taxes - Schedule of Comp

Income taxes - Schedule of Components of Income Tax Expense Benefit (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)	Mar. 31, 2019CNY (¥)
Income Tax Disclosure [Abstract]
Current income tax expense		¥ 1,018	¥ 149	¥ 0
Deferred tax expense	$ (288)	(1,889)	(661)	(141)
Total	$ (133)	¥ (871)	¥ (512)	¥ (141)

Income taxes - Schedule of Defe

Income taxes - Schedule of Deferred Tax Assets And Tax Liabilities (Detail) - CNY (¥) ¥ in Thousands	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Deferred tax assets:
Net accumulated loss-carry forward	¥ 143,426	¥ 106,320
Deferred deductible advertising expense	940	1,780
Allowance	130	159
Contract liabilities	413	1,821
Accruals	5,069	2,459
Less: Valuation allowance	(149,978)	(112,539)	¥ (82,972)
Net deferred tax assets	0	0
Deferred tax liabilities:
Recognition of intangible assets arising from asset acquisition and business combination	(6,119)	(8,009)
Unrealized fair value change of the available-for-sale debt investments	(2,839)	(2,582)
Net deferred tax liabilities	¥ (8,958)	¥ (10,591)

Income taxes - Summary of Valua

Income taxes - Summary of Valuation Allowance (Detail) - CNY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Beginning balance	¥ 112,539	¥ 82,972
Change of valuation allowance	37,439	29,567
Ending balance	¥ 149,978	¥ 112,539

Income taxes - Additional Infor

Income taxes - Additional Information (Detail) - CNY (¥) ¥ in Millions	Jul. 25, 2018	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Income tax rate		25.00%	25.00%	25.00%
Income tax holiday, description	the entity could enjoy a tax holiday of 2-year CIT exemption and subsequently 3-year 12.5% preferential tax rate
Change of valuation allowance		¥ 150	¥ 112.5
Operating loss carry forwards		¥ 574	¥ 425
HK [Member] | Maximum [Member]
Income tax rate		16.50%
HK [Member] | Minimum [Member]
Income tax rate		8.25%
CHINA [Member]
Income tax rate		25.00%
Preferential tax rate		15.00%

Ordinary Share - Additional Inf

Ordinary Share - Additional Information (Detail) $ / shares in Units, ¥ in Thousands, $ in Thousands	1 Months Ended		12 Months Ended
	Feb. 28, 2021USD ($)shares	Oct. 31, 2020USD ($)shares$ / shares	Mar. 31, 2021USD ($)$ / sharesshares	Mar. 31, 2021CNY (¥)shares	Mar. 31, 2020$ / sharesshares	Mar. 31, 2019shares
Common Stock, Shares, Issued					22,238,454
Common Stock, Shares, Outstanding					22,238,454
Number of shares per ADS		0.75
Proceeds from IPO		$ 64,000	$ 60,090	¥ 393,698
IPO [Member]
Proceeds from IPO | $			$ 50,000
Common Class A [Member]
Common Stock, Shares, Issued			54,505,108		0
Common Stock, Shares, Outstanding			54,505,108		0
stock issued during period		5,250,000
Common Stock, Par or Stated Value Per Share | $ / shares			$ 0.001		$ 0.001
Common Class A [Member] | IPO [Member]
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.001
Stock Repurchased and Retired During Period, Shares	521,924
Stock Repurchased and Retired During Period, Value | $	$ 4,800
Common Class B [Member]
Common Stock, Shares, Issued			13,037,729		0
Common Stock, Shares, Outstanding			13,037,729		0
Common Stock, Par or Stated Value Per Share | $ / shares			$ 0.001		$ 0.001
Preferred Stock, Conversion Basis			one-for-one basis	one-for-one basis
Common Class B [Member] | IPO [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities		12,204,604
ADS [Member]
Share price | $ / shares		$ 10
ADS [Member] | IPO [Member]
Sale of Stock, Number of Shares Issued in Transaction		7,000,000
ADS [Member] | Over-Allotment Option [Member]
Sale of Stock, Number of Shares Issued in Transaction		1,050,000
Series A Redeemable Convertible Preferred Shares [Member]
Convertible Preferred Shares, Outstanding			0		10,340,000
Series A Redeemable Convertible Preferred Shares [Member] | IPO [Member]
Convertible Preferred Shares, Outstanding		10,340,000
Stock Issued During Period, Shares, Conversion of Convertible Securities		7,844,137
Preferred Stock, Conversion Basis		1: 0.76
Series B Redeemable Convertible Preferred Shares [Member]
Convertible Preferred Shares, Outstanding			0		9,067,384
Series B Redeemable Convertible Preferred Shares [Member] | IPO [Member]
Convertible Preferred Shares, Outstanding		9,067,384
Stock Issued During Period, Shares, Conversion of Convertible Securities		8,557,980
Preferred Stock, Conversion Basis		1:0.94
Series C Plus Redeemable Convertible Preferred Shares [Member] | IPO [Member]
Convertible Preferred Shares, Outstanding		6,734,459
Stock Issued During Period, Shares, Conversion of Convertible Securities		6,883,520
Preferred Stock, Conversion Basis		1:1.02
Series C Redeemable Convertible Preferred Shares [Member]
Convertible Preferred Shares, Outstanding			0		5,518,101
Preferred Stock, Conversion Basis			one-for-one basis	one-for-one basis
Series C Preferred Stock [Member]
stock issued during period			0	0	0	0
Series C Preferred Stock [Member] | IPO [Member]
Convertible Preferred Shares, Outstanding		833,125

Convertible redeemable prefer_3

Convertible redeemable preferred shares - Summary of Preferred Shares Activities for the Periods (Detail) ¥ in Thousands, $ in Millions	12 Months Ended
	Mar. 31, 2021USD ($)shares	Mar. 31, 2021CNY (¥)shares	Mar. 31, 2020USD ($)shares	Mar. 31, 2020CNY (¥)shares	Mar. 31, 2019USD ($)shares	Mar. 31, 2019CNY (¥)shares
Schedule of Preferred Stock by Class [Line Items]
Issuance		¥ 395,071
Accretion on the Preferred Shares to redemption value	$ (18)	(121,000)	$ 28.9	¥ 204,800	$ 51.9	¥ 392,600
Deemed dividend to preferred shareholders		¥ 12,000		¥ 400
Series A Preferred Shares [Member]
Schedule of Preferred Stock by Class [Line Items]
Balance Beginning, (in shares) | shares	10,340,000	10,340,000	10,340,000	10,340,000	10,340,000	10,340,000
Balance Beginning		¥ 484,122		¥ 424,930		¥ 287,629
Issuance, (in shares) | shares	0	0	0	0	0	0
Issuance		¥ 0		¥ 0		¥ 0
Accretion on the Preferred Shares to redemption value		(22,677)		59,192		137,301
Deemed dividend to preferred shareholders		¥ 0		¥ 0		¥ 0
Conversion of convertible redeemable preferred shares upon completion of the IPO (in shares) | shares	(10,340,000)	(10,340,000)
Conversion of convertible redeemable preferred shares upon completion of the IPO		¥ (461,445)
Balance Ending, (in shares) | shares	0	0	10,340,000	10,340,000	10,340,000	10,340,000
Balance Ending		¥ 0		¥ 484,122		¥ 424,930
Series B Preferred Shares [Member]
Schedule of Preferred Stock by Class [Line Items]
Balance Beginning, (in shares) | shares	9,067,384	9,067,384	9,067,384	9,067,384	9,067,384	9,067,384
Balance Beginning		¥ 527,682		¥ 463,560		¥ 321,636
Issuance, (in shares) | shares	0	0	0	0	0	0
Issuance		¥ 0		¥ 0		¥ 0
Accretion on the Preferred Shares to redemption value		(23,345)		64,122		141,924
Deemed dividend to preferred shareholders		¥ 0		¥ 0		¥ 0
Conversion of convertible redeemable preferred shares upon completion of the IPO (in shares) | shares	(9,067,384)	(9,067,384)
Conversion of convertible redeemable preferred shares upon completion of the IPO		¥ (504,337)
Balance Ending, (in shares) | shares	0	0	9,067,384	9,067,384	9,067,384	9,067,384
Balance Ending		¥ 0		¥ 527,682		¥ 463,560
Series C Preferred Shares [Member]
Schedule of Preferred Stock by Class [Line Items]
Balance Beginning, (in shares) | shares	5,518,101	5,518,101	5,518,101	5,518,101	5,518,101	5,518,101
Balance Beginning		¥ 420,419		¥ 370,869		¥ 275,986
Issuance, (in shares) | shares	0	0	0	0	0	0
Issuance		¥ 0		¥ 0		¥ 0
Accretion on the Preferred Shares to redemption value		(88,954)		49,550		94,883
Deemed dividend to preferred shareholders		¥ 0		¥ 0		¥ 0
Conversion of convertible redeemable preferred shares upon completion of the IPO (in shares) | shares	(5,518,101)	(5,518,101)
Conversion of convertible redeemable preferred shares upon completion of the IPO		¥ (331,465)
Balance Ending, (in shares) | shares	0	0	5,518,101	5,518,101	5,518,101	5,518,101
Balance Ending		¥ 0		¥ 420,419		¥ 370,869
Series C+ Preferred Shares [Member]
Schedule of Preferred Stock by Class [Line Items]
Balance Beginning, (in shares) | shares	0	0	0	0	0	0
Balance Beginning		¥ 0		¥ 0		¥ 0
Issuance, (in shares) | shares	6,734,459	6,734,459	0	0	0	0
Issuance		¥ 656,448		¥ 0		¥ 0
Accretion on the Preferred Shares to redemption value		6,360		0		0
Deemed dividend to preferred shareholders		¥ 0		¥ 0		¥ 0
Conversion of convertible redeemable preferred shares upon completion of the IPO (in shares) | shares	(6,734,459)	(6,734,459)
Conversion of convertible redeemable preferred shares upon completion of the IPO		¥ (662,808)
Balance Ending, (in shares) | shares	0	0	0	0	0	0
Balance Ending		¥ 0		¥ 0		¥ 0
Series D Preferred Shares [Member]
Schedule of Preferred Stock by Class [Line Items]
Balance Beginning, (in shares) | shares	2,526,026	2,526,026	2,526,026	2,526,026	2,296,387	2,296,387
Balance Beginning		¥ 188,183		¥ 168,415		¥ 140,859
Issuance, (in shares) | shares	0	0	0	0	229,639	229,639
Issuance		¥ 0		¥ 0		¥ 13,662
Accretion on the Preferred Shares to redemption value		(7,179)		19,768		13,367
Deemed dividend to preferred shareholders		¥ 0		¥ 0		¥ 527
Conversion of convertible redeemable preferred shares upon completion of the IPO (in shares) | shares	(2,526,026)	(2,526,026)
Conversion of convertible redeemable preferred shares upon completion of the IPO		¥ (181,004)
Balance Ending, (in shares) | shares	0	0	2,526,026	2,526,026	2,526,026	2,526,026
Balance Ending		¥ 0		¥ 188,183		¥ 168,415
Series D-1 Preferred Shares [Member]
Schedule of Preferred Stock by Class [Line Items]
Balance Beginning, (in shares) | shares	2,178,530	2,178,530	1,089,265	1,089,265	0	0
Balance Beginning		¥ 164,282		¥ 73,409		¥ 0
Issuance, (in shares) | shares	0	0	1,089,265	1,089,265	1,089,265	1,089,265
Issuance		¥ 0		¥ 82,048		¥ 68,138
Accretion on the Preferred Shares to redemption value		577		8,825		5,075
Deemed dividend to preferred shareholders		¥ 0		¥ 0		¥ 196
Conversion of convertible redeemable preferred shares upon completion of the IPO (in shares) | shares	(2,178,530)	(2,178,530)
Conversion of convertible redeemable preferred shares upon completion of the IPO		¥ (164,859)
Balance Ending, (in shares) | shares	0	0	2,178,530	2,178,530	1,089,265	1,089,265
Balance Ending		¥ 0		¥ 164,282		¥ 73,409
Series D-2 Preferred Shares [Member]
Schedule of Preferred Stock by Class [Line Items]
Balance Beginning, (in shares) | shares	1,182,803	1,182,803	0	0	0	0
Balance Beginning		¥ 89,464		¥ 0		¥ 0
Issuance, (in shares) | shares	0	0	1,182,803	1,182,803	0	0
Issuance		¥ 0		¥ 89,447		¥ 0
Accretion on the Preferred Shares to redemption value		2,850		17		0
Deemed dividend to preferred shareholders		¥ 0		¥ 0		¥ 0
Conversion of convertible redeemable preferred shares upon completion of the IPO (in shares) | shares	(1,182,803)	(1,182,803)
Conversion of convertible redeemable preferred shares upon completion of the IPO		¥ (92,314)
Balance Ending, (in shares) | shares	0	0	1,182,803	1,182,803	0	0
Balance Ending		¥ 0		¥ 89,464		¥ 0
Series E Preferred Shares [Member]
Schedule of Preferred Stock by Class [Line Items]
Balance Beginning, (in shares) | shares	1,042,623	1,042,623	0	0	0	0
Balance Beginning		¥ 78,553		¥ 0		¥ 0
Issuance, (in shares) | shares	4,842,587	4,842,587	1,042,623	1,042,623	0	0
Issuance		¥ 353,893		¥ 74,830		¥ 0
Accretion on the Preferred Shares to redemption value		11,495		3,322		0
Deemed dividend to preferred shareholders		¥ 12,039		¥ 401		¥ 0
Conversion of convertible redeemable preferred shares upon completion of the IPO (in shares) | shares	(5,885,210)	(5,885,210)
Conversion of convertible redeemable preferred shares upon completion of the IPO		¥ (455,980)
Balance Ending, (in shares) | shares	0	0	1,042,623	1,042,623	0	0
Balance Ending		¥ 0		¥ 78,553		¥ 0

Convertible redeemable prefer_4

Convertible redeemable preferred shares - Summary of Preferred Shares Activities for the Periods as Follows (Detail) (Parenthetical) - CNY (¥) ¥ in Thousands	1 Months Ended		12 Months Ended
	Aug. 31, 2020	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Schedule of Preferred Stock by Class [Line Items]
Dividends, preferred Stock			¥ 12,000	¥ 400
Series C+ Preferred Shares [Member]
Schedule of Preferred Stock by Class [Line Items]
Dividends, preferred Stock			¥ 0	¥ 0	¥ 0
Series D-1 Warrant [Member] | Series D-1 Preferred Shares [Member]
Schedule of Preferred Stock by Class [Line Items]
Debt instrument converted shares issued		1,089,265
Series D-2 Warrant [Member] | Series D-2 Preferred Shares [Member]
Schedule of Preferred Stock by Class [Line Items]
Debt instrument converted shares issued		963,139
Series C+ CMB Warrant [Member] | Series C+ Preferred Shares [Member]
Schedule of Preferred Stock by Class [Line Items]
Debt instrument converted shares issued	6,734,459
Series D-2 CW Notes [Member] | Series D-2 Preferred Shares [Member]
Schedule of Preferred Stock by Class [Line Items]
Debt instrument converted shares issued		112,648
Series D-2 DL Notes [Member] | Series D-2 Preferred Shares [Member]
Schedule of Preferred Stock by Class [Line Items]
Debt instrument converted shares issued		107,016

Convertible redeemable prefer_5

Convertible redeemable preferred shares - Additional Information (Detail) $ / shares in Units, ¥ in Thousands	Aug. 19, 2020USD ($)$ / sharesshares	Aug. 19, 2020CNY (¥)	Mar. 31, 2020CNY (¥)shares	Mar. 23, 2020shares	Mar. 06, 2020$ / sharesshares	Feb. 10, 2020USD ($)shares	Jan. 01, 2020USD ($)shares	Nov. 21, 2019USD ($)shares	Jun. 17, 2019USD ($)shares	Jun. 17, 2019CNY (¥)shares	Jun. 16, 2019CNY (¥)shares	Jan. 16, 2019shares	Aug. 03, 2018shares	Jun. 19, 2018USD ($)shares	Jun. 19, 2018CNY (¥)shares	Nov. 13, 2017USD ($)shares	Oct. 25, 2017shares	Sep. 08, 2017USD ($)	Sep. 08, 2017CNY (¥)	Mar. 21, 2016USD ($)shares	Jan. 26, 2016USD ($)shares	Jan. 07, 2016USD ($)	Jan. 07, 2016CNY (¥)	Jul. 07, 2015shares	May 13, 2015$ / shares	May 03, 2015USD ($)shares	May 03, 2015CNY (¥)shares	Feb. 07, 2014USD ($)shares	Feb. 07, 2014CNY (¥)shares	Apr. 03, 2013shares	Nov. 19, 2012USD ($)shares	Oct. 15, 2012USD ($)	Oct. 15, 2012CNY (¥)	Oct. 31, 2020USD ($)	Mar. 31, 2021USD ($)$ / sharesshares	Mar. 31, 2021CNY (¥)shares	Mar. 31, 2020USD ($)shares	Mar. 31, 2020CNY (¥)shares	Mar. 31, 2019USD ($)shares	Mar. 31, 2019CNY (¥)shares	Mar. 31, 2021CNY (¥)	Aug. 19, 2020CNY (¥)shares	Jan. 26, 2016CNY (¥)
Stock issued during period, value, new issues | ¥																																				¥ 395,071
Dividends, preferred stock | ¥																																				¥ 12,000		¥ 400
Equity method investments | ¥			¥ 3,104																																			¥ 3,104			¥ 2,973
Number of share options exercised during the period.																																					1,299,954	1,299,954
Stockholders' equity note, stock split, conversion ratio																																			1	1
Proceeds from IPO																																		$ 64,000,000	$ 60,090,000	¥ 393,698
Preferred stock, liquidation preference, value | $																																			$ 653,000,000
Percentage of interest calculation on preference shares																																			8.00%						8.00%
Debt conversion, converted instrument, terms																																			24 months	24 months
Debt conversion, converted instrument, rate																																			7.00%	7.00%
Accretion on the Preferred Shares to redemption value																																			$ (18,000,000)	¥ (121,000)	$ 28,900,000	¥ 204,800	$ 51,900,000	¥ 392,600
IPO [Member]
Proceeds from issuance of convertible preferred stock | $																																			800,000,000
Proceeds from IPO | $																																			$ 50,000,000
Series E Warrant [Member]
Class of warrants or rights exercise price | $ / shares					$ 10.3251
Common Stock [Member]
Conversion of ordinary shares into Class A and Class B ordinary shares , Shares																																			(22,238,454)	(22,238,454)
Shares issued, price per share | $ / shares																																			$ 0.2882
Series A Preferred Shares [Member]
Stock issued during period																														7,238,000	3,102,000
Stock issued during period, value, new issues | $																															$ 11,000,000
Payments of stock issuance costs																																$ 300,000	¥ 1,700
Series B Preferred Shares [Member]
Stock issued during period																												9,067,384	9,067,384
Stock issued during period, value, new issues | $																												$ 19,000,000
Payments of stock issuance costs																												$ 300,000	¥ 1,900
Series C Preferred Shares [Member]
Stock issued during period																										5,518,101	5,518,101
Stock issued during period, value, new issues | $																										$ 25,500,000
Payments of stock issuance costs																										$ 400,000	¥ 2,700
Stock cancelled during period, shares																								865,585
Stock re-issued during period, value | $																						$ 4,000,000
Dividends, preferred stock																						$ 700,000	¥ 4,900
Series C+ Preferred Shares [Member]
Stock issued during period																					552,005
Stock issued during period, value, new issues | $																					$ 3,800,000
Stock cancelled during period, shares																				552,005
Stock re-issued during period, value | $																				$ 0
Class of warrant issued during period , shares																				552,005	6,734,459
Class of warrant issued during period ,value | $																				$ 3,800,000	$ 46,200,000
Class of warrants or rights exercise price | $ / shares	$ 6.86
Number of warrants or rights outstanding.	6,734,459																																									6,734,459
Adjustments to additional paid in capital, fair value | ¥		¥ 656,400
Preferred stock, liquidation preference, percentage																																			130.00%						130.00%
Series C+ Preferred Shares [Member] | Preferred Stock [Member]
Stock issued during period, value, new issues	$ 46,000,000	303,000
Series C+ Preferred Shares [Member] | Common Stock [Member]
Stock issued during period, value, new issues | ¥		¥ 312,500
Series C+ Preferred Shares [Member] | Guangcheng Shanghai Information Technology Co Ltd [Member]
Equity method investments																					$ 46,200,000																						¥ 303,200
Series C Plus Preferred Stock [Member]
Stock issued during period																																			6,734,459	6,734,459	0	0	0	0
Stock issued during period, value, new issues | ¥																																				¥ 656,448		¥ 0		¥ 0
Dividends, preferred stock | ¥																																				0		0		0
Accretion on the Preferred Shares to redemption value | ¥																																				¥ 6,360		¥ 0		¥ 0
Series C Plus Preferred Stock [Member] | CMB Investment [Member]
Principal amount of loan	$ 46,000,000																																									¥ 303,000
Series D Convertible Redeemable Preferred Shares [Member]
Stock issued during period																803,735	1,492,652
Stock issued during period, value, new issues | $																$ 20,000,000
Payments of stock issuance costs																		$ 200,000	¥ 1,100
Conversion of ordinary shares into Class A and Class B ordinary shares , Shares													229,639
Series D-1 Convertible Redeemable Preferred Shares [Member]
Stock issued during period														1,089,265	1,089,265
Stock issued during period, value, new issues | $														$ 10,000,000
Dividends, preferred stock														$ 25,000	¥ 100
Debt conversion, converted instrument, warrants or options issued													1,089,265
Series D-1 Convertible Redeemable Preferred Shares [Member] | Series D-1 Warrant [Member]
Number of share options exercised during the period.			1,089,265
Series D-2 Convertible Redeemable Preferred Shares [Member]
Debt conversion, converted instrument, warrants or options issued												963,139
Series D-2 Convertible Redeemable Preferred Shares [Member] | Series D-1 Warrant [Member]
Number of share options exercised during the period.			963,139
Series D-2 Convertible Redeemable Preferred Shares [Member] | Series D-2 CW Notes And Series D-2 DL Notes [Member]
Debt conversion, converted instrument, warrants or options issued				219,664
Series D-3 Convertible Redeemable Preferred Shares [Member] | Series D-3 Warrant A [Member]
Debt conversion, converted instrument, warrants or options issued											154,395
Debt instrument converted value | ¥											¥ 10,000
Series D-3 Convertible Redeemable Preferred Shares [Member] | Series D-3 Warrant B [Member]
Debt conversion, converted instrument, warrants or options issued											617,580
Debt instrument converted value | ¥											¥ 40,000
Series E Convertible Redeemable Preferred Shares [Member]
Stock issued during period						290,555	4,842,587		290,555	290,555
Stock issued during period, value, new issues | $						$ 3,000,000	$ 50,000,000		$ 3,000,000
Payments of stock issuance costs									$ 21,244	¥ 100
Dividends, preferred stock | $						$ 400,000	$ 12,000,000
Series E Convertible Redeemable Preferred Shares [Member] | Nanjing Xingmu [Member]
Stock issued during period, shares, acquisitions								461,513
Stock issued during period, value, acquisitions | $								$ 4,800,000
Series E Convertible Redeemable Preferred Shares [Member] | Series E Warrant [Member]
Class of warrants or rights exercise price | $ / shares					$ 10.3251
Debt conversion, converted instrument, warrants or options issued					205,767
Series A Preferred Stock [Member]
Stock issued during period																																			0	0	0	0	0	0
Stock issued during period, value, new issues | ¥																																				¥ 0		¥ 0		¥ 0
Dividends, preferred stock | ¥																																				0		0		0
Preferred stock, liquidation preference, percentage																																			180.00%						180.00%
Accretion on the Preferred Shares to redemption value | ¥																																				¥ (22,677)		¥ 59,192		¥ 137,301
Series A Preferred Stock [Member] | Maximum [Member]
Preferred stock, convertible, conversion price | $ / shares																									$ 1.40
Series A Preferred Stock [Member] | Minimum [Member]
Preferred stock, convertible, conversion price | $ / shares																									1.06
Series B Preferred Stock [Member]
Stock issued during period																																			0	0	0	0	0	0
Stock issued during period, value, new issues | ¥																																				¥ 0		¥ 0		¥ 0
Dividends, preferred stock | ¥																																				0		0		0
Preferred stock, liquidation preference, percentage																																			180.00%						180.00%
Accretion on the Preferred Shares to redemption value | ¥																																				¥ (23,345)		¥ 64,122		¥ 141,924
Series B Preferred Stock [Member] | Maximum [Member]
Preferred stock, convertible, conversion price | $ / shares																									2.22
Series B Preferred Stock [Member] | Minimum [Member]
Preferred stock, convertible, conversion price | $ / shares																									$ 2.10
Series E Preferred Stock [Member]
Stock issued during period																																			4,842,587	4,842,587	1,042,623	1,042,623	0	0
Stock issued during period, value, new issues | ¥																																				¥ 353,893		¥ 74,830		¥ 0
Dividends, preferred stock | ¥																																				12,039		401		0
Preferred stock, liquidation preference, percentage																																			110.00%						110.00%
Accretion on the Preferred Shares to redemption value | ¥																																				¥ 11,495		¥ 3,322		¥ 0
Series D-3 Preferred Stock [Member]
Preferred stock, liquidation preference, percentage																																			140.00%						140.00%
Series D-2 Preferred Stock [Member]
Preferred stock, liquidation preference, percentage																																			140.00%						140.00%
Series D-1 Preferred Stock [Member]
Preferred stock, liquidation preference, percentage																																			140.00%						140.00%
Series D Preferred Stock [Member]
Stock issued during period																																			0	0	0	0	229,639	229,639
Stock issued during period, value, new issues | ¥																																				¥ 0		¥ 0		¥ 13,662
Dividends, preferred stock | ¥																																				0		0		527
Preferred stock, liquidation preference, percentage																																			140.00%						140.00%
Accretion on the Preferred Shares to redemption value | ¥																																				¥ (7,179)		¥ 19,768		¥ 13,367
Series C Preferred Stock [Member]
Stock issued during period																																			0	0	0	0	0	0
Stock issued during period, value, new issues | ¥																																				¥ 0		¥ 0		¥ 0
Dividends, preferred stock | ¥																																				0		0		0
Preferred stock, liquidation preference, percentage																																			140.00%						140.00%
Accretion on the Preferred Shares to redemption value | ¥																																				¥ (88,954)		¥ 49,550		¥ 94,883
Series A And B Preferred Shares [Member]
Percentage of redemption price of preference shares																																			180.00%						180.00%

Redeemable non-controlling in_2

Redeemable non-controlling interests - Additional Information (Detail) - CNY (¥) ¥ in Thousands	Oct. 31, 2020	Mar. 31, 2021
Redeemable preferred shares issued amount		¥ 413,377
Accretion of redemption value of the redeemable non-controlling interest		(138)
Yoken Holding Limited [Member]
Redeemable preferred shares issued amount	¥ 6,000
Percentage of preferred shares redeemable at redemption price measured by Interest per year Since Issuance of shares	10.00%
Accretion of redemption value of the redeemable non-controlling interest		¥ 100

Borrowings, other debts and d_3

Borrowings, other debts and derivative liabilities - Summary of Short-term Debt (Detail) ¥ in Thousands, $ in Thousands	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)
Debt Disclosure [Abstract]
Bank borrowings		¥ 85,566	¥ 32,738
Other borrowings		0	42,485
Total short-term borrowings	$ 13,061	¥ 85,566	¥ 75,223

Borrowings, other debts and d_4

Borrowings, other debts and derivative liabilities - Summary of Long-term Debt Instruments (Detail) - CNY (¥) ¥ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Debt Disclosure [Abstract]
Bank borrowings	¥ 68,075	¥ 48,191
Other borrowings	0	4,957
Total long-term borrowings	¥ 68,075	¥ 53,148

Borrowings, other debts and d_5

Borrowings, other debts and derivative liabilities - Additional Information (Detail) $ / shares in Units, ¥ in Thousands

Mar. 31, 2021CNY (¥)

Oct. 23, 2020USD ($)$ / sharesshares

Oct. 23, 2020CNY (¥)shares

Oct. 01, 2020USD ($)

Mar. 31, 2020USD ($)shares

Mar. 31, 2020CNY (¥)shares

Mar. 23, 2020shares

Mar. 06, 2020CNY (¥)shares

Dec. 27, 2019USD ($)

Dec. 27, 2019CNY (¥)

Dec. 03, 2019USD ($)

Dec. 03, 2019CNY (¥)

Nov. 02, 2019

Aug. 09, 2019

Jun. 16, 2019CNY (¥)shares

May 27, 2019USD ($)$ / shares

May 27, 2019CNY (¥)

Jan. 16, 2019USD ($)$ / sharesshares

Jun. 30, 2020CNY (¥)

Mar. 31, 2021USD ($)

Mar. 31, 2021CNY (¥)

Mar. 31, 2020CNY (¥)

Mar. 31, 2019CNY (¥)

Dec. 16, 2021CNY (¥)

Mar. 31, 2021CNY (¥)

Mar. 08, 2021CNY (¥)

Mar. 31, 2020CNY (¥)

Mar. 06, 2020$ / shares

Mar. 01, 2020USD ($)

Jan. 31, 2020CNY (¥)

Oct. 31, 2019USD ($)

Oct. 31, 2019CNY (¥)

Jun. 16, 2019$ / shares

May 31, 2019USD ($)

May 31, 2019CNY (¥)

Aug. 03, 2018USD ($)shares

Aug. 03, 2018CNY (¥)shares

Borrowings Other Debts And Other Liabilities [Line Items]

Short term bank borrowings outstanding

¥ 85,566

¥ 32,738

Long term bank borrowings

68,075

48,191

Long term borrowings other

0

4,957

Gain loss on extinguishment of debt

$ 1,045,000

¥ 6,846

¥ 10,095

Receivable for the issuance of ordinary shares

$ 63,094,000

413,377

9

Debt Conversion, Converted Instrument, Rate

7.00%

7.00%

Long-term Debt

¥ 153,641

Repayments Of Debt

$ 11,295,000

¥ 74,000

43,533

¥ 65,798

Proceeds from Issuance of Debt

$ 13,408,000

¥ 87,846

162,501

¥ 57,638

Debt Modification Threshold Percentage For Not substantial

10.00%

10.00%

Currency Swap [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Derivative, Notional Amount

¥ 26,500

Foreign Currency Exchange Rate

6.6280

Settlement Date

Dec. 10, 2021

Dec. 10, 2021

Gain (Loss) on Derivative, Net

¥ 190

Series D2 DL Notes [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Payment of debt issuance costs

¥ 200

Debt instrument converted value | $

$ 1,000,000

Debt instrument conversion price per share | $ / shares

$ 9.34

Debt Conversion, Converted Instrument, Amount | $

$ 1,000,000

Debt Conversion, Converted Instrument, Rate

8.00%

Debt Instrument, Convertible, Renewal Maturity Days

30 months

Series D2 Preferred Shares [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Debt instrument converted shares issued | shares

107,016

Series D3 Warrant A [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Payment of debt issuance costs

¥ 200

Debt Instrument, Periodic Payment, Principal

¥ 10,000

Debt Instrument, Periodic Payment, Interest

700

Debt instrument, term

6 months

Series D3 Warrant B [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Payment of debt issuance costs

¥ 200

Debt Instrument, Periodic Payment, Principal

40,000

Debt Instrument, Periodic Payment, Interest

¥ 1,500

Debt instrument, term

6 months

Series D One Preferred Shares [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Fair value of temporary equity issued

¥ 82,000

Gain loss on extinguishment of debt

10,000

Series D Two Preferred Shares [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Fair value of temporary equity issued

¥ 73,000

Series D3 Preferred Shares [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Debt Conversion, Converted Instrument, Rate

10.00%

Debt Instrument, Interest Rate During Period

10.00%

Class Of Warrants Or Rights Extension Period

0 days

Series D3 Preferred Shares [Member] | Series D3 Warrant A [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Class of warrants or rights exercise price | $ / shares

$ 9.65

Debt Conversion, Converted Instrument, Warrants or Options Issued | shares

154,395

Series D3 Preferred Shares [Member] | Series D3 Warrant B [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Class of warrants or rights exercise price | $ / shares

$ 9.65

Debt Conversion, Converted Instrument, Warrants or Options Issued | shares

617,580

Superb Origin International Limited [Member] | Series D One Preferred Shares [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Debt instrument converted shares issued | shares

1,089,265

1,089,265

Debt instrument converted value | $

$ 10,000,000

Debt Conversion, Converted Instrument, Amount | $

$ 10,000,000

Superb Origin International Limited [Member] | Series D Two Preferred Shares [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Debt instrument converted shares issued | shares

963,139

963,139

Debt instrument converted value | $

$ 9,000,000

Debt Conversion, Converted Instrument, Amount | $

$ 9,000,000

Series D One Warrant [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Class of warrants or rights number of securities called by the warrants or rights | shares

1,089,265

1,089,265

Debt instrument convertible carrying value at the time of conversion

11,000

Debt Conversion, Original Debt, Amount

11,000

Series D Two Warrant [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Debt instrument convertible carrying value at the time of conversion

9,000

Debt Conversion, Original Debt, Amount

9,000

Yoken Series A One Warrant [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Class of warrants or rights exercise price | $ / shares

$ 7.14

Series E Warrant [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Class of warrants or rights number of securities called by the warrants or rights | shares

205,767

Class of warrants or rights exercise price | $ / shares

$ 10.3251

Class of warrants or rights outstanding value

¥ 2,500

Class of Warrant or Right, Date from which Warrants or Rights Exercisable

Mar. 6, 2020

Guangcheng [Member] | Series D Two Warrant [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Class of warrants or rights number of securities called by the warrants or rights | shares

963,139

Chong Li [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Debt instrument face value

¥ 128,000

Long-term Debt, Term

5 years

5 years

Long term loan due to the related party non current | $

$ 95,000,000

Chong Li [Member] | Series D One And D Two Preferred Shares [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Receivable for the issuance of temporary equity | $

$ 94,800,000

Chong Li [Member] | Common Class A [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Receivable for the issuance of ordinary shares | $

$ 100,800,000

Chong Li [Member] | Superb Origin International Limited [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Equity method investment ownership interest

100.00%

100.00%

Investor One [Member] | Yoken Series A One Warrant [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Class of warrants or rights number of securities called by the warrants or rights | shares

360,000

Debt instrument convertible carrying value at the time of conversion

$ 2,500,000

¥ 18,000

Debt Conversion, Original Debt, Amount

$ 2,500,000

18,000

Investor Two [Member] | Yoken Series A One Warrant [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Class of warrants or rights number of securities called by the warrants or rights | shares

200,000

Debt instrument convertible carrying value at the time of conversion

$ 1,400,000

10,000

Debt Conversion, Original Debt, Amount

$ 1,400,000

¥ 10,000

Long Term Bank Loan [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Short term borrowings collateral given

¥ 68,100

¥ 0

Long term borrowings collateral given

¥ 68,100

¥ 0

Long term borrowings weighted average interest rate at a point in time

6.00%

4.15%

4.15%

6.00%

Other Long Term Bank Loan [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Long term borrowings other

$ 6,000,000

¥ 42,500

Long term borrowings fixed rate of interest rate percentage

6.00%

6.00%

Long term debt stated rate of interest

6.00%

6.00%

Loan From Preferred Shareholder [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Debt instrument face value

$ 700,000

¥ 5,000

Related party transaction rate of interest

4.00%

4.00%

Loan For Series D One Warrant [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Debt instrument convertible carrying value at the time of conversion

79,000

Debt Conversion, Original Debt, Amount

79,000

Loan For Series D One Warrant [Member] | Guangcheng [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Debt instrument face value

$ 10,000,000

¥ 66,500

Long-term Debt, Term

18 months

18 months

Payment of debt issuance costs

$ 30,000

¥ 100

Loan For Series D One Warrant [Member] | Guangcheng [Member] | Amendment To The Maturity Date [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Long-term Debt, Term

36 months

36 months

Loan For Series D Two Warrant [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Debt instrument convertible carrying value at the time of conversion

67,000

Debt Conversion, Original Debt, Amount

¥ 67,000

Loan For Series D Two Warrant [Member] | Guangcheng [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Long term borrowings fixed rate of interest rate percentage

10.00%

Long-term Debt, Term

36 months

36 months

18 months

Payment of debt issuance costs

$ 300,000

¥ 2,000

Long term debt stated rate of interest

10.00%

Class of warrants or rights exercise price | $ / shares

$ 9.34

Series D Two CW Notes [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Debt instrument face value | $

$ 1,000,000

Debt instrument conversion price per share | $ / shares

$ 8.88

Series D Two CW Notes [Member] | Debt Instrument Converted Into Redeemable Preferred Stock [Member] | Series D Two Preferred Shares [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Debt instrument converted shares issued | shares

112,648

Loan For Series D3 Warrant A [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Payment of debt issuance costs

200

other gain (losses),Net

4,900

Loan For Series D3 Warrant A [Member] | Guangcheng [Member] | Series D3 Preferred Shares [Member] | Series D3 Warrant A [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Debt instrument convertible carrying value at the time of conversion

¥ 10,000

Debt Conversion, Original Debt, Amount

10,000

Loan For Series D3 Warrant B [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Payment of debt issuance costs

¥ 200

other gain (losses),Net

4,900

Loan For Series D3 Warrant B [Member] | Guangcheng [Member] | Series D3 Preferred Shares [Member] | Series D3 Warrant B [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Debt instrument convertible carrying value at the time of conversion

40,000

Debt Conversion, Original Debt, Amount

¥ 40,000

Series D Two DL Notes [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Long term borrowings fixed rate of interest rate percentage

14.00%

Debt instrument face value | $

$ 10

Long-term Debt, Term

6 months

Long term debt stated rate of interest

14.00%

Long Term Debt Extended Maturity Period

6 months

6 months

Series D Three PICC Notes [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Payment of debt issuance costs

$ 40,000

¥ 300

Gain loss on extinguishment of debt

¥ 600

Debt instrument conversion price per share | $ / shares

$ 9.34

Long Term Debt Extended Maturity Period

6 months

6 months

Threshold Percentage of Stock Price Trigger

5.00%

5.00%

Stock Price Trigger | $ / shares

$ 9.34

Long-term Debt

¥ 76,300

Repayments Of Debt | $

$ 10,000,000

Payments Of Interest On Debt | $

$ 1,100,000

Loan for Yoken Series A-1 Warrant [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Long term borrowings fixed rate of interest rate percentage

10.00%

10.00%

Long term debt stated rate of interest

10.00%

10.00%

Debt instrument converted shares issued | shares

120,000

120,000

Proceeds from Issuance of Debt

¥ 18,000

Loan for Yoken Series A-1 Warrant [Member] | Yoken Series A One Warrant [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Class of warrants or rights outstanding value

¥ 19,900

Interest Expense Reversed

¥ 1,400

Beneficial Conversion Feature

¥ 9,400

Short-term Investments [Member] | Long Term Bank Loan [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Debt instrument unused borrowing capacity

¥ 14,000

¥ 4,300

Short Term Bank Loan [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Short term borrowings weighted average interest rate at a point in time

5.04%

4.52%

4.52%

5.04%

Debt instrument unused borrowing capacity

¥ 222,300

¥ 100,300

Short Term Bank Loan [Member] | Short-term Investments [Member]

Borrowings Other Debts And Other Liabilities [Line Items]

Short term borrowings collateral given

37,800

0

Long term borrowings collateral given

¥ 37,800

¥ 0

Borrowings, other debts and d_6

Borrowings, other debts and derivative liabilities - Summary of Maturities of Long-term Debt (Detail) ¥ in Thousands	Mar. 31, 2021CNY (¥)
Debt Disclosure [Abstract]
2022	¥ 85,566
2023	68,075
Total	¥ 153,641

Borrowings, other debts and d_7

Borrowings, other debts and derivative liabilities - Summary of Other Short Term Debt (Detail) - CNY (¥) ¥ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Series D Three Picc Notes [Member]
Short-term Debt [Line Items]
Other Short-term Borrowings	¥ 0	¥ 76,252

Borrowings, other debts and d_8

Borrowings, other debts and derivative liabilities - Summary of Other Long Term Debt (Detail) ¥ in Thousands, $ in Thousands	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)
Debt Instrument [Line Items]
Other Debt Noncurrent	$ 66,133	¥ 433,292	¥ 165,774
Loan For Series C Plus Warrant [Member]
Debt Instrument [Line Items]
Other Debt Noncurrent		312,535
Loan For Series D Three Warrant A [Member]
Debt Instrument [Line Items]
Other Debt Noncurrent			11,192
Loan For Series D Three Warrant B [Member]
Debt Instrument [Line Items]
Other Debt Noncurrent			41,824
Loan From Chong Li [Member]
Debt Instrument [Line Items]
Other Debt Noncurrent		100,842	94,758
Loan For Yoken Series A One Warrant [Member]
Debt Instrument [Line Items]
Other Debt Noncurrent		¥ 19,915	¥ 18,000

Borrowings, other debts and d_9

Borrowings, other debts and derivative liabilities - Summary of Fair Value of Derivative Liabilities (Detail) - CNY (¥) ¥ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Schedule Of Derivative Liabilities At Fair Value [Line Items]
Derivative Liability	¥ 9,996	¥ 14,351
Conversion Feature Of Yoken Series A One Warrant [Member]
Schedule Of Derivative Liabilities At Fair Value [Line Items]
Derivative Liability	9,362
Conversion Feature Of Series D Three CMB Warrant A [Member]
Schedule Of Derivative Liabilities At Fair Value [Line Items]
Derivative Liability		2,377
Conversion Feature Of seriesD threeCMB warrant B [Member]
Schedule Of Derivative Liabilities At Fair Value [Line Items]
Derivative Liability		9,473
Series E Warrant [Member]
Schedule Of Derivative Liabilities At Fair Value [Line Items]
Derivative Liability	444	¥ 2,501
Forward exchange swap [Member]
Schedule Of Derivative Liabilities At Fair Value [Line Items]
Derivative Liability	¥ 190

Share-based compensation - Summ

Share-based compensation - Summary of Stock Option Activity (Detail) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement, Disclosure [Abstract]
Number of shares, Outstanding, beginning	4,856,972	5,686,454
Number of shares, Exercisable, beginning		1,299,954
Number of shares, Granted	998,000	915,097
Number of shares, Exercised		(1,299,954)
Number of shares, Forfeited	(342,750)	(444,625)
Number of shares, Outstanding, ending	5,512,222	4,856,972	5,686,454
Weighted average exercise price, Outstanding, beginning	$ 2.26	$ 1.49
Weighted average exercise price, Exercisable, beginning		0.001
Weighted average exercise price, Granted	4.13	4.03
Weighted average exercise price, Exercised	3.49	0.001
Weighted average exercise price, Forfeited	$ 3.36	2.45
Weighted average exercise price, Outstanding, ending		$ 2.26	$ 1.49
Weighted average remaining contractual term, Outstanding		6 years 8 months	5 years 10 months 10 days
Weighted average remaining contractual term, Exercisable	6 years 3 months 25 days		5 years 6 months 24 days
Aggregate intrinsic value, Outstanding, beginning	$ 39,472,000	$ 34,717,000
Aggregate intrinsic value, Exercisable, beginning		9,878,000
Aggregate intrinsic value, Outstanding, ending	$ 29,360,000	$ 39,472,000	$ 34,717,000
Weighted average fair value, Outstanding, beginning	$ 2.72	$ 1.68
Weighted average fair value, Exercisable		$ 1.83
Weighted average fair value, Granted	2.49	$ 5.02
Weighted average fair value, Forfeited	4	1.89
Weighted average fair value, Outstanding, ending	$ 3.28	$ 2.72	$ 1.68

Share-based compensation - Su_2

Share-based compensation - Summary of Options Measured At Fair Value, Valuation Assumptions (Detail) - $ / shares	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	44.41%	43.49%
Risk-free interest rate	0.94%	0.87%
Expected dividend yield	0.00%	0.00%
Contractual term (in years)	10 years	10 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise multiple	$ 2.8	$ 2.8
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise multiple	$ 2.2	$ 2.2

Share-based compensation - Addi

Share-based compensation - Additional Information (Detail) $ / shares in Units, ¥ in Millions	1 Months Ended	12 Months Ended
	Apr. 30, 2019$ / sharesshares	Mar. 31, 2021USD ($)shares	Mar. 31, 2021CNY (¥)shares	Mar. 31, 2020USD ($)shares	Sep. 01, 2020shares	Mar. 31, 2019USD ($)	Aug. 01, 2018shares	Sep. 27, 2012shares
Share Based Payment Arrangement [Line Items]
Percentage of entitlement to vest earn by employees		25.00%	25.00%
Share based compensation arrangement by share based payment award options granted		998,000	998,000	915,097
Share based compensation arrangement by share based payment award options exercised				1,299,954
Share based compensation arrangement by share based payment award options outstanding intrinsic value | $		$ 29,359,582		$ 39,471,589		$ 33,010,332
Unrecognised share based compensation expenses | $		$ 3,212,747,000		$ 12,954,410,000
Weighted average vesting period		6 years 3 months 18 days	6 years 3 months 18 days	6 years 8 months 12 days
Share based compensation expense recognized until the completion of a qualified IPO | $				$ 0
Share based compensation expense			¥ 10.9	$ 0
Cumulative share based compensation expense | ¥			¥ 44.1
Employees and Non Employees [Member]
Share Based Payment Arrangement [Line Items]
Share based compensation arrangement by share based payment award options granted		998,000	998,000	915,097
Fair value of options granted amount | $		$ 4,120,000		$ 3,860,000
Management Participants [Member]
Share Based Payment Arrangement [Line Items]
Share based compensation arrangement by share based payment award options exercised	1,299,954
Share based compensation arrangement by share based payment award options exercised price per share | $ / shares	$ 0.001
2012 Global Share Plan [Member]
Share Based Payment Arrangement [Line Items]
Shares reserved for future issuances								1,061,500
2018 Global Share Plan [Member]
Share Based Payment Arrangement [Line Items]
Shares reserved for future issuances					5,987,836		5,987,836
Amended 2018 Global Share Plan [Member]
Share Based Payment Arrangement [Line Items]
Shares reserved for future issuances					8,987,836

Employee benefits - Additional

Employee benefits - Additional Information (Detail) - CNY (¥) ¥ in Millions	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Compensation Related Costs [Abstract]
Employee benefits costs	¥ 6	¥ 7	¥ 7

Fair value measurements - Summa

Fair value measurements - Summary of Company's Financial Assets and Liabilities (Detail) - CNY (¥) ¥ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt investments	¥ 71,357	¥ 70,328
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	168,546
Available-for-sale debt investments	71,357	70,328
Total assets	239,903
Derivative liabilities	9,996	14,351
Fair Value, Recurring [Member] | Significant other observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	168,546
Total assets	168,546
Derivative liabilities	190
Fair Value, Recurring [Member] | Significant unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt investments	71,357	70,328
Total assets	71,357
Derivative liabilities	¥ 9,806	¥ 14,351

Fair value measurements - Sum_2

Fair value measurements - Summary of Roll Forward of Major Level 3 Investments (Detail) - CNY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Available-for-sale Securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of Level 3 investments , Beginning Balance	¥ 70,328	¥ 16,050	¥ 13,767
New addition		50,000
Unrealized fair value change of the available-for-sale debt investments	1,029	4,278	2,283
Fair value of Level 3 investments , Ending Balance	71,357	70,328	16,050
Derivative Financial Instruments, Liabilities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of Level 3 investments, Beginning Balance	14,351	35,524	1,333
New addition	9,391	13,487	32,099
Unrealized fair value change of the derivative liabilities	(11,559)	(13,345)	2,274
Disposal of Series D-3 Notes (Note 20)	(2,377)
Conversion of Series D Notes (Note 20)			(182)
Conversion of Series D-1 Notes (Note 20)		(10,701)
Conversion of Series D-2 Notes (Note 20)		(10,614)
Fair value of Level 3 investments , Ending Balance	¥ 9,806	¥ 14,351	¥ 35,524

Fair value measurements - Sum_3

Fair value measurements - Summary of Significant Unobservable Inputs (Detail) - Available-for-sale Securities [Member]	Mar. 31, 2021	Mar. 31, 2020
Weighted Average Cost Of Capital [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	1,650	1,650
Weighted Average Cost Of Capital [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	1,500	1,500
Lack of marketability discount [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	2,300	2,300
Lack of marketability discount [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	1,700	1,700
Risk-free rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	287	224
Risk-free rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	288	186
Expected volatility [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	4,226	4,813
Expected volatility [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	4,179	3,986
Probability Liquidation Scenario [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	4,000	4,000
Probability Redemption Scenario [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	4,000	4,000
Probability IPO Scenario [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	2,000	2,000

Fair value measurements - Sched

Fair value measurements - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Detail) - $ / shares	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-free rate	0.94%	0.87%
Expected volatility	44.41%	43.49%
Expected expiry years (in years)	10 years	10 years
Derivative Financial Instruments, Liabilities [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-free rate		0.19%
Risk-free rate , Minimum	0.00%
Risk-free rate , Maximum	0.90%
Expected volatility		55.14%
Expected volatility , Minimum	41.05%
Expected volatility , Maximum	52.33%
Expected expiry years (in years)		6 months
Maximum [Member] | Derivative Financial Instruments, Liabilities [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Share Price	$ 7.19	$ 10.74
Expected expiry years (in years)	4 years 6 months 21 days
Minimum [Member] | Derivative Financial Instruments, Liabilities [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Share Price	$ 5.57	$ 8.24
Expected expiry years (in years)	6 months

Net Loss per share - Schedule o

Net Loss per share - Schedule of Earnings Per Share, Basic and Diluted (Detail) ¥ / shares in Units, ¥ in Thousands, $ in Thousands		12 Months Ended
		Mar. 31, 2021USD ($)shares	Mar. 31, 2021CNY (¥)¥ / sharesshares	Mar. 31, 2020CNY (¥)¥ / sharesshares	Mar. 31, 2019CNY (¥)¥ / sharesshares
Numerator:
Net loss attributable to Boqii Holding Limited			¥ (194,444)	¥ (179,024)	¥ (234,241)
Accretion on convertible redeemable preferred shares		$ 18,449	120,873	(204,796)	(392,550)
Accretion on redeemable non-controlling interests			(138)
Deemed dividend to preferred shareholders			(12,547)	(1,142)	(723)
Net loss attributable to ordinary shareholders			¥ (86,256)	¥ (384,962)	¥ (625,514)
Denominator:
Weighted average number of ordinary shares used in computing net loss per share, Basic and diluted | shares	[1]	66,953,610	66,953,610	22,238,454	22,238,454
Net loss per share attributable to ordinary shareholders:
Basic and diluted | ¥ / shares			¥ (1.29)	¥ (17.31)	¥ (28.22)
[1]	Options exercisable for a minimal exercise price (the “Penny Stock”) are included in the denominator of basic loss per share calculation once there are no further vesting conditions or contingencies associated with them, as they are considered issuable shares. Basic net loss per share is computed using the weighted average number of ordinary shares outstanding and the Penny Stock during the period. Diluted net loss per share is computed using the weighted average number of ordinary shares and dilutive potential ordinary shares outstanding and the Penny Stock during the period.

Net Loss per share - Schedule_2

Net Loss per share - Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share (Detail) - shares	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Preferred Shares Weighted Average [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	0	26,072,893	25,083,831
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	2,585,103	0	0

Related party transactions - Su

Related party transactions - Summary of Major Related Parties and Their Relationships With The Company (Detail)	12 Months Ended
	Mar. 31, 2021
Nanjing Xingmu [Member]
Schedule Of Transactions Between Related Parties [Line Items]
Name of related parties	Nanjing Xingmu
Relationship with the company	An equity investee of the Company before November 1, 2019
Nanjing Animal Pharmaceutical [Member]
Schedule Of Transactions Between Related Parties [Line Items]
Name of related parties	Nanjing Animal Pharmaceutical
Relationship with the company	An equity investee of the Company
Shanghai Yichong [Member]
Schedule Of Transactions Between Related Parties [Line Items]
Name of related parties	Shanghai Yichong
Relationship with the company	An equity investee of the Company
Wuhan Chunzhijin [Member]
Schedule Of Transactions Between Related Parties [Line Items]
Name of related parties	Wuhan Chunzhijin
Relationship with the company	An equity investee of the Company
Beijing Petdog [Member]
Schedule Of Transactions Between Related Parties [Line Items]
Name of related parties	Beijing Petdog
Relationship with the company	An available-for-sale debt investee that the Company has significant influence
Yingzhi (Lisa) Tang [Member]
Schedule Of Transactions Between Related Parties [Line Items]
Name of related parties	Yingzhi (Lisa) Tang
Relationship with the company	A senior management of the Company
Di (Jackie) Chen {Member]
Schedule Of Transactions Between Related Parties [Line Items]
Name of related parties	Di (Jackie) Chen
Relationship with the company	A senior management of the Company
Ying (Christina) Zhang [Member]
Schedule Of Transactions Between Related Parties [Line Items]
Name of related parties	Ying (Christina) Zhang
Relationship with the company	A senior management of the Company
Fei Wang [Member]
Schedule Of Transactions Between Related Parties [Line Items]
Name of related parties	Fei Wang
Relationship with the company	A senior management of the Company
Yan Jiang [Member]
Schedule Of Transactions Between Related Parties [Line Items]
Name of related parties	Yan Jiang
Relationship with the company	A senior management of the Company

Related party transactions - _2

Related party transactions - Summary of Related Party Transactions And Balances (Detail) - CNY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Related Party Transaction [Line Items]
Purchase of merchandise	¥ 250	¥ 796	¥ 2,533
Loans granted to related parties	6,890	1,937	17,848
Beijing Petdog [Member]
Related Party Transaction [Line Items]
Sales of goods		2,316
Online marketing and information services	410	315
Nanjing Xingmu [Member]
Related Party Transaction [Line Items]
Purchase of merchandise		751	2,533
Nanjing Animal Pharmaceutical [Member]
Related Party Transaction [Line Items]
Purchase of merchandise	250	45
Loans granted to related parties	500	1,000
Wuhan Chunzhijin [Member]
Related Party Transaction [Line Items]
Loans granted to related parties	5,690
Yan Jiang [Member]
Related Party Transaction [Line Items]
Loans granted to related parties	200		17,848
Ying (Christina) Zhang [Member]
Related Party Transaction [Line Items]
Loans granted to related parties		152
Di (Jackie) Chen {Member]
Related Party Transaction [Line Items]
Loans granted to related parties		785
Fei Wang [Member]
Related Party Transaction [Line Items]
Loans granted to related parties	¥ 500

Related party transactions - Ad

Related party transactions - Additional Information (Detail) $ in Thousands

Dec. 31, 2019CNY (¥)

Mar. 31, 2021CNY (¥)

Jan. 31, 2021CNY (¥)

Jul. 31, 2020CNY (¥)

Jun. 30, 2020CNY (¥)

Mar. 31, 2020CNY (¥)

Oct. 31, 2019CNY (¥)

Sep. 30, 2019CNY (¥)

Mar. 31, 2019CNY (¥)

Nov. 30, 2018CNY (¥)

Jul. 31, 2018USD ($)

Jul. 31, 2018CNY (¥)

Related Party Transaction [Line Items]

Long-term Debt, Gross

¥ 500,000

Due from Related Parties

¥ 11,521,000

¥ 1,015,000

One Year Loan Agreement [Member]

Related Party Transaction [Line Items]

Debt Instrument, Face Amount

¥ 650,000

Debt Instrument, Interest Rate, Stated Percentage

4.00%

Nanjing Animal Pharmaceutical [Member] | Twelve Month Interest Free Loan Agreement [Member]

Related Party Transaction [Line Items]

Debt Instrument, Face Amount

¥ 1,000,000

¥ 500,000

Wuhan Chunzhijin [Member]

Related Party Transaction [Line Items]

Debt Instrument, Face Amount

¥ 5,700,000

Fei Wang [Member] | One Year Loan Agreement [Member]

Related Party Transaction [Line Items]

Debt Instrument, Face Amount

¥ 500,000

Debt Instrument, Interest Rate, Stated Percentage

4.00%

Debt Instrument, Collateral Amount

¥ 515,000

Yingzhi (Lisa) Tang [Member]

Related Party Transaction [Line Items]

Debt Instrument, Face Amount

¥ 1,500,000

Due from Related Parties

2,521,000

1,015,000

¥ 4,000,000

Yingzhi (Lisa) Tang [Member] | Two Year Loan Agreement [Member]

Related Party Transaction [Line Items]

Debt Instrument, Face Amount

¥ 1,500,000

Debt Instrument, Interest Rate, Stated Percentage

9.00%

Yingzhi (Lisa) Tang [Member] | Forty Month Loan Agreement [Member]

Related Party Transaction [Line Items]

Debt Instrument, Face Amount

¥ 1,000,000

$ 150

¥ 1,000,000

Debt Instrument, Interest Rate, Stated Percentage

6.00%

6.00%

6.00%

Di (Jackie) Chen {Member] | Twelve Month Interest Free Loan Agreement [Member]

Related Party Transaction [Line Items]

Debt Instrument, Face Amount

¥ 700,000

Debt Instrument Renewal period

1 year

Di (Jackie) Chen {Member] | Forty Month Loan Agreement [Member]

Related Party Transaction [Line Items]

Due from Related Parties

¥ 1,250,000

Yan Jiang [Member]

Related Party Transaction [Line Items]

Due from Related Parties

¥ 9,000,000

Yan Jiang [Member] | Two Year Loan Agreement [Member]

Related Party Transaction [Line Items]

Debt Instrument, Face Amount

¥ 9,000,000

¥ 9,000,000

Debt Instrument, Interest Rate, Stated Percentage

9.00%

9.00%

Related party transactions - _3

Related party transactions - Summary of Related Party Transaction (Detail) - CNY (¥) ¥ in Thousands	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Related Party Transaction [Line Items]
Staff advances	¥ 10	¥ 6	¥ 528
Advances provided to related parties	2,073	3,350	2,720
Loans granted from related parties		11,700	5,014
Yingzhi (Lisa) Tang [Member]
Related Party Transaction [Line Items]
Staff advances	10
Loans granted from related parties		1,450	5,014
Di (Jackie) Chen {Member]
Related Party Transaction [Line Items]
Staff advances		6	528
Loans granted from related parties		1,250
Nanjing Animal Pharmaceutical [Member]
Related Party Transaction [Line Items]
Advances provided to related parties	2,073
Wuhan Chunzhijin [Member]
Related Party Transaction [Line Items]
Advances provided to related parties		3,350	2,720
Yan Jiang [Member]
Related Party Transaction [Line Items]
Loans granted from related parties		¥ 9,000

Related party transactions - _4

Related party transactions - Summary of Transactions Due From Related Parties (Detail) - CNY (¥) ¥ in Thousands	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Schedule Of Transactions Due From Related Parties [Line Items]
Prepayments to related parties	¥ 2,023		¥ 138
Loans to related parties	2,147	1,937
Beijing Petdog [Member]
Schedule Of Transactions Due From Related Parties [Line Items]
Trade receivables from related parties		1,564
Nanjing Xingmu [Member]
Schedule Of Transactions Due From Related Parties [Line Items]
Prepayments to related parties			138
Nanjing Animal Pharmaceutical [Member]
Schedule Of Transactions Due From Related Parties [Line Items]
Prepayments to related parties	2,023
Loans to related parties	500	1,000
Wuhan Chunzhijin [Member]
Schedule Of Transactions Due From Related Parties [Line Items]
Other receivables from related parties	7,295	2,481	3,795
Yingzhi (Lisa) Tang [Member]
Schedule Of Transactions Due From Related Parties [Line Items]
Loans to related parties	10
Yan Jiang [Member]
Schedule Of Transactions Due From Related Parties [Line Items]
Loans to related parties	200
Di (Jackie) Chen {Member]
Schedule Of Transactions Due From Related Parties [Line Items]
Loans to related parties	785	785
Ying (Christina) Zhang [Member]
Schedule Of Transactions Due From Related Parties [Line Items]
Loans to related parties	152	152
Fei Wang [Member]
Schedule Of Transactions Due From Related Parties [Line Items]
Loans to related parties	¥ 500

Related party transactions - _5

Related party transactions - Summary of Transactions Due To Related Parties (Detail) - CNY (¥) ¥ in Thousands	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019	Nov. 30, 2018
Schedule Of Transactions Due To Related Parties [Line Items]
Advances from related parties	¥ 36		¥ 150
Long-term loan from related parties		11,521	1,015
Nanjing Animal Pharmaceutical [Member]
Schedule Of Transactions Due To Related Parties [Line Items]
Trade payables to related parties	874	45
Beijing Petdog [Member]
Schedule Of Transactions Due To Related Parties [Line Items]
Advances from related parties	36
Wuhan Chunzhijin [Member]
Schedule Of Transactions Due To Related Parties [Line Items]
Advances from related parties			150
Yingzhi (Lisa) Tang [Member]
Schedule Of Transactions Due To Related Parties [Line Items]
Long-term loan from related parties		2,521	1,015	¥ 4,000
Yan Jiang [Member]
Schedule Of Transactions Due To Related Parties [Line Items]
Long-term loan from related parties		¥ 9,000

Commitments and contingencies -

Commitments and contingencies - Additional Information (Detail) - CNY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Capital commitment amount	¥ 0	¥ 0

Restricted net assets - Additio

Restricted net assets - Additional Information (Detail)	Mar. 31, 2021
Maximum [Member]
Percentage of annual profit after tax to statutory reserves	50.00%
Percentage of annual profit after tax to general reserves	10.00%
Percentage of restrictions placed on net assets of the Company subsidiaries	25.00%
Minimum [Member]
Percentage of annual profit after tax to statutory reserves	10.00%

Condensed financial informati_3

Condensed financial information of the parent company - Summary of Condensed Balance Sheet Statements (Detail) ¥ in Thousands, $ in Thousands	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020USD ($)	Mar. 31, 2020CNY (¥)	Mar. 31, 2019CNY (¥)	Mar. 31, 2018CNY (¥)
Current assets:
Cash and cash equivalents	$ 44,605	¥ 292,237		¥ 88,352
Prepayments and other current assets	13,013	85,261		76,720
Total current assets	106,047	694,792		279,090
Non-current assets:
Other non-current asset	627	4,111		11,019
Total non-current assets	28,355	185,782		178,105
Total assets	134,402	880,574		457,195
Current liabilities
Short-term borrowings	13,061	85,566		75,223
Accrued liabilities and other current liabilities	4,587	30,055		37,883
Derivative liabilities	1,526	9,996		14,351
Total current liabilities	33,063	216,613		311,895
Non-current liabilities
Long-term borrowings	10,390	68,075		53,148
Total non-current liabilities	80,942	530,322		246,409
Total liabilities	114,005	746,935		558,304
Mezzanine equity:
Redeemable Non-controlling Interest, Equity, Carrying Amount
Receivable for issuance of preferred shares				(94,758)
Shareholders' deficit:
Common Stock Value
Statutory Reserves	465	3,047		2,627
Additional paid-in capital	499,498	3,272,612
Accumulated other comprehensive loss	(3,079)	(20,172)		11,204
Accumulated deficit	(421,240)	(2,759,882)		(2,016,758)
Receivable for issuance of ordinary shares	63,094	413,377		9
Total shareholders' deficit	12,618	82,674		(2,002,797)
Total liabilities, mezzanine equity and shareholders' deficit	134,402	880,574		457,195
Parent Company [Member]
Current assets:
Cash and cash equivalents	2,791	18,285	$ 175	1,145	¥ 9	¥ 14
Prepayments and other current assets	184,396	1,208,128		686,819
Total current assets	187,187	1,226,413		687,964
Non-current assets:
Other non-current asset	53	344		7,943
Total non-current assets	53	344		7,943
Total assets	187,240	1,226,757		695,907
Current liabilities
Short-term borrowings				42,485
Accrued liabilities and other current liabilities	766	5,017		12,126
Other debts, current				76,252
Derivative liabilities	68	444		14,816
Total current liabilities	834	5,461		145,679
Non-current liabilities
Long-term borrowings				4,957
Negative carrying amount of subsidiaries	173,788	1,138,622		690,121
Total non-current liabilities	173,788	1,138,622		695,078
Total liabilities	174,622	1,144,083		840,757
Mezzanine equity:
Redeemable Non-controlling Interest, Equity, Carrying Amount				1,857,947
Receivable for issuance of preferred shares				(94,758)
Shareholders' deficit:
Common Stock Value				139
Statutory Reserves	465	3,047		2,627
Additional paid-in capital	499,498	3,272,612
Accumulated other comprehensive loss	(3,079)	(20,172)		11,204
Accumulated deficit	(421,240)	(2,759,882)		(2,016,758)
Receivable for issuance of ordinary shares	(63,094)	(413,377)		(9)
Total shareholders' deficit	12,618	82,674		(2,002,797)
Total liabilities, mezzanine equity and shareholders' deficit	187,240	1,226,757		695,907
Parent Company [Member] | Series A Redeemable Convertible Preferred Shares [Member]
Mezzanine equity:
Redeemable Non-controlling Interest, Equity, Carrying Amount				484,122
Parent Company [Member] | Series B Redeemable Convertible Preferred Shares [Member]
Mezzanine equity:
Redeemable Non-controlling Interest, Equity, Carrying Amount				527,682
Parent Company [Member] | Series C Redeemable Convertible Preferred Shares [Member]
Mezzanine equity:
Redeemable Non-controlling Interest, Equity, Carrying Amount				420,419
Parent Company [Member] | Series D Redeemable Convertible Preferred Shares [Member]
Mezzanine equity:
Redeemable Non-controlling Interest, Equity, Carrying Amount				188,183
Parent Company [Member] | Series D-1 Redeemable Convertible Preferred Shares [Member]
Mezzanine equity:
Redeemable Non-controlling Interest, Equity, Carrying Amount				164,282
Parent Company [Member] | Series D-2 Redeemable Convertible Preferred Shares [Member]
Mezzanine equity:
Redeemable Non-controlling Interest, Equity, Carrying Amount				89,464
Parent Company [Member] | Series E Redeemable Convertible Preferred Shares [Member]
Mezzanine equity:
Redeemable Non-controlling Interest, Equity, Carrying Amount				¥ 78,553
Parent Company [Member] | Common Class A [Member]
Shareholders' deficit:
Common Stock Value	56	364
Parent Company [Member] | Common Class B [Member]
Shareholders' deficit:
Common Stock Value	$ 12	¥ 82

Condensed financial informati_4

Condensed financial information of the parent company - Summary of Condensed Balance Sheet Statements (Parenthetical) (Detail) - $ / shares	Mar. 31, 2021	Mar. 31, 2020
Condensed Balance Sheet Statements, Captions [Line Items]
Common Stock, Shares, Issued		22,238,454
Common Stock, Shares, Outstanding		22,238,454
Parent Company [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	153,000,000	153,000,000
Common Stock, Shares, Issued	0	22,238,454
Common Stock, Shares, Outstanding	0	22,238,454
Parent Company [Member] | Series A Redeemable Convertible Preferred Shares [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Convertible Preferred Shares, Par Value Per Share	$ 0.001	$ 0.001
Convertible Preferred Shares, Authorized	11,000,000	11,000,000
Convertible Preferred Shares, Issued	0	10,340,000
Convertible Preferred Shares, Outstanding	0	10,340,000
Parent Company [Member] | Series B Redeemable Convertible Preferred Shares [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Convertible Preferred Shares, Par Value Per Share	$ 0.001	$ 0.001
Convertible Preferred Shares, Authorized	10,000,000	10,000,000
Convertible Preferred Shares, Issued	0	9,067,384
Convertible Preferred Shares, Outstanding	0	9,067,384
Parent Company [Member] | Series C Redeemable Convertible Preferred Shares [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Convertible Preferred Shares, Par Value Per Share	$ 0.001	$ 0.001
Convertible Preferred Shares, Authorized	6,000,000	6,000,000
Convertible Preferred Shares, Issued	0	5,518,101
Convertible Preferred Shares, Outstanding	0	5,518,101
Parent Company [Member] | Series D Redeemable Convertible Preferred Shares [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Convertible Preferred Shares, Par Value Per Share	$ 0.001	$ 0.001
Convertible Preferred Shares, Authorized	3,000,000	3,000,000
Convertible Preferred Shares, Issued	0	2,526,026
Convertible Preferred Shares, Outstanding	0	2,526,026
Parent Company [Member] | Series D-1 Redeemable Convertible Preferred Shares [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Convertible Preferred Shares, Par Value Per Share	$ 0.001	$ 0.001
Convertible Preferred Shares, Authorized	3,000,000	3,000,000
Convertible Preferred Shares, Issued	0	2,178,530
Convertible Preferred Shares, Outstanding	0	2,178,530
Parent Company [Member] | Series D-2 Redeemable Convertible Preferred Shares [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Convertible Preferred Shares, Par Value Per Share	$ 0.00001	$ 0.00001
Convertible Preferred Shares, Authorized	2,000,000	2,000,000
Convertible Preferred Shares, Issued	0	1,182,803
Convertible Preferred Shares, Outstanding	0	1,182,803
Parent Company [Member] | Series E Redeemable Convertible Preferred Shares [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Convertible Preferred Shares, Par Value Per Share	$ 0.001	$ 0.001
Convertible Preferred Shares, Authorized	7,000,000	3,000,000
Convertible Preferred Shares, Issued	0	1,042,623
Convertible Preferred Shares, Outstanding	0	1,042,623
Parent Company [Member] | Common Class A [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	129,500,000	0
Common Stock, Shares, Issued	54,505,108	0
Common Stock, Shares, Outstanding	54,505,108	0
Parent Company [Member] | Common Class B [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	15,000,000	0
Common Stock, Shares, Issued	13,037,729	0
Common Stock, Shares, Outstanding	13,037,729	0

Condensed financial informati_5

Condensed financial information of the parent company - Summary of Statements of Comprehensive Loss (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020USD ($)	Mar. 31, 2020CNY (¥)	Mar. 31, 2019USD ($)	Mar. 31, 2019CNY (¥)
Condensed Statement of Income Captions [Line Items]
Sales and marketing expenses	$ 24,451	¥ 160,201		¥ 128,387		¥ 157,482
General and administrative expenses	17,396	113,972		54,277		67,007
Loss from operations	(31,440)	(205,995)		(137,386)		(201,130)
Interest income	2,679	17,553		400		114
Interest expense	4,220	27,650		59,268		18,654
Other (expense)/income, net	1,730	11,332		6,984		(9,814)
Fair value change of derivative liabilities	(1,735)	(11,369)		(13,345)		2,274
Net loss attributable to Boqii Holding Limited's ordinary shareholders	(29,676)	(194,444)		(179,024)		(234,241)
Less: Accretion on the Preferred Shares to redemption value	(18,000)	(121,000)	$ 28,900	204,800	$ 51,900	392,600
Less: Accretion on redeemable non-controlling interests to redemption value	21	138
Less: Deemed dividend to preferred shareholders	(1,915)	(12,547)		(1,142)		(723)
Net loss attributable to Boqii Holding Limited's ordinary shareholders	(13,163)	(86,256)		(384,962)		(627,514)
Net loss	(29,489)	(193,216)		(175,933)		(231,526)
Other comprehensive income (loss):
Foreign currency translation adjustment, net of nil tax	4,907	32,148		(2,021)		(3,808)
Unrealized securities holding gains	(118)	(772)		(3,209)		(1,711)
Total comprehensive loss	(34,278)	(224,592)		(170,703)		(226,007)
Parent Company [Member]
Condensed Statement of Income Captions [Line Items]
Sales and marketing expenses	(1,965)	(12,875)		0
General and administrative expenses	(2,144)	(14,050)		(4,631)		(812)
Total operating expenses	(4,109)	(26,925)		(4,631)		(812)
Loss from operations	(4,109)	(26,925)		(4,631)		(812)
Interest income	2,353	15,416
Interest expense				(12,578)		(5,624)
Share of losses of subsidiaries	(29,221)	(191,458)		(134,660)		(225,531)
Other (expense)/income, net	(459)	(3,008)		(40,500)		0
Fair value change of derivative liabilities	1,760	11,531		13,345		(2,274)
Net loss attributable to Boqii Holding Limited's ordinary shareholders	(29,676)	(194,444)		(179,024)		(234,241)
Less: Accretion on the Preferred Shares to redemption value	18,449	120,873		(204,796)		(392,550)
Less: Accretion on redeemable non-controlling interests to redemption value	(21)	(138)
Less: Deemed dividend to preferred shareholders	(1,915)	(12,547)		(1,142)		(723)
Net loss attributable to Boqii Holding Limited's ordinary shareholders	(13,163)	(86,256)		(384,962)		(627,514)
Net loss	(29,676)	(194,444)		(179,024)		(234,241)
Other comprehensive income (loss):
Foreign currency translation adjustment, net of nil tax	(4,907)	(32,148)		2,021		3,808
Unrealized securities holding gains	118	772		3,209		1,711
Total comprehensive loss	$ (34,465)	¥ (225,820)		¥ (173,794)		¥ (228,722)

Condensed financial informati_6

Condensed financial information of the parent company - Summary of Condensed Cash Flow Statements (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2021USD ($)	Mar. 31, 2021CNY (¥)	Mar. 31, 2020CNY (¥)	Mar. 31, 2019CNY (¥)
Condensed Cash Flow Statements, Captions [Line Items]
Net cash used in operating activities	$ (37,772)	¥ (247,486)	¥ (165,912)	¥ (206,224)
Net cash used in investing activities	(28,147)	(184,417)	(75,056)	(22,562)
Net cash provided by financing activities	98,979	648,491	295,032	199,313
Cash and cash equivalents at beginning of the year		88,352
Cash and cash equivalents at end of the year	44,605	292,237	88,352
Parent Company [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Net cash used in operating activities	(7,297)	(47,806)
Net cash used in investing activities	(89,892)	(588,953)	(184,354)	(99,221)
Net cash provided by financing activities	100,792	660,366	155,712	81,206
Effects of foreign exchange rate changes on cash and cash equivalents	(987)	(6,465)	29,778	18,010
Net increase (decrease) in cash and cash equivalents	2,616	17,140	1,136	(5)
Cash and cash equivalents at beginning of the year	175	1,145	9	14
Cash and cash equivalents at end of the year	$ 2,791	¥ 18,285	¥ 1,145	¥ 9